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Abstract 
 
 Chemical methods for protein modification are of utmost importance as they 
allow the mimicking of post-translational modifications that occur in living cells. In 
addition, they allow exogenous modifications that are the basis for protein 
enrichment (e.g. biotin labelling), structural analysis (e.g. FRET based studies) and 
visualisation studies (e.g. fluorescent tagging). Furthermore, chemical modification 
of proteins enables the synthesis of protein-drug conjugates and the tuning of drug 
pharmacokinetics.  
 Bromomaleimides represent the first of a new class of reagents that can be 
efficiently used for the fast, highly selective and reversible either by addition to a 
single cysteine or by bridging of disulphide bonds. In order to generate analogous 
reagents with potentially improved properties, a library of novel analogues was 
synthesised, each bearing different leaving groups on the double bond of the 
maleimide. For each, the thiol reactivity, water-solubility, and cross-reactivity with 
reducing agents were assessed using a single cysteine mutant of the Grb2 SH2 
protein. Disubstituted analogues were tested as disulphide bridging reagents using 
the small model peptide somatostatin. Phenoxymaleimides were investigated as 
particularly interesting reagents of attenuated reactivity. They were found to 
efficiently form a succinimide bridge across the disulphide bond of somatostatin. 
This novel succinimide bridging was further demonstrated on the octoretide peptide, 
on Fab and scFv antibody constructs. Minimal cross-reactivity of 
phonoxymaleimides with TCEP enabled addition of TCEP after addition of 
phenoxymaleimide, which is believed to reduce the risk of disulphide scrambling.  
Furthermore, the formation of the succinimide bridge was found to be reversible and 
the resultant released cysteine could be trapped with a maleimide or 
bromomaleimide. The result was a dual labelled protein conjugate. This represents 
a novel method for the dual labelling of disulphide containing biomolecules, allowing 
the preparation of various dual labelled somatostatin conjugates. 
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I Introduction 
I.1 Introduction to chemical modification of proteins 
 Proteins are responsible for the majority of functions in living organisms; they 
act as structural supports, as catalysts, and they control the signalling within and 
between cells. One of nature’s ways to generate functionalised proteins from a 
limited number of genes is via post-translational modifications (PTM), such as 
acylation, glycosylation, phosphorylation, methylation and ubiquitinylation, which 
provide versatility to proteins by modulating their properties and functions.1 All post-
translation modifications play key roles in cellular processes. Examples include 
glycosylation which is involved particularly in cell-cell recognition and signalling; 
acylation with fatty acids which is key to membrane localization and the regulation of 
hydrophobic interactions between proteins or proteins and cell membranes; and 
ubiquitination which often precedes protein degradation.2 
 The need to understand biological processes and the role of proteins within 
them, and also the utility of proteins in therapeutic agents have triggered a lot of 
research centered around the proteome. This has been enabled by major 
developments in bioanalytical techniques such as LC-MS, ELISA, HPLC, micro gel-
electrophoresis, tandem MS and high-field NMR. 
By chemically modifying proteins, scientists are able to mimic the PTMs that 
occur inside living cells. This can provide insights into the function of proteins in 
biological processes, their structure and the properties of their functional groups. 
Fig. 1 shows the most common approach for probing PTMs, promoted as the 
‘tagging via substrate’ approach by Tate et al..2 This strategy involves using a 
modified substrate, normally labelled with a small chemical handle. The tag must not 
interfere with the recognition between the substrate and the enzyme. Once the 
enzymatic reaction occurs and the target undergoes the PTM, a chemical reagent is 
added which is designed such that it reacts only with the chemical label on the 
substrate. This reagent is also designed as to allow further purification by affinity 
and characterisation, for example by containing biotin tags or fluorophores. 
13 
 
Fig. 1. Representation of the ‘tagging via substrate’ approach (image taken from Heal et. al.)2 
 Such an approach was employed by Wright et al.3 to investigate the N-
myristoylation of proteins in P. falciparum, the parasite that induces malaria in sub-
Saharan Africa, and subsequently prove that N-myristoyltransferase represents an 
antimalarial drug target. 
Moreover, chemical modification of proteins (CMP) may be used to achieve 
exogenous synthetic modifications such as the introduction of fluorescent tags for 
cell imaging4–6 or for FRET-based structural studies.7,8 Spin labels have enabled 
conformational studies and the development of biosensors9,10 while affinity tags 
such as biotin11,12 allow purification of the protein. 
Another area in which CMP is important is therapeutics, for the synthesis of 
protein-drug conjugates,13–16 of biosensors17,18 for diagnosis and for modulating drug 
pharmacokinetics (e.g. increasing in vivo half-life by attaching a PEG chain19,20). 
Oncaspar® (pegaspargase) is just one example of a FDA approved protein based 
drug whose properties have been successfully improved by pegylation. Unpegylated 
asparaginase, the active enzyme that is responsible in this case for killing leukaemia 
cells, induces allergic reactions and has a in vivo half-life of 20 h. The commercially 
available drug contains a 5 kDa PEG chain which is correlated with a significantly 
decreased adverse immune response and an improved in vivo half-life of 357 h.21  
In order for a reaction to be applicable to proteins, peptides and other 
biological macromolecules, it needs to fulfil many requirements. Probably the most 
important of all is to have a high selectivity for the targeted amino acid in the 
presence of many other similar residues in the system. In addition to this, the 
reaction needs to be biocompatible, meaning that it needs to take place under 
conditions that ensure the stability and retention of the activity of the biomolecules 
involved in the transformation. This generally means aqueous media with minimal 
amount of organic solvent, low to ambient temperature and at or near neutral pH. 
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Furthermore, it is useful if the reaction tolerates the presence of salts and 
surfactants that are often needed for protein stability. For in cell applications in 
particular, the reaction is ideally quick and the reagents involved exhibit low toxicity. 
The ideal labelling reagents would be highly selective, highly reactive and 
require minimal amounts of organic solvent in order to dissolve in the reaction 
mixture. Full conversion of the targeted protein is also desirable to avoid separation 
of unreacted protein, which can be tedious and generally leads to a reduction in the 
yield of the transformation. Longer reaction times, the addition of a denaturant to 
favour a reaction at a less solvent accessible site or of excess reagent to speed up 
the process are commonly employed to achieve full conversion. The drawback of 
using excess labelling reagent is in some cases the decreased side chain selectivity 
and of using a denaturant a greater risk of conformational change of the biomolecule 
which could result in loss of activity. 
The combined requirements of chemoselectivity, speed, stability and toxicity 
of the labelling reagents makes the development of methods for the selective CMP a 
significant challenge for chemists and biologists and hampers the application of 
many chemistry techniques. However, due to the intensive studies that have been 
conducted in the past couple of decades, we now have access to multiple strategies 
that allow various specific bioconjugations and even in cell tagging studies, as 
documented by various reviews that deal with this topic.22,23 
There are two main strategies for achieving CMP: either by a) specifically 
modifying a native amino acid present in the protein of interest or b) incorporating an 
unnatural amino acid that contains a bioorthogonal functionality that will serve as 
point of attachment. This label is ideally inert towards the other groups present in the 
biomolecule and will solely react with the labelling reagent. Only the former strategy 
will be considered in the following sections. 
I.2 Modification of native amino acids 
 Although the chemical modification of most of the 21 different naturally 
occurring amino acids have been reported, the focus has been mostly on lysine and 
cysteine labelling. This is a consequence of the higher nucleophilicity of these two 
amino acids compared to the rest, which enables the selective reaction with 
electrophilic reagents. The following sections will focus on the main strategies 
employed for their labelling. 
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I.2.1 Modification of lysine 
 Lysine residues have received a lot of attention due to their importance in 
many post-translational modifications and also due to the wide range of chemical 
methods available to target amino groups. Lysines are labelled at the ε-amino group 
(pKa ~ 10.5). The most frequently employed strategy for lysine labelling is acylation 
with anhydrides (e.g. acetic anhydride,24 succinic anhydride25), activated esters (e.g. 
N-hydroxy succinimidyl esters),26 sulfonyl chlorides27 and isothiocyanates28 (Scheme 
1a-d). A recent paper describes the efficient use of iminoboronates in the efficient 
and reversible lysine modification (Scheme 1e).29 The imines formed are stabilised 
by the nitrogen-boron interaction but can be cleaved upon addition of glutathione 
(GSH).  
 
Scheme 1. Modification of lysine with (a) succinic anhydride, (b) N-hydroxy succinimide ester, (c) 
sulfonyl chlorides, (d) isocyanates and (e) aldehydes 
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Unfortunately, most of the reagents mentioned above do not react 
exclusively with lysines, being prone to react with other α-amino groups and also 
with tyrosine, histidine and cysteine.30 A common feature of these reactions is that 
an alkaline pH, generally higher than 8, is required; this is to approach the pKa of the 
lysine and therefore ensure that a significant amount of the amino groups are 
deprotonated (neutral). Together with the high abundance of lysines in proteins, this 
represents a serious drawback when site-selective modification is required. 
Generally the reaction outcome is a Gaussian distribution of products and is difficult 
to direct the labelling onto a specific lysine residue.31 Lastly, another disadvantage 
of labelling lysines emerges from the fact that they are positively charged, therefore 
labelling alters the overall charge of the protein. 
I.2.2 Modification of cysteine 
In contrast, cysteine has a very low natural abundance (2.26%),32 and even 
more, most of the them are tied up in disulphide bonds and therefore are unreactive 
unless reduced. In addition to that, cysteine is highly nucleophilic and is not charged 
therefore by labelling with neutral tags the charge of the protein will not change. 
These features, combined with the possibility of inserting a single cysteine at a 
chosen location via site-directed mutagenesis render cysteine the favourite target for 
site-directed labelling. 
The basis for cysteine modification is that, under physiological conditions, 
cysteine has a high propensity to form the thiolate anion (pKa = 8.2). Therefore, it is 
natural to believe that by using carefully chosen electrophiles, preferential reactivity 
can be achieved.  
At this point, it is important to mention that the situation is far more complex 
in the context of biological systems as the reactivity of sulfhydryl groups is highly 
modulated by the local environment. A series of studies have been conducted with 
the purpose of a better understanding of the effects of factors such as the protein 
structure, conformation, neighbouring groups and pH on the reactivity of cysteine 
residues. 
To begin with, it is essential to clarify that the reactive species is the thiolate 
anion (S-) rather than the thiol (SH) itself.33,34 This is why the modification of 
sulfhydryl groups in proteins is optimal when performed at a pH between 7 and 9. 
Bednar34 showed in 1990 that the reactivity of the only sulfhydryl group in chalcone 
isomerase is varies by up to five orders of magnitude with the conformation of the 
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enzyme. The ionic strength of the solution is another factor that can influence the 
reactivity of the individual thiols, as stated by Stauffer and Karlin.35 The residues in 
proximity to the targeted cysteine group can also exert a significant influence on the 
pKa. This is generally valid for proximal cationic groups such as the side chains of 
lysine or arginine side chains that stabilize the thiolate thus contributing to the 
depression of the pKa value of the cysteine.36,37 
As mentioned before, most cysteines in proteins are found tied up in 
disulphide bonds, also called cystines (Fig. 2). They are formed during or post-
protein folding and are generally responsible for helping to maintain the tertiary 
structure, afford increased stability and therefore retain the activity of the protein. 
Reducible disulphides are also involved in the regulation of gene expression and 
have catalytic activity.38 
 
Fig. 2. Structures of (a) cysteine and (b) cystine 
 The challenge with cystine modification derives from the fact that these 
residues are responsible for contributing to the preservation of the natural tertiary 
structure39–41 of the proteins and that its cleavage leads, in some cases, to the loss 
of biological activity.42,43 Engineering an artificial disulphide bond into a protein to 
increase its stability is common.44 
In conclusion, the above mentioned features make cysteine a very attractive 
target when site-selective modification of proteins is required. This is proven by the 
numerous studies in the area which describe the use of this strategy in the study of 
protein activity,45 protein visualisation46 and for carrying out structural studies.47  
A selection of the most commonly used approaches developed to install 
selective chemical functionality on cysteine, together with some recent applications 
will be presented in the following sections.  
I.2.2.1  Alkylation of cysteine 
From a mechanistic point of view, alkylation of cysteine proceeds via SN2 
nucleophilic substitution or via conjugate addition. 
Alkylation of cysteine by nucleophilic substitution is possible with a wide 
variety of electrophiles; the first reagents to be reported were the α-halocarbonyl 
compounds such as iodoacetamides48 (Scheme 2a) or chloroacetic acid.49 
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Haloacetic acids are generally far slower than the corresponding haloacetamides 
and by changing the halogen it is possible to slow down or speed up the reaction, 
depending on the requirement.50 Among the haloacetamides, the order of reactivity 
is I > Br >> Cl. These compounds can be easily functionalised allowing the 
introduction of useful tags in the protein, such as fluorophores,51,52 spin labels53 
radiolabels54 and sugars55. Despite being characterised by a high cysteine specificity 
there have been reports of side reactions involving other residues such as histidine, 
lysine, methionine and tyrosine.56–59 Furthermore, the slow rate of reaction suggests 
that these compounds are not compatible with applications when short reaction 
times are required. This can be overcome by adding excess reagent but this can 
lead, as mentioned before to unspecific labelling. 
 
Scheme 2. Alkylation of cysteine with (a) iodoacetamide and (b) maleimide 
Faster reagents are represented by conjugate acceptors such as maleimides 
(Scheme 2b),60 vinyl sulfones61 and 4-vinyl pyridine.62,63 In these cases the alkylation 
proceeds via a conjugate addition reaction. The most frequently used reagents are 
N-substituted maleimides, as they react quickly, give no by-products and have high 
thiol specificity. Also, the nitrogen atom in the ring allows facile functionalisation; 
many such functionalised maleimide reagents are now commercially available.  
Examples of the application of N-substituted maleimides range from 
performing measurements of thiols in biological fluids,64 in vivo imaging studies,65,66 
structural and functional studies of proteins67–69 and synthesis of protein-drug 
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conjugates70,71 to the development of bioconjugates such as artificial 
metalloenzymes72 and biosensors.73 
In his studies on the reactivity of N-ethyl maleimide 1 (Scheme 3) with the 
amino acid glycylalanine and the the α and β chains of haemoglobin, Smyth74,75 
highlights the risks when using this reagent for specific cysteine targeting. 
Conditions that favour the specificity towards thiols are a pH below 7 (to reduce the 
risk of side reactions with amino groups, which at an acidic pH would be protonated, 
therefore no longer available for nucleophilic attack) and the use of minimal 
quantities of reagents. 
The thiosuccinimide 2 formed in the reaction between a cysteine containing 
protein or a simple thiol and maleimide is generally stable, limiting its application 
when temporary modification of proteins is required. However, there are some 
reports in the literature that describe the degradation of the product in strong 
reducing environments, such as the cytoplasm of cells76–78 where the concentration 
of glutathione can reach 15 mM.79  
Scheme 3 shows the proposed mechanism for the degradation process 
observed, together with the hydrolysis that generally accompanies the process. The 
first step is a retro-Michael addition to regenerate maleimide 1, which can then react 
with other thiols in the system, generally glutathione. The equilibrium is significantly 
shifted to the side of thiosuccinimide 2. Both the starting material, thiosuccinimide 2 
and the product, glutathiosuccinimide 3 can undergo hydrolysis. The resulting 
thiosuccinic acids 4 and 5 respectively can no longer undergo the retro-Michael 
addition.  
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Scheme 3. Degradation pathway of thiosuccinimide 2 in the presence of glutathione 
 Baldwin et al.80 studied the kinetics of the retro-Michael addition and 
exchange reactions undergone by thiosuccinimide in reducing environments, 
highlighting the potential of using this strategy for a controlled release of drugs or 
degradation of materials. They have found that the formation of 1 from 2 is the rate 
determining step in the formation of 3, the addition of glutathione to maleimide being 
very fast. The paper includes a kinetic study of the thiol-glutathione exchange and 
concludes that the kinetics of the transformation is significantly dependent on the 
nature of the thiol substituent (Fig. 3). For example, substituents such as 4-
mercaptophenylacetic acid (pKa = 6.6, blue trace in Fig. 3) will favor the retro-
Michael addition while substituents such as 3-mercaptopropionic acid (pKa = 10.3, 
green trace in Fig. 3) will give thiosuccinimides that are fully stable under the 
conditions tested. The thiosuccinimide adducts of thiols with intermediate pKas, such 
as the N-acetyl-cysteine (pKa = 9.5, red trace in Fig. 3) will undergo the Michael-
addition reaction but at a slower rate compared to the one bearing less acidic 
substituents.  
 
Fig. 3. Reaction profiles for the thiol - GSH exchange for various thiosuccinimides (taken from Baldwin 
et al.)80 
The same paper highlights the potential use of the thiosuccinimide-based 
strategy as a drug-delivery strategy complimentary to the disulphide-mediated 
release, which is a well-established strategy in drug delivery.81 The time-scales of 
the two strategies are very different: while the half-lives of disulphides in highly 
reducing environments (10 mM GSH) are less than 1 h, those of thiosuccinimides 
are between 20 - 80 h.80 
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In conclusion, the thiosuccinimide-based strategy may find applications in 
therapeutics, when a slower release of the drug is required. Without disregarding the 
wide scope of the transformations, the competing hydrolysis reaction reduces its 
versatility. 
I.2.2.2  Oxidation of cysteine 
Thiol oxidation is the basis for some post-translational modifications (e.g. S-
glutathionation)82 and protein folding.83,84 Thiol groups react readily with disulphides 
or selenocysteines, as confirmed by the various disulphide-containing bioconjugates 
that have been prepared using this method (Scheme 4).90–92 5,5’-dithiobis(2-
nitrobenzoicacid), known as Ellman’s reagent (Scheme 4), is a standard reagent for 
measuring the concentration of cysteine residues in proteins88 that has also been 
used for the modification of cysteine containing proteins such as human89 and 
chicken haemoglobin.90  
 
Scheme 4. Reaction of cysteine with disulphides 
These transformations can be easily reversed by adding excess of a thiol 
such as 2-mercaptoethanol 6 and dithiothreitol 7 (DTT). Consequently, disulphides 
are unstable in the cytoplasm of cells due to the high concentrations of glutathione 
present there. This feature has turned them into attractive targets as drug delivery 
vehicles.91,92 
Disadvantages of these methods include lack of control over the reaction 
progress and formation of dimers. To address these points, alkyl 
alkanethiosulphonate reagents have been developed. They react rapidly and 
selectively with cysteine, providing the corresponding mixed disulphides and sulfinic 
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acid as the by-product of the reaction. Examples include methyl 
methanethiosulfonate 8 (Scheme 5) but there are also bis-functional reagents such 
as 1,2-ethanediyl bismethanethiosulfonate (Fig. 4a).  
 
Scheme 5. Disulphide formation from cysteine and methanethiosulfonate 8 
A series of derivatives of the latter (mono-, di- and triacidic acid 
methanethiosulfonates), (Fig. 4b) were used to investigate the effect of adding 
negative charges on the activity of the enzyme subtilisin Bacillus lentus,93 while 1,2-
ethanediyl bismethanethiosulfonate was used to cross-link and probe 
conformational changes of Escherichia coli AcrBtransporter during its functional 
cycle.94 
 
Fig. 4. Examples of bis-functional methanethiosulfonates: (a) 1,2-ethanediyl bismethanethiosulfonate; 
(b) mono-, di- and triacidic acid methanethiosulfonates 
I.2.2.3 Desulfurisation at cysteine 
a) Disulphide contraction to thioether 
 The methodology for the desulfurisation of cystine has been developed by 
Harpp and Gleason.95 Its importance resides in the fact that it renders the starting 
disulphide constructs into the corresponding thioethers which, as opposed to 
disulphides are stable under reducing conditions.  
This transformation is achieved by the use of aminophosphines such as 
P(Et2N)3 and P(Me2N)3 (Scheme 6). In their study, Harpp and Gleason investigated 
the scope and mechanism of the reaction and provided the first example of 
transformation of a glycosidic disulphide protein conjugate into the corresponding 
thioether (Scheme 6). This is of valuable importance when considering the biological 
activity of various thiosugars.  
 
Scheme 6. Disulphide contraction to thioether on a protein substrate 
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More recent applications based on this strategy come from the Davis96 group 
which showed that the strategy is efficient for the synthesis of thioether-linked 
glycoproteins and glycopeptides.  
b) Reductive removal of cysteine thiol 
This strategy is outlined in Scheme 7 and consists of a metal-mediated 
dechalcogenation. As it converts cysteine to alanine, it has gained considerable 
importance especially after the development of native chemical ligation.97 
 
Scheme 7. Desulfurization of cysteine to alanine 
Palladium/H2,98 nickel/H299 and palladium/Al2O398 represent standard 
conditions for achieving this transformation. However these methodologies require a 
large excess of the metal which can potentially affect other functionalities present in 
the protein (methionine and the acetamidomethyl (Acm), the latter being a common 
protecting group). A large excess of the metal can cause epimerization of secondary 
alcohols and the reduction of other thiols, thioethers and thioesters. Danishefsky et 
al.100 developed an alternative methodology, based on free radicals derived from 
combining tris(2-carboxyethyl)phosphine (TCEP), tert-butylthiol and a water soluble 
radical initiator, VA-044 (Scheme 7) which they successfully applied on glycopeptide 
and polypetide systems. The tert-butyl thiol acts as a proton source and while it is 
not essential for the reaction, it was shown that it speeds up the reaction. Their 
method is cysteine specific and involves milder conditions. 
I.2.2.4 Oxidative elimination of cysteine 
The conversion of cysteine and serine to dehydroalanine (Fig. 5) is now a 
well-established post-translational modification, favoured by exposure to heat and 
alkali.101 In vitro experiments showed that the oxidative elimination of alkylated 
derivatives of cysteine and selenocysteine leads to dehydroalanine (Dha). Early 
methods involved incubating the protein with alkali but this is not recommended due 
24 
 
to side reactions such as the the addition of lysine residues onto the newly formed 
Dha.102  
 
Fig. 5. Structure of dehydroalanine 
Bernades et al.103 have reported on O-mesytilenesulfonylhydroxylamine 9 
(MSH) as a useful reagent for the fast, selective and efficient modification of 
cysteine residues via Dha (Scheme 8). Their strategy is based on the formation of 
Dha when cysteine is treated with excess MSH under basic conditions. The Dha 
moiety can then be reacted with thiol nucleophiles to give the corresponding 
thioethers (Scheme 9). The strength of this method was proven on a single cysteine 
mutant of the subtilisin Bacilus lentus (S156C) serine protease as model system; it 
was shown that the method allows the fast and efficient introduction of tags that 
correspond to post-translational modifications such as phosphorylation, 
glucosylation, farnesylation and N-methylation/acylation of lysines. No cross-
reactivity with other amino acids was observed. The same group reported on the 
efficient use of dibromodiamine 10 (DBDA) for Dha formation (Scheme 9). They 
exemplified the utility of this method in a study on the synthesis of various histones 
bearing diverse post-translational modifications.104 
 
Scheme 8. Oxidative elimination of cysteine to dehydroalanine and further functionalisation with thiol 
species on a protein substrate 
I.2.2.5 Metal-mediated modifications at cysteine and derivatives 
One powerful method for cysteine modification which has emerged in recent 
years is olefin metathesis. For a long time, this type of chemistry was inaccessible to 
chemical biologists as the methodology was not suitable for aqueous systems. The 
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development of water-soluble catalysts triggered extensive studies on the 
application of this methodology on biological systems. 
The Davis105,106 research group is one of the promoters of this strategy. Their 
strategy takes advantage of the enhanced reactivity of allyl sulphides in cross 
metathesis. The first step is the incorporation of an allyl sulphide (and more recently 
the allyl selenide) moiety on the cysteine via Dha formation, which is followed by the 
cross metathesis step (Scheme 9). The methodology proved successful for a very 
wide range of alkane substrates, including functionalised sugars. This set of 
examples shows the potential of this strategy to allow easy access to glycopeptides. 
 
Scheme 9. Olefin metathesis at S-allyl cysteine on a protein substrate 
Another emerging strategy involves palladium catalysed cross-coupling 
reactions, mainly the Suzuki-Miyaura coupling. In 2009, Chalker et al.107 reported on 
the novel water-soluble catalyst 11 that provided higher conversions compared with 
previously reported attempts to apply this reaction to proteins. The strategy requires 
the incorporation of a p-iodophenylalanine via UAG amber codon suppression; this 
residue will then undergo a Suzuki-Miyaura reaction in the presence of the Pd based 
catalyst and boronic acid (Scheme 10). In this study the protein model system 
employed was a single cysteine mutant of the subtilisin from Bacillus lentus (S156C) 
serine protease. 
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Scheme 10. Suzuki-Miyaura coupling on a protein substrate 
 The first report on gold-mediated cysteine modification of peptides came 
from Chan et al..108 They reported the highly efficient and selective labelling of 
cysteines in peptides and proteins when using various functionalised allenes in the 
presence of a mixture of AuCl-AgOTf. The strategy was used to label reduced 
RNaseA protein, leading to the hydroxyl vinyl thioether protein conjugate 12 
(Scheme 11).  
 
Scheme 11. Gold-catalysed cysteine labelling with allenes on a protein substrate 
 In conclusion, metal-mediated reactions are emerging as very powerful tools 
for chemical modification of proteins. 
I.2.2.6 Photo-induced cysteine labelling 
 In recent years, the thermally or photochemically induced radical additions of 
thiols to alkene or alkynes - known as the thiol-ene and the thiol-yne couplings 
respectively, and first reported in the mid-1900s109 - have gained significant 
importance in both polymer science and bioconjugation, as proven by numerous 
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applications described in the literature.110–112 A detailed review on the thiol-ene 
reaction is provided by Bowman and Hoyle,113 while the Dondoni group has 
published on the less exploited thiol-yne reaction.114,115 These reactions are 
biocompatible due to a series of properties such as efficiency, orthogonality to a 
wide range of functional groups, compatibility with water and oxygen and no need of 
metal catalysts. The transformation allows the introduction of various tags and the 
resulting product is generally stable under a wide range of conditions (acidic and 
basic, oxidizing and reducing environments). 
The reaction mechanism for the thiol-yne reaction is depicted in Scheme 
12.116 The first step is the thiyl radical 13 addition to the alkene to give, after 
hydrogen abstraction from another thiol molecule, the thioether product 14. The 
main side product in this transformation is disulphide 15 arising from thiol homo-
coupling. However, this problem can be fixed by using a small thiol such as DTT 
which will regenerate the thiol.  
 
Scheme 12. Mechanism for the thiol-ene reaction 
 In the area of site-selective modification of protein, the thiol-ene and thiol-yne 
reactions have been used to mimic post-translational modifications such as 
acetylation117 and glycosylation,115,118 to introduce tags containing lanthanide binding 
sites for paramagnetic NMR119 and to form photo-switchable bridges,120 as a way of 
controlling conformational domains in biomolecules.  
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I.2.3 Cystine (disulphide bond) modification 
Traditional methods involved cleavage of the cystine by oxidation with 
sodium periodate in 0.1 M to 1.0 M HCl to give two molecules of cysteic acid 16 
(Scheme 13).121  
 
Scheme 13. Modification of cystine with sodium periodate 
An alternative was represented by the use of sodium sulphite which, when 
reacted with a disulphide bond at pH 8 - 9, gives the S-sulfo derivative of cysteine 
17 and cysteine (Scheme 14). The addition of an oxidising agent such as cupric ions 
or o-iodosobenzoate ensures that all cysteines are converted to the S-sulfo product. 
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Scheme 14. Sulfitolysis of cystine 
Despite the fact that these transformations have provided a useful insight 
into the study of proteins and the roles of disulphide bonds, they are often 
accompanied by side reactions such as methionine oxidation123 and tyrosine 
modification.124 
More recently,125 the modification of disulphide residues in proteins is 
achieved via reduction of the disulphide bond followed by alkylation of the resulting 
thiol groups with alkylating agents (e.g. α-haloacetamides), (Scheme 15).  
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Scheme 15. Cystine reduction followed by alkylation of cysteine 
The reduction step employs thiols such as 2-mercaptoethanol 6126 and 
dithiothreitol 7127 (Scheme 4) or trialkylphosphines such as n-tributylphosphine 18 128 
and tris(2-carboxyethyl)phosphine 19 129,130 (TCEP), (Fig. 6). 2-mercaptoethanol, 
dithiothreitol and TCEP are particularly useful due to their solubility in water. 
 
Fig. 6. Commonly employed trialkylphosphine based reducing agents 
It is noteworthy to mention that during the reduction step, disulphide 
scrambling followed by protein aggregation is possible, as the conformation of many 
proteins depends on the disulphide bonds. Ideally the labelling strategy would 
introduce the tag very rapidly and retain the bridge. Also, the design of bridging 
reagents should ensure that the conformational changes induced to the biomolecule 
by the labelling reagent are kept to a minimum. 
Brocchini and co-workers131–133 developed a strategy that allows 
functionalisation of disulphides whilst following these principles. Their solution was 
to use a reagent able to rebridge the two cysteine residues, mimicking the role of the 
disulphide bond; in this way, it is hoped that the protein’s structure and function are 
unaltered. The bridging reagent 20 consists of an α,β-unsaturated carbonyl 
compound with a sulfonyl as a leaving group at the β’ position (Scheme 16).  
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Scheme 16. Strategy for disulphide bridging with PEG functionalised reagent 
An additional advantage of reagent 20 is its size; the bridge formed between 
the two thiol groups is just three carbon atoms, which lowers the possibility of 
inducing a significant change in the protein structure upon its incorporation. 
Additionally, it can be easily synthesised. Balan et al.132 successfully applied their 
strategy for the modification of the tripeptide glutathione, the cyclic peptide hormone 
somatostatin, the tetrameric protein L-asparaginase, and to the disulphides in 
interferon α-2b (IFN). An important limitation of this strategy is the fact that in the 
time between the reduction of the disulphide bond and the alkylation of the thiols, 
processes such as disulphide scrambling,134 aggregation135,136 and loss of 
activity62,137 of the protein could occur.  
I.3 Bromomaleimides in protein modification 
In 2009, the Baker group reported on bromomaleimides as the first of a new 
class of reagents that could be efficiently used for the selective and reversible 
modification of cysteine.138 
Firstly it was shown that the commercially available N-Boc-Cys-OMe 21, 
which was used as a model for the amino acid cysteine reacts extremely rapidly (<1 
min) and cleanly with bromomaleimide 22, giving thiomaleimide 23 quantitatively. 
The reaction is a two-step transformation involving the attack of the thiol on the 
double bond of the maleimide, followed by elimination of the bromide. 
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Thiomaleimide 23 is susceptible to further nucleophilic attack due to the double 
bond in the ring. The same paper describes how this feature was used to 
demonstrate the ease of reversing the reaction, by using excess TCEP 19, the 
commonly used water soluble phosphine (Scheme 17). 
 
Scheme 17. Bromomaleimide 22 addition to cysteine 21, followed by TCEP induced cleavage of the 
resulting thiomaleimide 23 
 Initial competition experiments between bromomaleimide 22 and maleimide 
showed that the former is faster in reacting with the protected cysteine 21 (Scheme 
18a). In another competition experiment, the protected cysteine 21, in the presence 
of equimolar quantities of propylamine and bromomaleimide 22, was shown to react 
solely with the latter (Scheme 18b) - suggesting the potential use of this reagent to 
selectively label cysteine over lysine in the context of a biological system. 
 
 
Scheme 18. Competition experiments involving bromomaleimides 
Further studies into the utility of bromomaleimides in biological systems were 
carried out in collaboration with the groups of Professor Caddick (UCL, Chemistry) 
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and of Professor Waksman (Birkbeck, ISMB). The most relevant results are 
highlighted in the following paragraphs. 
Scheme 19 illustrates how dibromomaleimide 25 was used to label the Grb2 
SH2 (L111C) adaptor protein 26 and how product 27 was further functionalised with 
thioglucose and glutathione respectively.139  
 
 
Scheme 19. Reversible modification of Grb2 SH2 (L111C) 26 (PDB id: 3MXC) with dibromomaleimide 
25 followed by further functionalisation with thioglucose or GSH  
Reactions were fast and reached full conversion within minutes and required 
as little as 1 eq. of the labelling reagent. The cleavage of the protein conjugates was 
also performed. Cleavage to afford the initial protein proved facile when using 
excess (100 eq.) of glutathione or 2-mercaptoethanol. This shows that 
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thiomaleimides are susceptible to thiol exchange in the presence of excess thiol and 
establishes the addition of excess thiol as a useful method to reverse the 
transformation.  
A direct application of bromomaleimides in the temporary labelling of protein 
is in the biotin-labelled protein enrichment. The biotin-avidin interaction is a well 
established technique for protein purification, however it suffers from the limitation 
that harsh conditions are required to release the protein (e.g. high concentration of 
denaturant, high temperatures and very low pH) after immobilisation.140 It was 
shown by Ryan141 et al., by using bromomaleimide 28 that biotinylation using a 
thiomaleimide linker allows cleavage under mild conditions of the immobilised 
protein, affording the native protein 26 (Scheme 20). 
 
Scheme 20. Reversible biotinylation of Grb2 SH2 (L111C) with bromomaleimide 28  
 Whilst the utility of bromomaleimides as reversible cysteine labelling 
reagents is a major asset, there are cases where a permanent, irreversible 
transformation is desired. The Baker and Caddick groups reported on the controlled 
hydrolysis of the N-aryl maleimides leading to the corresponding maleamic acids 
that are no longer cleavable in thiol rich media.141 The hydrolysis protocol that was 
established is an elegant way to render the attachment of maleimide irreversible. 
The concept was demonstrated on Grb2 SH2 (L111C), (Scheme 21). 
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Scheme 21. Thiol cleavable and thiol non-cleavable Grb2 SH2 (L111C) conjugates 
The use of dibromomaleimides for the modification of disulphide bonds was 
also investigated. Similarly to the work of Brocchini and co-workers, the Baker group 
tested the ability of dibromomaleimides to act as bridging reagents that could insert 
into the disulphide bonds of proteins, while retaining the structure and function of the 
macromolecule.142 
Indeed, various functionalised dibromomaleimides were incorporated in the 
single disulphide of somatostatin 29. Somatostatin is a 14-amino acid cyclic peptide 
with widespread effects on brain, pancreas, gut and central nervous system 
functions. It inhibits the release of the growth hormone as well as insulin, rennin, 
acetylcholine, calcitonin and various other hormones143. Octreotide and lanreotide, 
analogues of somatostatin, are being used in the treatment of acromegaly.144 
Somatostatin 29 contains a single disulphide bridge between Cys3 and Cys14, 
essential for maintaining the active conformation, which provided a suitable model 
system for testing the reactivity of disulphides towards double bonds.145 
The reaction was shown to work well when using N-fluorescein 
dibromomaleimide 30, affording the fluorescent bridged somatostatin conjugate 31 
in quantitative conversion after 10 min (Scheme 22). The process consisted of two 
steps: 1) reduction of the disulphide with TCEP 19 (1.1 eq.) and 2) addition of 
dibromomaleimide 30 (1.1 eq.). 
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Scheme 22. Stepwise bridging of disulphide bond in somatostatin with N-fluorescein 
dibromomaleimide 30 
Even though the bridging rate is high, the strategy suffers from the same 
limitations as other established methodologies for disulphide bridging: risk of protein 
aggregation, disulphide scrambling and subsequent loss of activity in the time that 
passes from the moment the bond is reduced and the moment it is fully bridged. To 
eliminate the risk of disulphide scrambling, it would be beneficial to trap the cysteine 
groups, released after treatment of the disulphide with the reducing agent with the 
bridging reagent as soon as possible. So ideally, the reduction and bridging steps 
would take place in tandem, which will henceforth be referred to as an “in situ” 
process. This involves mixing the disulphide bond containing biomolecule, the 
reducing and the bridging reagents altogether: the bridging would occur as soon as 
the disulphide is reduced. A crucial condition for the development of such an in situ 
process is that the bridging reagent does not show any cross-reactivity with the 
reducing agent. Dibromomaleimides proved not to satisfy this condition, undergoing 
TCEP attack. To solve this problem, dithiophenolmaleimide 32 was developed. The 
new protocol consists in the addition of TCEP (3 eq.) to a pre-mixed solution of 
somatostatin 29 and dithiophenolmaleimide 32 (5 eq.). Under these conditions, the 
reaction was complete in less than 20 min, affording bridged somatostatin 33. 
Furthermore, the reaction could be reversed by adding excess 2-mercaptoethnaol 
(100 eq.), (Scheme 23).  
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Scheme 23. In situ somatostatin bridging with dithiomaleimide 32 
As mentioned before, one risk of choosing disulphide labelling as a 
bioconjugation strategy is that by perturbing the disulphide bond, the biomolecule 
loses its biological activity. To test whether the maleimide bridge insertion affected 
the activity of the peptide, the synthesised maleimide bridged analogues were 
subjected to patch-clamping. The result was favourable, showing that the 
bioconjugates still maintained the reported activity in the activation of GIRK 
channels.142  
Some essential advantages of using disubstituted maleimides over the 
reagents used by Brocchini and co-workers are the fact that no asymmetric centre is 
introduced into the system and that the bridge between the two sulphur atoms is of 
just two carbons connected by a double bond; hence, the conformational changes in 
the protein are expected to be minimal. 
The Baker and Caddick groups have also shown that the bridging with N-
functionalised dithiophenolmaleimides is also efficient on larger substrates such as 
scFv antibody fragments (Scheme 24).146 They have shown that the bridged 
products retain full binding activity and display good plasma stability. The successful 
antigen detection by spin labelled ds-scFv 33 was achieved by continuous-wave 
electron paramagnetic resonance (cw-EPR) which highlights the potential of using 
this bridging strategy for diagnosis. 
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Scheme 24. Bridging of ds-scFv 33 with functionalised dithiophenomaleimides (representation of the 
protein was taken from Schumacher et. al.)146 
Jones et al.147 have successfully used dithiophenolmaleimides in atom 
transfer radical polymerisation. In 2011 they reported on the first example of an 
unprotected maleimide-functionalised initiator tolerant to polymerisation conditions 
and used the resulting dithiophenol maleimide functionalised polymers such as 34 to 
bridge the disulphide bond in the 32-amino acid peptide hormone calcitonin 35 
(Scheme 25). Dibromomaleimide-based functional ATRP initiators were also tested 
but these led to polymerisation inhibition and therefore the dibromomaleimide 
moiety, essential for the disulphide bridging, was added to the polymer at a later 
stage.148 
 
Scheme 25. Disulphide bridging of sCT with polymer via maleimide linker  
(Jones et al.)147 
The potential of substituted maleimides as drug carriers was also explored. 
Using a series of bromomaleimide-GFP (green fluorescent protein) conjugates 
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(Scheme 26), designed as FRET pairs, the release of the protein in the mammalian 
cells was demonstrated (by microinjection).149 The cleavage of the bioconjugates is 
based on the reaction with the excess glutathione present in the cytoplasm and on 
the ability on thiomaleimides to undergo thiol exchange. 
 
Scheme 26. Cleavage of GFP-rhodamine conjugates with maleimide linker in the presence of GSH 
 Another area where bromomaleimides have proven useful was in the 
synthesis of metallocarbonyl complex-based protein biomarkers and also enzyme 
inhibitors, as shown by Rudolf et al..150 These applications are based on the fact that 
maleimidato metallocarbonyl complexes display a strong IR absorbance between 
1950 - 2060 cm-1, where biomolecules do not absorb and on their ability to 
covalently attach to cysteine groups in enzymes. It was shown that the 
metallocarbonyl bromomaleimide complex 36 reacts efficiently with the single 
cysteine in papain, inhibiting its activity of the enzyme. Furthermore, the resulting 
papain thiomaleimide conjugate 37 can be cleaved by addition of TCEP, 
regenerating the catalytically active enzyme (Scheme 27). 
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Scheme 27. (a) Synthesis of maleimidato metallocarbonyl complex 36 and (b) Reaction between 36 
and the cysteine in papain 
All these examples show that bromomaleimides are very versatile 
trifunctional scaffolds with various applications in the area of site-selective protein 
modification: temporary blockage of an active cysteine residue, protein purification, 
quantitative and qualitative analysis of proteins, probing binding sites, synthesis of 
bioconjugates and drug delivery.  
I.4 Methods for the dual modification of proteins 
The ability to introduce homogenously and site-specifically two different 
functionalities onto a protein can give rise to new potential application. Examples 
include pegylation of a protein-drug conjugate to increase its in vivo half-life or 
fluorescent tagging of protein-drug conjugates for visualisation studies. Additionally, 
the incorporation of two fluorophores that form a FRET pair, enables FRET based 
structural studies of proteins.  
Solid phase synthesis facilitates differential labelling of peptides, simply by 
incorporating already labelled amino acids or non-natural amino acids which will 
allow the subsequent labelling with the desired tag.151 So far, several approaches - 
based both on chemical and molecular biology methods - have been developed for 
the differential modification of proteins. The most representative methodologies will 
be reported, as well as some of their applications. 
A general feature of the methods currently available is that they require 
either the introduction of one or more amino acids at a chosen location (this can be 
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done by site-directed mutagenesis) or of a non-natural amino acid (by the 
modification of the cellular ribosomal machinery).  
Each extra step (with or without purification) involved in the preparation of 
the dual labelled biomolecules contributes to the decrease of the overall yield and 
makes the method more tedious and time-consuming. While for some applications 
such as FRET, sub-milligram quantities of labelled protein are necessary, for stop-
flow experiments used to investigate reaction kinetics, much larger amounts of 
protein are required. In this context, simpler and more general methodologies that 
are suitable for scale-up are needed. 
The major hurdle when sequential covalent modification of two different sites 
of a protein is attempted is orthogonality. Ideally each of the two labelling reagents 
would exclusively react with its target. In the absence of this selectivity, 
heterogeneous product mixtures are formed, which are associated with tedious and 
generally very low-yielding purification steps. Currently, there are several strategies 
for selectively modifying one amino acid in the presence of others: (a) targeting two 
natural amino acids that display very different reactivities,152–154 (b) targeting a 
natural and a non-natural amino acid155,156 or (c) targeting two orthogonal non-
natural amino acids.157,158 A separate set of dual modification strategies are based 
on the incorporation in the biomolecule of a dual-labelled moiety that contains two 
orthogonal groups (e.g. azide and alkyne, azide and ketone) which can then be 
labelled with the two tags that are required for the application.159,160 As with all 
protein engineering techniques, care should be taken that the modifications made 
do not induce any significant conformational changes or loss of activity of the native 
protein. This is achieved by designing mutations that are as conservative as 
possible and that do not interfere with the residues known to be involved in the 
protein function. 
A representative example of dual labelling based on two natural amino acids 
that display different reactivities is detailed in a study by Ratner et al..161 Using 
Escherichia coli adenylate kinase (AKe) as a model protein, they have generated a 
series of dual cysteine mutants for which they have calculated the rate constants 
specific to each of the cysteines when reacted with a reference reagent (Ellman’s 
reagent). When designing mutants, the 3-D structure of the native protein is a very 
useful tool as several factors that are known to affect the reactivity of the cysteine 
can be estimated in this way. Such factors include solvent accessibility, 
neighbouring group effects and hydrogen bonding. From all the mutant candidates, 
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AKe (V169C/A188C) was selected for having the highest ratio (106) between the 
rate constants of two cysteine groups. This was then sequentially labelled with a 
donor - (I-Py) [N-(1-pyrenylmethyl)iodoacetamide] - and acceptor - (Cl-Bi 
[monochlorobimane] - fluorophore molecule respectively, known to form a FRET pair 
(Scheme 28).  
 
Scheme 28. Dual labelling strategy of a dual cysteine mutant of AKe  
In the end, the doubly labelled protein 38 was purified by hydrophobic 
interaction chromatography. The protocol was efficient as overall yields ranged 
between 70% and 90% affording tens of milligrams of product. Additionally, the dual 
modified AKe mutant retained full enzymatic activity and reversible folding-unfolding 
transition ability. FRET based analysis of the dual modified AKe allowed the team to 
calculate distances between the two modified residues upon folding and unfolding 
and therefore get more insight into its conformation. 
Another pair of naturally occurring amino acids that can be easily 
incorporated and that show a significant difference in reactivity is cysteine and 
selenomethionine. Selenomethionine was shown to react with electrophiles such as 
iodoacetamides154 and benzyl bromide162 derivatives but not with maleimides. 
Therefore it was envisaged that a pair or cysteine and selenomethionine can be 
selectively labelled, without cross-reactivity. The efficiency of the strategy was 
shown on the double mutants of the streptococcal protein CAMP factor and 
calmodulin protein, each containing a selenomethionine and cysteine residue 
respectively: first the cysteine was labelled with a functionalised maleimide 39 and 
then the selenomethionine was labelled with a functionalised iodoacetamide 40 
(Scheme 29).154  
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Scheme 29. Dual labelling strategy shown on double mutants of the CAMP factor and calmodulin 
(CaM) proteins 
A drawback of this strategy is the stability of selenomethionine, which in 
certain situations, especially when in close proximity to carboxylic acid side chains, 
can undergo side reactions. 
Chrochet et al.’s163 strategy is based on the orthogonality between cysteine 
labelling with maleimides and the transamination reaction involving amino-terminal 
group. The transamination reaction is mediated by pyridoxal 5’-phosphate and 
results in the installation of a ketone or aldehyde at the N-terminus of the protein, 
which can then be reacted chemoselectively with alkoxyamine-based reagents via 
oxime formation. Using this strategy, they have dual labelled mutants of single 
cysteine mutants of the periplasmic binding protein (PBP) with two commercially 
available fluorophores (Alexa Fluor 488 and TAMRA) which then can act as 
biosensors for monitoring the protein binding to specific ligands (Scheme 30). The 
limitation of this method is that, while the cysteine can be inserted in various 
positions, the second label is restricted to the N-terminus of the protein. 
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Scheme 30. Chemoselective labelling of a) the N-terminus and b) of the inserted cysteine (Crochet et 
al.)163 
The combination of thiol and click chemistry makes the approach chosen by 
the Pluckthun155 group for the dual functionalisation of the Designed Ankyrin Repeat 
Proteins (DARPins) very efficient and versatile. DARPins are a new class of 
therapeutic proteins that can be used as an alternative to antibodies.164 They can be 
expressed as to contain clickable methionine surrogates such as azidohomoalanine 
(Aha) or homopropargylglycine (Hpg) at the N-terminus, whilst retaining their native 
activity. This is done after ensuring that the only codon for methionine is the one at 
the N-terminus by performing the expression in a methionine auxotrophic medium to 
which the clickable methionine surrogate had been previously added. In addition, 
they are also devoid of cysteines therefore a single cysteine can be inserted via site-
directed mutagenesis allowing single attachment of cysteine specific reagents. The 
group exploited these two features and synthesised several examples of Aha or Hpg 
and single cysteine containing DARPin mutants which they then functionalised with 
a PEG chain via a strain-promoted azido - alkyne cycloaddition and with a 
fluorophore via maleimide conjugate addition (Scheme 31). The dual labelled 
DARPins were used to measure binding kinetics on tumour cells.  
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Scheme 31. Strategy for the chemoselective dual functionalisation of DARPins (Simon et al.)155 
Another approach involving the incorporation of two non-natural amino acids 
used for the dual functionalisation of calmodulin, which was then used to probe the 
conformational changes of this protein upon binding to Ca2+ and the M13 peptide.157 
The two unnatural amino acids introduced were p-acetylphenylalanine and 
alkynyllysine which were then labelled with two fluorophores that form a FRET pair 
(Cyanine 3 and Cyanine 5) using a hydrazine reaction and a Cu-catalysed azido-
alkyne cycloaddition reaction respectively (Scheme 32). 
 
Scheme 32. Dual labelling strategy based on the modification of two unnatural amino acids (Park et 
al.)157 
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If the two labels are not required to be on different amino acids, then the 
easiest approach is to label the biomolecule with a multifunctional tag that either 
contains the two labels desired or can be subsequently chemoselectively modified 
with the desired labels. A very useful such scaffold is represented by the vinyl 
sulfone bifunctional tag reagent 41 (Scheme 33) developed by Santoyo-Gonzales et 
al. that are designed to target cysteines.159 In this paper the two tags on the 
bifunctional reagent 41 were a fluorophore (rhodamine B) and biotin while the model 
system employed was Horse Radish Peroxidase 42. 
 
Scheme 33. One-step (red arrow) vs. two-step strategy (blue arrows) for the dual functionalisation of 
Horse Radish Peroxidase (Santoyo-Gonzales et al.)159 
Enzymatic approaches for the dual modification of proteins have gained 
significant importance.165,166 These methods use sortases that catalyse 
transpeptidation reactions. Target proteins are engineered to have, at both ends, the 
recognition site necessary for the enzyme. In the presence of a labelled peptide, the 
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transpeptidation reaction will take place, thus incorporating the label into the protein. 
However, this approach is limited to the labelling of the terminal protein region. 
A representative study is provided by Antos et al.167 who describe the site-
specific N- and C- terminal labelling of two different proteins (eGFP and UCHL3) 
using sortases of different selectivities: sortase A from Staphylococcus aureus 
(SrtAstaph) and the truncated form of sortase A, Δ59-StrAstaph.The two model proteins 
contain a LPXTG-His6x motif at the C-terminus which is recognized by the sortase A 
and at the other end a MLVPRG amino acid sequence, which acts as a protecting 
group for the N-terminus of the glycine (Scheme 34). The dual functionalisation 
protocol starts with the labelling of the protein C-terminus by the peptide AA-TMR 
which contains the first tag, rhodamine B. At this stage purification of 43 is required: 
the His6x-tagged SrtAstaph is removed by Ni-affinity column and the unreacted 
peptide by using a desalting column. Next, treatment with thrombin results in the 
deprotection of the N-terminal glycine residue. The resulting N-terminus of the 44 is 
then coupled to the second peptide which contains the recognition motif needed for 
the attachment of Δ59-StrAstaph and, at the other end, the second tag, fluorescein.  
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Scheme 34. (a) Tetramethylrhodamine-labelled peptide for SrtAstrept-mediated modification. (b) 
Fluorescein labelled peptide for Δ59-SrtAstrept-mediated modification (c) Strategy for the dual 
functionalisation of a protein using enzymatic approach (Ploegh et al.)167 
Other approaches for the dual modification of proteins are the expressed 
protein ligation (EPL) and protein trans-splicing (PTS) protein-ligation methods. 
They are protein semi-synthesis approaches that allow the synthesis of the target 
protein from smaller polypeptidic fragments. Both rely on the use of inteins, a class 
of peptides that undergo self-cleavage when inserted into the precursor protein.168 
A site-specific two-color protein labelling strategy that utilizes PTS is 
described by Yang et al..169 The model protein is an Ubiquitin dimer 45, with the two 
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Ubiquitin domains joined by a 14-amino acid linker rich in glycine residues. Two 
mutations have been performed to allow the site-selective labelling of each of the 
two fragments: the 47th amino acid (originally a glycine) on the N-terminal ubiquitin 
and the 7th amino acid (originally threonine) on the C-terminal ubiquitin were 
mutated into a cysteine (Scheme 35a). The protein was then divided at the second 
serine within the linker and expressed as the two fragments: Ub-IntN-6xHis and 
MBP-IntC-Ub, where MBP is the maltose binding protein, necessary for the 
stabilization of the protein and 6xHis is a histidine tag that will allow facile 
purification (Scheme 35b).  
 
Scheme 35. (a) Di-ubiquitin dimer 45 linked by a peptide linker; (b) Protein trans-splicing between the 
two intein fused fragments (Yang et al.)169 
The first labelling step takes place at the cysteine on the MBP-IntC-Ub 46 
and is achieved by addition of a maleimide fluorophore (Scheme 36). Upon mixing 
of Ub-IntN-6xHis 48 with the newly labelled MBP-IntC-Ub 46, the two intein 
fragments undergo folding to give the MBP-IntC and IntN6xHis (held together by 
non-covalent interactions) and the labelled di-Ub 49. Finally the second cysteine in 
the di-Ub 49 is labelled using a second maleimide fluorophore giving the dual 
labelled protein, 50. 
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Scheme 36. Trans-splicing strategy for the dual labelling of di-Ubiquitin (Yang et al.)169  
EPL has proven useful for the dual labelling of the repeat protein CTPR3 
(Consensus TetatricoPeptide Repeat) with a fluorescent pair, as reported by 
D’Andrea et al..170 EPL consists of the ligation of a C-terminal protein containing an 
N-terminal cysteine residue (either obtained by solid phase synthesis or 
recombinantly) with the thioester N-terminal fragment. To allow dual labelling, each 
fragment is mutated as to be easily singly labelled with the desired tag. In the study 
of D’Andrea et al., the N-terminal cysteine residue in 51 is expressed as a fusion 
protein with the MxeGyrA intein and has a 6xHis tag for purification purposes 
(Scheme 37). Construct 51 undergoes partial splicing and is then subjected to 
excess thiol to release the intein moiety and form the thioester N-terminal fragment 
52. This is labelled with a maleimide fluorophore and then coupled via native 
chemical ligation with the C-terminal protein fragment 53, containing a N-terminal 
cysteine. Once the two protein fragments are joined together, the second labelling 
with another maleimide fluorophore is achieved, giving the dual labelled protein 55. 
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Scheme 37. Expressed protein ligation strategy for the dual labelling of CTPR3 protein (D’Andrea et 
al.)170 
Both EPL and protein trans-splicing are powerful methods that have allowed 
studies in areas such as electrophysiology for the monitoring of membrane proteins 
such as ion channels,171 NMR by the introduction of specific isotopes172 and optical 
spectrscopy173,174 all with the aim of probing protein structure and function. An 
additional strength of these ligation methods is that they can be applied to the 
synthesis and modification of cyclic polypeptides such as cyclotides.175  
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I.5 Purpose of this work 
 Continuing the work that has been done in the Baker group, the current 
project addresses the problem of achieving higher selectivity for cysteine and 
cystine site-selective modification. Aiming to prove that the efficient cysteine 
labelling and disulphide bridging reported in the previous sections are not restricted 
to bromomaleimides, the scope of the substituent(s) on the double bond of the 
maleimide will be explored. 
A library of novel substituted maleimide reagents will be developed that will 
allow us to determine the influence of the substituent on the reactivity of the 
compound. Our hypothesis is that by controlling the chemistry of this class of 
compound, we will be able to tune properties such as thiol selectivity, reactivity, 
solubility and cross-reactivity with reducing agents and consequently make use of 
substituted maleimides more efficiently. 
The starting point for the creation of this library will be the mono- and 
dibromomaleimides respectively. Some of our targeted compounds are shown in 
Fig. 7.  
 
Fig. 7. Selected targeted mono- and disubstituted maleimide analogues 
It is expected that the reactivity of these analogues towards thiols and also 
the regioselectivity of the reaction is dictated by the substituents on the double bond. 
When predicting the influence of a substituent, several effects need to be 
considered: sterics, electronic effects (inductive and mesomeric) and leaving group 
ability. Therefore by carefully choosing the substituents, a range of reagents with 
tuned reactivity and properties will be accessed. 
Once synthesised, the reactivity of monosubstituted maleimide analogues 
towards cysteine will be tested on the model systems used previously in our group: 
firstly on the protected cysteine 21 (Scheme 38a) and then on the single cysteine 
mutant Grb2 SH2 (L111C) 26 (Scheme 38b). 
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Disubstituted maleimide analogues are potential cystine labelling reagents, 
therefore the model that will be used is somatostatin 29 (Scheme 38c). The 
applicability of the reagents for both the stepwise and in situ disulphide bridging will 
be studied. 
 
Scheme 38. Predicted reaction profiles for monosubstituted analogues towards (a) N-Boc protected 
methyl ester cysteine 21; (b) Grb2 SH2 (L111C) protein and of (c) disubstituted analogues towards 
somatostatin 
The nitrogen atom represents a useful point of attachment for useful 
functionalities such as fluorophores, PEG chains, drug molecules and affinity tags. 
An electron withdrawing group on the double bond is expected to activate the 
reagent towards thiol attack while an electron donating group is expected to have 
the opposite effect. This means that a monosubstituted maleimide bearing an 
electron withdrawing substituent (e.g. sulfoxy, sulfonyl) should react faster with thiols 
compared to a monosubstituted maleimide bearing an electron donating substituent 
(e.g. amino, alkoxy). Furthermore, the nature of substituent is expected to have an 
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effect on the regioselectivity of the reaction with thiols. Fig. 8 shows the effects 
taking place in the molecule, in the presence of an electron withdrawing group 
(EWG) and of an electron donating group (EDG) respectively. The former lowers the 
electron density in the β-position, rendering the β-carbon atom more electrophilic. 
Consequently, the thiol is expected to add β with respect to the substituent. EDGs 
are expected to have the opposite effect, deactivating the β-position and thus 
directing the nucleophile attack α with respect to the substituent.  
 
Fig. 8. Electronic effects induced by the substituents on the double bond 
Table 1 summarises the electronic effects that the substituents explored in 
this work are expected to display on the maleimide core. 
Substituent Mesomeric effect Inductive effect 
Halogens Electron donating Electron withdrawing 
Amino Electron donating Electron withdrawing 
Alkoxide Electron donating Electron withdrawing 
Aryloxide Electron donating Electron withdrawing 
Sulfonyl Electron withdrawing Electron withdrawing 
Thiol Electron donating Electron withdrawing 
Sulfoxy Electron withdrawing Electron withdrawing 
Table 1. Electronic effects of various substituents 
Other factors that are expected to influence the rate of thiol addition are size 
(bulkier groups are expected to hinder the approach of thiols) and leaving group 
ability (this can be correlated to the value of the pKa). While sulfoxy, halides are 
good leaving groups, alkoxy and amino groups are poor leaving groups. Thiol attack 
onto maleimides bearing poor leaving groups is expected to lead to the addition 
product only (Scheme 39). 
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Scheme 39. Expected reaction profile for the thiol addition to monosubstituted maleimides bearing a 
poor leaving group 
By performing reactions between the synthesised analogues and the model 
systems mentioned above 21, 26 and 29 we expect to as asses properties that are 
critical in bioconjugation: stability under physiological conditions, water-solubility and 
cross-reactivity with other reagents. This will allow the selection of the most suitable 
reagents depending on the requirements of the envisaged application. 
Novel applications of the new analogues in the area of site-selective 
chemical modification of proteins will also be investigated, with a particular focus on 
therapeutic proteins.  
II Results and Discussion 
This chapter will be divided in five parts.  
The first part, Chapter II.1, concerns the synthesis of the library of 
compounds. The synthetic section will be followed by Chapter II.2 dealing with the 
investigation of the utility of the novel reagents for the site-selective cysteine 
labelling and disulphide bridging. The next section, Chapter II.3, contains the kinetic 
study which was designed to quantitatively compare the reactivity of the 
monosubstituted maleimides.  Chapter II.4 introduces the use of 
phenoxymaleimides for achieving an efficient succinimide bridging of disulphide 
bond containing biomolecules. The scope and optimization of this novel labelling 
strategy, together with a novel synthetic route for the nitrogen functionalisation of 
phenoxymaleimides will be discussed. Finally, Chapter II.5 reports on a novel dual 
labelling of disulphide containing biomolecules. Its scope and optimization will be 
discussed.  
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II.1 Synthesis of the library of compounds 
II.1.1 Synthesis of bromomaleimides 
Whilst dibromomaleimide and N-methyl dibromomaleimide are commercially 
available, the monosubstituted bromomaleimides had to be synthesised. The 
synthesis was first attempted using the method previously established in our lab.138 
This two-step procedure consists of the addition of bromine to the maleimide, 
followed by base-induced hydrogen bromide elimination (Scheme 40). As soon as 
the formation of clean dibromosuccinimides 56 and 58 was confirmed by 1H-NMR, 
they were immediately subjected to the dehydrobromination conditions (1.1 - 1.3 eq. 
of triethylamine in THF). The synthesis of N-methyl bromomaleimide 57 following 
this route was straightforward, affording the desired N-methyl bromomaleimide 57 in 
a satisfactory overall yield (65%). However, this was not the case for 
bromomaleimide 22. Despite several attempts, the reaction was unsuccessful 
several times, yielding no more than 29% as an overall yield, which decreased upon 
scaling-up.  
 
Scheme 40. Synthesis of bromomaleimides 57 and 22 using the classical procedure 
It was assumed that the side reaction preventing facile synthesis of 22 is 
oligomerisation or polymerisation, triggered by the deprotonation imide in the ring 
(pKa~10.8),176 which is plausible considering the basic reaction conditions. Once 
deprotonated, the negatively charged nitrogen could act as a nucleophile in a 
conjugate addition to another maleimide molecule and this sequence could 
continue, leading to oligomers and polymers. Another possibility is that the resulting 
enolate can add to another maleimide. Triethylamine and DBU were tested as 
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bases, as well as a new strategy consisting of the initial protection of the amino 
group with a Boc group, chosen based on its stability under basic conditions.  
It was then decided to take a closer look at the previously employed 
procedure and purify the intermediate succinimide 58, in order to avoid the 
possibility that any impurities from the first step interfered with the elimination step. 
To our surprise, the result of flash chromatography on silica gel of the crude 
dibromosuccinimide was a 1 : 4 (molar ratio, based on 1H-NMR) inseparable mixture 
of the dibromosuccinimide 58 and the bromomaleimide 22. It was postulated that 
silica, due to its acidic character, promotes enolisation of dibromosuccinimide, 
leading to elimination of hydrogen bromide and subsequent formation of 
bromomaleimide 22 (Scheme 41). 
 
Scheme 41. Postulated mechanism for the formation of bromomaleimide 22  
It was decided to take advantage of this result and try to establish a new 
methodology for the synthesis of the bromomaleimides via an acid induced 
elimination of hydrogen bromide. Fig. 9 summarises some of the conditions tested. 
The transformation did not take place in the presence of a catalytic amount of acid 
(0.1 eq. p-toluenesulfonic acid) or even with a stoichiometric amount of base - silver 
acetate. The starting material was fully recovered in both cases. Silica, probably due 
to a combination of the effects of the acidic and basic sites present in its structure, 
gave satisfactory results even when the reaction was scaled-up. However, the 
procedure was very long (entry 4, Fig. 9). Gratifyingly, the combination of using 3 
eq. of sodium acetate and acetic acid as solvent, gave excellent results (82% 
isolated yield) in short reaction times (3 h), (entry 5, Fig. 9). The addition of base is 
needed to trap the bromide as sodium bromide salt; it was shown that otherwise the 
hydrogen bromide would inhibit reaction. 
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Entry 58 (mg) Reagent (eq.) Solvent 
Reaction time, 
temperature 
22 (%) 
1 100 AgOAc (1.eq.) EtOAc 15 h @ r.t. 0a 
2 100 p-TsOH (0.1 eq.) EtOAc/CH2Cl2 15 h @ r.t. 0a 
3 100 p-TsOH (0.1 eq.) Toluene 
2 h @ 100 °C, then 13 
h @ r.t. 
0a 
4 500 Silica (10g) CH2Cl2 
48h @ r.t., then 6 h on 
the rotaevaporator @ 
50 °C 
91 
5 500  NaOAc (3 eq.) Acetic acid 1.5 h @ reflux 82 
a Starting material did not react, based on 1H-NMR of crude mixture at the end of the reaction 
Fig. 9. Optimisation of the synthesis of bromomaleimide 22 
This new methodology was applied to both substrates and gave good results 
on a multi-gram scale (Scheme 42). 
 
Scheme 42. Novel route for the synthesis of bromomaleimides 22 and 57 
In conclusion, a fast, reliable and scalable methodology was developed for 
the synthesis of bromomaleimides. Bromomaleimide 22 is of considerable 
importance due to the possibility of functionalisation on the nitrogen atom, e.g. via a 
Mitsunobu reaction. However, for the purpose of building a library of compounds, 
the main target will be the N-methyl maleimides (both mono- and disubstituted). This 
avoids complications that may arise from the unprotected secondary imine.  
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II.1.2 Synthesis of thiomaleimides 
The synthesis of thiomaleimides 59 and 60 was achieved according to 
literature procedures,177 via the conjugate addition of the n-hexanethiol to 
bromomaleimide 22 and N-methyl bromomaleimide 57 respectively, in the presence 
of sodium acetate in methanol (Scheme 43). 
 
Scheme 43. Synthesis of thiomaleimides 59 – 60 
Treatment of N-methyl maleimide 57 with thiophenol under the same 
conditions as above, afforded the desired product 61 in a much lower yield (17%, 
isolated yield), the major product being the double addition product, 
dithiosuccinimide 63 (Scheme 44). Compound 62 was not isolated but its identity is 
confirmed by the 1H-NMR of the fraction containing impure 61. The formation of the 
double addition product suggests that the addition of thiophenol to thiomaleimide 61 
is as fast if not faster than the addition to the starting material, bromomaleimide 57. 
This outcome constrasts with the single thiol addition observed for the formation of 
thiomaleimide 60 and an explanation can be proposed by the relative contributions 
of the sulphur atoms to the electronics of the maleimide ring. In the case of 
thiomaleimide 60 the sulphur lone pair is readily available leading to mesomeric 
donation into the ring, deactivating it as conjugate acceptor. In the case of 
thiomaleimide 61 the sulphur lone pair is conjugated with the aromatic ring, reducing 
its mesomeric effect into the maleimide and thus retaining its electrophilicity. 
 
Scheme 44. Synthesis of thiolmaleimide 61 via a conjugate addition reaction 
With the aim of reducing the rate of formation of the diaddition product 62, 
the addition of thiophenol to N-methyl bromomaleimide 57 was performed at various 
temperatures between -70 °C and 20 °C. The desired product was obtained, as 
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confirmed by 1H-NMR, without dithiosuccinimide 62, at a temperature of -55 °C. 
Following the optimised protocol, thiomaleimide 61 was obtained in an optimised 
yield of 61%, the rest being unreacted starting material as seen in the 1H-NMR of 
the crude mixture (Scheme 45). 
 
Scheme 45. Optimised synthesis of the thiomaleimide 61 
The corresponding dithioether maleimides 63 and 64 were also synthesised 
in satisfactory yields, via the conjugate addition of the corresponding thiol to the 
commercially available N-methyl dibromomaleimide 65 (Scheme 46). The conditions 
for these reactions have been adapted from a literature procedure.142 
 
Scheme 46. Synthesis of dithiomaleimides 63 and 64 
II.1.3 Synthesis of sulfoxymaleimides 
With thiomaleimides 60, 61, 63 and 64 in hand, we set out to synthesise the 
corresponding sulfoxy analogues. This was attempted using m-chloroperbenzoic 
acid (m-CPBA) as the oxidising agent. It was shown that side reactions can be 
avoided by adding the oxidising agent dropwise and by performing the addition at -
10 °C. In this way, sulfoxymaleimide 66 was obtained quantitatively from 
thiomaleimide 60 (Scheme 47).  
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Scheme 47. Oxidation of thiomaleimide 60 to sulfoxymaleimide 66 
Despite literature precedent stating a quantitative yield for the synthesis of 
sulphoxymaleimide 67,178 when this protocol was followed, the crude 
sulphoxymaleimide product 67 contained approximately 15% (molar percent, based 
on 1H-NMR) of an unidentified product. The formation of the product is confirmed by 
a peak at 7.18 ppm, corresponding to the hydrogen on the double bond and by the 
peak at 2.98 ppm, corresponding to the methyl group on the nitrogen (Fig. 10). 
Attempts to purify it by flash chromatography and by washing it with sodium 
bicarbonate and sodium sulfite failed, due to the instability of product 67 on the silica 
gel. 
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Fig. 10. Oxidation of thiomaleimide 61 and the 1H-NMR spectrum of the resulting crude mixture 
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The oxidation of dithiomaleimides 63 and 64 was also performed and led in 
both cases to the mono oxidised products 68 and 69 (Scheme 48). Our attempts to 
further oxidise the products by longer reaction times and excess reagent failed as 
more degradation occurred. Compounds 68 and 69, however, were stable on silica 
gel which allowed purification by flash chromatography. 
 
Scheme 48. Oxidation of dithiomaleimides 63 and 64 
II.1.4 Synthesis of sulfonylmaleimides 
The first synthetic pathway explored for the synthesis of sulfonylmaleimides 
was the oxidation of the thioether maleimides. The oxidation of sulphides, using 
reagents such as H2O2, m-CPBA, KMnO4, CrO3/HIO5 is the most popular method to 
synthesise sulfones.179 Firstly, the oxidation of thiomaleimide 60 was attempted 
using 2 eq. of m-CPBA (at 0 °C for the duration of the addition, then at room 
temperature) but this led to very complex reaction mixture, containing side-products 
postulated to be derived from attack of the oxidising agent on the double bond (Fig. 
11). The reaction was attempted again, starting from sulfoxymaleimide 66 to which 1 
eq. m-CPBA was added but that too was unsuccessful. A different approach, based 
on H2O2 and ammonium heptamolibdate ((NH4)6Mo7O24∙4H20) as catalyst,179 also 
failed to give the desired product. The analysis of the crude mixtures could not be 
properly quantified due to the instability of some of the products (sulfoxymaleimides, 
epoxides) on silica gel.  
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Substrate Oxidising agent, (eq) Eq. Solvent Time (h) Temperature 
60 m-CPBA 2 CH2Cl2 21 0 °C → r.t. 
66 m-CPBA 1 CH2Cl2 10 0 °C → r.t. 
60 H2O2, (NH4)6Mo7O24∙4H2O 4 MeOH 0.5 r.t. 
Fig. 11. Unsuccessful oxidation conditions 
Scheme 49 outlines the retrosynthetic analysis for the synthesis of 
sulfonemaleimides wherein the key step is the base-induced dehalogenation of 
chlorinated sulfonylsuccinimide. These can be obtained by chlorination of the 
commercially available maleimide or N-methyl maleimide respectively. 
 
Scheme 49. Retrosynthetic route to sulfonylmaleimides 
First the Michael addition of sodium benzenesulfinate to maleimide and N-
methyl maleimide was explored (Scheme 50).180 The reaction is reversible but in a 
buffered aqueous medium, the formation of the product is favoured by its 
precipitation. Once the sulfonylsuccinimides 70 and 71 were obtained, they were 
chlorinated with N-chlorosuccinimide in carbon tetrachloride. Chlorination took place 
only in the α-position with respect to the sulfonyl. However, solids 72 and 73 were 
obtained as an inseparable mixture with succinimide 74 - the by-products of this 
reaction - and the unreacted chlorinating agent. Unfortunately, purification by flash 
chromatography or by recrystallization did not allow isolation of the desired 
products. 
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Scheme 50. Synthesis of the chlorinated sulfonylsuccinimides 72 and 73 
Another alternative to get sulfonemaleimides is to oxidise the 
sulfonylsuccinimides 70 and 71 to the corresponding maleimides by using an 
oxidising agent such as 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ), MnO2 or 
SeO2. A literature search on this topic yielded several papers describing DDQ 
oxidations of indolesuccinimides to the corresponding maleimides.181,182 Also, Duan 
et al. reported on the oxidation of a phenyl substituted succinimide using a mixture 
of DEAD and K2CO3.183 MnO2 is a mild oxidising agent,184 used for oxidations of 
activated bonds such as benzylic or allylic, while SeO2 is a stronger oxidising agent 
used successfully in the synthesis of various natural products.185,186 All of these 
protocols were tested and were found to be unsuccessful, the succinimide remaining 
inert under the reaction conditions (Scheme 51). 
 
Scheme 51. Attempts to oxidise succinimide 71  
A final oxidation reagent that was investigated was investigated was Oxone®. 
It was decided to first test the oxidising ability of this reagent on dithiosuccinimide 
62, as this avoids possible side reactions involving the double bond. 
Dithiosuccinimide 62 was obtained via conjugate addition of 2.2 eq. thiophenol to 
bromomaleimide 57 in excellent yield (95%), (Scheme 52a). The reaction between 
dithiosuccinimide 62 and Oxone® was performed in a mixture of methanol and 
64 
 
water, to ensure the solubility of all reactants. Surprisingly, instead of the expected 
di-oxidised product, product 76 was isolated in 23% yield (Scheme 52b). 
 
Scheme 52. a) Synthesis of dithiosuccinimide 62 and b) its oxidation with Oxone® 
One of the postulated mechanisms for the formation of 76 is depicted in 
Scheme 53. Once intermediate 77 is formed, the sulfoxy group abstracts the acidic 
proton α to the carbonyl, leading to sulfonylmaleimide 75. This intermediate is too 
reactive to be isolated and in the presence of excess methanol, undergoes attack on 
the double bond to afford the isolated product 76. 
 
Scheme 53. Postulated mechanism for the formation of 76 
In order to avoid the attack of the methoxy group, the reaction was 
performed in a mixture of water and tert-BuOH (Scheme 54). It was expected that 
the more bulky tert-butoxide group would not react with sulfonylmaleimide 75. This 
assumption proved correct however, in this case intermediate 75 reacted with the 
other solvent - water - as certified by the isolated product, 78.  
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Scheme 54. Oxidation of dithiosuccinimide 62 with Oxone® 
As the α-proton to the carbonyl in compound 62 was responsible for the 
formation of side products 76 and 78, it was decided to attempt this reaction on 
dithiomaleimide 63 (Scheme 55). This time the number of equivalents of oxidizing 
agent was reduced to 3 due to the risk of the Oxone® attack on the double bond. 
Oxidation took place only on one of the sulphur atoms, giving compound 68 in 49% 
yield after 18 h at room temperature. This same product was obtained when the 
oxidizing agent used was m-CPBA, suggesting that oxidation of both sulphur atoms 
is disfavored.  
 
Scheme 55. Oxidation of dithiomaleimide 63 with Oxone® 
In conclusion, sulfonylmaleimides proved very difficult to synthetise. The 
reaction with Oxone® suggests that these reagents are extremely reactive, due to 
the sulfonyl group which strongly activates the double bond towards nucleophilic 
attack. Even more, this provides the proof that they are unstable in water therefore 
they would be unsuitable as protein modification reagents. 
II.1.5 Synthesis of selenomaleimides 
While the diselenomaleimides had been previously synthesised in our group, 
187 a method was required for the synthesis of the monosubstituted analogue 79. In 
analogy with thiomaleimide 61, we envisaged the risk of double addition; 
consequently, the optimised conditions for the synthesis of 61 were employed. After 
completion of the addition of a stoichiometric amount of N-methyl bromomaleimide 
57 to a solution of benzeneselenol in methanol (45 min) at  -55 °C and another 15 
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min of stirring at room temperature, the desired product 79 was obtained in an 
excellent yield (92%), (Scheme 56a). 
The synthesis of the diselenomaleimide 80 from N-methyl dibromomaleimide 
65 was less efficient (Scheme 56b). The large excess of benzeneselenol used is 
due to the poor quality of the reagent (which during storage oxidises to give the 
diselenide) and should not be associated with a decrease reactivity of the selenate 
(PhSe-) towards the double bond in the maleimide ring. 
 
Scheme 56. Synthesis of selenomaleimides 79 and 80 
II.1.6 Synthesis of selenoxymaleimides 
With the aim of further activating the maleimide reagents towards thiol attack, 
the oxidation of selenomaleimides 79 and 80 was attempted. The oxidising reagent 
of choice was m-CPBA and the reactions were performed at -15 °C for 4 h and then 
room temperature, overnight. 
Unfortunataly, the desired oxidation products could not be obtained. When 
m-CPBA was added to the selenomaleimide 79, a mixture of diselenide 81, 
unreacted starting material 79 and the unexpected benzoatemaleimide 82 was 
formed (Scheme 57). 
 
Scheme 57. Oxidation of selenomaleimide 79 
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The postulated mechanism leading to the formation of compound 82 is 
shown in Scheme 58. First, the m-CPBA oxidises the selenomaleimide 79 via the 
classical mechanism. The resulting benzoate ion 83 attacks the double bond in 84 
and displaces the highly reactive selenoxide leaving group to give 
benzoatemaleimide 82 and PhSeOH. To our knowledge, this is the first example of 
a benzoatemaleimide.  
 
Scheme 58. Postulated mechanism for the formation of benzoatemaleimide 82 
In the case of diselenomaleimide 80, no trace of the oxidation product could 
be isolated (Scheme 59). Flash chromatography afforded unreacted starting 
material 80 (11%) and diselenide 81 (12%), indicating extensive degradation. 
 
Scheme 59. Oxidation of diselenomaleimide 80 
II.1.7 Synthesis of halomaleimides 
 Chloromaleimides 85 and 86 were obtained by conjugate addition of 
tetrabutylammonium chloride to the corresponding bromomaleimides, 22 and 57. 
The transformations required excess chlorinating agent (6 eq.) and refluxing the 
reaction mixture for 7 - 12 h, though the products were obtained in good yields 
(Scheme 60). 
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Scheme 60. Synthesis of chloromaleimides 85 and 86 
 For the synthesis of the iodomaleimides, two procedures were first 
employed: addition of iodine to maleimide (Scheme 61a) and addition of sodium 
iodide to dibromosuccinimide using the Finkelstein reaction conditions (Scheme 
61b). Both reactions failed to yield the desired diiodosuccinimide 87: in the case of 
iodine addition, the maleimide was fully recovered at the end of the reaction, proving 
to be completely unreactive towards iodine, while for the Finkelstein reaction, the 
desired bromo-iodo exchange did not take place.  
 
Scheme 61. Attempts to synthesise diiodosuccinimide 87 
  Next, the conjugate addition of an iodide source to bromomaleimide 57 was 
considered. The reaction was initially performed using 2 eq. of sodium iodide in 
MeOH, but under these conditions bromomaleimide 57 proved to be completely 
stable (Scheme 62a). A larger excess of NaI (6.5 eq.) and acetone instead as 
solvent finally lead to the desired product, iodomaleimide 88, in very high yield 
(81%), (Scheme 62b).188 Acetone enables the precipitation of the sodium bromide 
formed, favouring the formation of 88 by pushing the equilibrium towards the product 
side.  
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Scheme 62. Conjugate addition of sodium iodide to bromomaleimide 57 
 Diiodomaleimides 89 and 90 were synthesised according to a similar 
literature procedure in 70% and 74% yield (Scheme 63).189 The products were 
isolated by filtration after addition of water to the reaction mixture. 
 
Scheme 63. Synthesis of diiodomaleimides 89 and 90 
A mixed halomaleimide was considered to be of interest as well, most 
importantly because it would give more insight into the regioselectivity of the thiol 
attack. Bromochloromaleimide 91 was synthesised in one step from 
chloromaleimide 86 by bromination with 3 eq. of bromine, at reflux (Scheme 64). 
 
Scheme 64. Synthesis of the mixed halomaleimide 91 
II.1.8 Synthesis of aminomaleimides 
Some examples of aminomaleimides were required to complete the 
proposed maleimide library. n-Propylamine and aniline were chosen as 
representatives for alkyl and aromatic primary amines and reacted with 
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bromomaleimide 57, in the presence of sodium acetate, according to similar 
literature procedures (Scheme 65).177,190 All attempts to displace the bromine with 4-
nitroaniline failed, probably due to the electron withdrawing effect of the nitro group. 
This reduces the nucleophilicity of the amine by decreasing the density of electrons 
on the amino group. 
 
Scheme 65. Synthesis of aminomaleimides 92, 93 and 94 
II.1.9 Synthesis of alkoxy- and phenoxymaleimides 
Methoxymaleimide 95 was synthesised according to a literature procedure in 
25% yield.191 The low yield is likely due to the formation of the diaddition product, 96, 
as indicated by the 1H-NMR of the crude (Scheme 66).The second attack of the 
methoxy group is expected to take place α to the oxygen in the methoxy group due 
to the mesomeric electron donating effect of the substituent. 
 
Scheme 66. Synthesis of methoxymaleimide 95 
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The conjugate addition of phenol to dibromomaleimide has been previously 
reported in the literature (Scheme 67a).191 The reaction uses a strong base such as 
potassium tert-butoxide and needs to be performed under dry conditions in order to 
prevent hydrolysis of the maleimide. The second addition is known192 to be slowed 
down by the addition of the first phenoxy group, as this group will deactivate the β-
position by increasing its electron density making the attack of a nucleophile more 
difficult. This may in part account for the isolation of the bromophenoxymaleimide 99 
in 22% yield and the low yield of diphenoxymaleimide 100 (30%). In the case of 
dibromomaleimide 25, the yields obtained from products 97 and 98 are even 
smaller, probably due to side-reactions involving the imine. Next, the reactivity of 
bromomaleimide 57 towards phenol was investigated. Gratifyingly, the 
phenoxymaleimide product 101 was obtained in a satisfactory yield (75%) after just 
1 h at room temperature (Scheme 67b). 
 
Scheme 67. Conjugate addition of phenol to a) dibromomaleimide 25 and 65 and b) bromomaleimide 
57 
Furthermore, the scope of the reaction of mono- and dibromomaleimides 
with phenols was explored. Bromomaleimide 57 proved to be reactive towards 
phenols bearing electron withdrawing groups such as esters and nitro groups, 
however reaction with 4-carboxyphenol failed to afford the desired product 102 
(Scheme 68). The difficulty encountered with the latter reaction arises from the fact 
that 4-carboxyphenol has two acidic sites, with relative acidities of the carboxylic 
acid and phenol functional groups of pKa ~4.48 and ~9.32 respectively.193 This 
means the carboxylic acid group will be deprotonated first, followed by the phenol. 
An excess of tert-BuOK (pKa of conjugated acid = 17) was used to ensure double 
deprotonation. However, the failure of the reaction indicates that the dianion derived 
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from 4-carboxyphenol is potentially not nucleophilic enough to undergo the addition 
on the double bond. 
 
Scheme 68. Conjugate addition of phenols to bromomaleimide 57 
In contrast, dibromomaleimide 65 reacted with activated phenols such as 4-
methoxyphenol to give diphenoxymaleimide 105 and failed to react with deactivated 
phenols bearing electron withdrawing groups such as ester and nitro. Even when 
performed on the more reactive diiodomaleimide 90, the reaction with methyl 4-
hydroxybenzoate yielded the expected diphenoxymaleimide 107 in a very modest 
yield (13%), accompanied by the monosubstituted product 108 (10%), (Fig. 12). 
When diiodomaleimide was reacted with 4-nitrophenol, only the monosubstituted 
maleimide 106 (47%) was formed. These results highlight the decrease in 
nucleophilicity of the phenol with the installation of more electron withdrawing 
groups on the phenyl ring. 
 
X R 
Phenol 
(eq.) 
t-BuOK (eq.) Time (h) 
Product 1 
code, yield 
(%) 
Product 2 
code, yield 
(%) 
Br H 2.1 2.5 24 98, 30 97, 22 
Br OMe 2.1 2.5 20 105, 13 - 
I NO2 2.2 2.5 64 - 106, 47 
I COOMe 2.2 2.5 24 107, 13 108, 10 
Br COOMe 1.1 1.1 10 - 109, 63 
Fig. 12. Addition of phenol to dibromomaleimide 65 and diiodomaleimide 90 
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II.2  Investigation of maleimide analogues as reagents for 
cysteine and disulphide bridging 
 Having synthesised the maleimide analogues described above, we 
proceeded to the next stage of the study: the testing of their reactivity towards 
cysteine. A selection of compounds was tested on our model systems: the protected 
cysteine 21, Grb2 SH2 (L111C) 26 and somatostatin 29. However, given our interest 
in protein labelling reagents, Grb2 SH2 (L111C) 26 was preferred to N-Boc-Cys-
OMe 21. The next section of this report contains the most significant results 
obtained. 
II.2.1 Reactivity of thiomaleimide 61 towards N-Boc-Cys-OMe 21 
 Treatment of the N-Boc-Cys-OMe 21 with a small excess (1.1 eq.) of 
thiomaleimide 61 in the presence of sodium acetate (1 eq.) resulted in a complex 
mixture of products, which could not be separated by flash chromatography. 
Scheme 69 shows tentatively proposed products observed in the 1H-NMR of the 
mixture. Dithiosuccinimide 111 can be present as four diastereoisomers which may 
serve to complicate their isolation. Given the complexity of the product mixture, it 
was concluded that this reagent is not useful for cysteine labelling.  
 
Scheme 69. Reaction of thiomaleimide 61 with the protected cysteine 21 
II.2.2 Reactivity of sulfoxymaleimides 
Sulfoxymaleimides bear a strongly electron withdrawing group on the double 
bond and are therefore expected to be highly reactive towards nucleophiles such as 
the thiol groups of cysteine. 
As for thiophenolmaleimide 61, the reactivity of sulfoxymaleimide analogues 
66 and 67 towards cysteine was first explored on the protected cysteine 21. The 
addition of stoichiometric amounts of the two sulfoxymaleimides 66 and 67 resulted 
in the expected thiomaleimide 110 in 74% and 59% yield respectively. The isolated 
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products were contaminated with <5% molar percent of the oxidised cysteine 112 
which could not be separated from the products by standard chromatographic 
means. The reactions were very fast, reaching completion within 5 min (Scheme 
70).  
 
Scheme 70. Reaction of sulfoxymaleimides 66 and 67 with the protected cysteine 21 
 Having shown that sulfoxymaleimides were successful in the labelling the 
protected cysteine 21, the next step was to explore their reactivity in a more relevant 
biological system. The study of the reactivity of N-methyl sulphoxymaleimide 66 
towards a cysteine in a protein was performed using Grb2 SH2 (L111C) 26 as a 
model system. Standard conditions for the Grb2 experiments, which were used 
throughout the entire study, were a protein concentration of 1 mg/mL in phosphate 
buffer pH 8 (50 mM) and 1.14 mM reagent stock solutions in DMF. When 100 eq. of 
the labelling reagent were used, the stock solution was 11.4 mM, to minimise the 
amount of organic solvent added to the reaction mixture. All reactions were carried 
out at 0 °C, using an ice bath. The progress of the reactions was monitored by LC-
MS, by calculating the ratios between the peak heights of the native and the 
modified protein in the mass spectrum. 
 As shown in Fig. 13, rapid (< 5 min) and complete labelling of protein 26 (M = 
14170) to give the Grb2-N-methyl-thiomaleimide conjugate 113 (M = 14280) was 
achieved using 4 eq. of sulphoxymaleimide 66. When 1 and 2 eq. of reagent 66 
were used, the conversion after 5 min was only 40% and 64% respectively. Longer 
reaction times did not improve the conversion, indicating that the starting material 
had degraded. This could be related to the strong electron withdrawing effect of the 
sulfoxy group, which renders the maleimide double bond more electrophilic 
therefore favouring hydrolysis. For the sake of comparison, the LC-MS data for the 
reaction between the Grb2 SH2 (L111C) 26 and 1 eq. of N-methyl bromomaleimide 
57 was also plotted.  
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Fig. 13. Labelling of Grb2 SH2 (L111C) with sulfoxymaleimide 66 
 To attempt to identify if sulfoxymaleimides were more reactive than 
bromomaleimides, a competition experiment between sulfoxymaleimide 66 and 
bromomaleimide 22 was designed. For this Grb2 SH2 (L111C) 26 was added to an 
equimolar mixture of the two reagents under investigation, using the same 
concentration of the protein, temperature and buffer as described above. LC-MS of 
the reaction mixture after 1 min shows that when 2 eq. of each of the reagents were 
used, the major product is the Grb2-thiomaleimide conjugate 114 (M = 14266), the 
one derived from bromomaleimide 22 (Fig. 14). The same experiment was repeated 
with 4 eq. of each of the two reagents led to the reversal of the product distribution, 
with the Grb2-N-methyl thiomaleimide conjugate 113 (M = 14280), the one derived 
from sulfoxymaleimide 66 as the major product (Fig. 14). This shows that 66 is 
indeed more reactive than 22 but due to the instability of sulfoxymaleimides in 
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aqueous environment, it must be used in excess, to allow the reagent to be present 
in stoichiometric quantity with respect to the protein to be labelled. 
 
 
Fig. 14. Competition experiment between bromomaleimide 22 and sulfoxymaleimide 66 
 The same comments made for compound 66 apply to compound 67; with 1 
eq. of sulfoxymaleimide 67, the conversion after 5 min was only 21% and after 1 h, 
39% (Fig. 15). From the reaction profiles we can observe that the reaction does not 
progress any further after 5 - 10 min. This is assumed to be due to the instability of 
this class of reagents in water. When 4 eq. of maleimide 67 were used, the 
conversion was 78% after 5 min and 95% after 1 h. 
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Fig. 15. Labelling of Grb2 SH2 (L111C) with sulfoxymaleimide 67 
In conclusion, the labelling of Grb2 SH2 (L111C) 26 can be achieved with 
sulfoxymaleimide 66 and 67. Sulfoxymaleimides appear to display an enhanced 
reactivity compared to bromomaleimdes. However this is achieved at the expense of 
their stability in aqueous environment which makes the addition of excess reagent 
mandatory for pushing the reaction to completion. In terms of practical use, there is 
no advantage in using sulfoxymaleimides over bromomaleimides. This result might 
also indicate that reagents faster than bromomaleimides might be too unstable to be 
used efficiently as protein labelling reagents. 
II.2.3 Reactivity of halomaleimides towards Grb2 SH2 (L111C) 
Having synthesised three different halomaleimides, the next step was to 
compare their reactivity towards cysteine and understand the correlation between 
the halogen substituent and the reactivity of the labelling reagent. The reactions of 
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the previously described halomaleimides 86, 57 and 88 with Grb2 SH2 (L111C) 26 
were performed under standard conditions (pH 8, 0 °C) and monitored by LC-MS. 
As shown in Fig. 16, the three halomaleimides display very similar reactivity. All 
reactions reached 100% conversion within 1 h leading to the Grb2-N-methyl 
thiomaleimide conjugate 113 (M = 14280) as the sole product. The only time point 
where a significant difference can be seen is the 5 min time point. Based on this, the 
order of reactivity is: 86 < 57 < 88. This is in accordance with the leaving group 
ability of the halogens (Cl < Br< I). A kinetic study was designed in order to compare 
their reactivity more rigorously (see Chapter II.3). 
 
 
Fig. 16. Labelling of Grb2 SH2 (L111C) with halomaleimides 86, 57 and 88 
In conclusion, the halomaleimides described above are efficient cysteine 
labelling reagents.  
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II.2.4 Reactivity of alkoxy- and phenoxymaleimides towards Grb2 SH2 
(L111C) 
 Compound 95 was designed as a representative of an alkoxy-substituted 
maleimide and compounds 101, 103 and 104 as examples of aryloxymaleimides. To 
the best of our knowledge, the use of such reagents in the area of protein 
modification has not been yet reported. The alkoxy and aryloxy substituents have an 
electron withdrawing effect by induction, due to the high electronegativity of oxygen 
and an electron donating effect by conjugation, enabled by the lone pair of electrons 
on the oxygen atom next to the double bond of the maleimide ring. The strong 
mesomeric effect is expected to activate the α-position to the substituent towards 
nucleophilic attack by increasing the density of electrons in the β-position. 
 Treatment of Grb2 SH2 (L111C) 26 with 100 eq. of methoxymaleimide 95 
led, after 2 h, to a mixture of Grb2-N-methyl thiosuccinimide conjugate 115 (M = 
14312), (84%) and Grb2-N-methyl thiomaleimide conjugate 113 (M = 14280), (16%).  
 
 
Fig. 17. Reaction of Grb2 SH2 (L111C) with methoxymaleimide 95 
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Due to the strong mesomeric effect of the methoxy group, the thiol attack is 
expected to be α to the oxygen leading to the succinimide conjugate 115 (M = 
14312) as drawn in Fig. 17. The high percentage is due to the poor leaving group 
ability of the methoxy group. The need for such a large amount of reagent and the 
long reagent times highlight the fact that the alkoxymaleimides are very unreactive 
compared to the halomaleimides. This is correlated to the strong electron donating 
effect of the alkoxy group. 
To further investigate the regioselectiviy of the thiol addition to 
methoxymaleimide 95, it was decided to use n-hexane thiol as a model thiol as this 
would allow 1H-NMR analysis of the product. When 10 eq. of n-hexanethiol were 
reacted with methoxymaleimide 95, product 116 was obtained almost quantitatively 
(90%) proving that the thiol attack took place α to the oxygen (Scheme 71). This is 
to be expected based on the strong mesomeric and inductive effects of exerted by 
the methoxy group and supports the structure that was proposed for the protein 
conjugate 115. 
 
Scheme 71. Reaction between n-hexanethiol and methoxymaleimide 95 
As seen in Fig. 18, phenoxymaleimides are significantly less reactive than 
bromomaleimide 57. Reaction of Grb2 SH2 (L111C) 26 with 1 eq. of each of the 
various analogues results in moderate conversions (30% - 60%) after 1 h. All 
reactions led to the formation of the expected product, Grb2-N-methyl thiomaleimide 
conjugate 113 (M = 14280) only. The difference in the reactivity between 101 and 
103 and 104 respectively indicates that fine tuning of the reactivity of these 
compounds is possible by installing substituents on the phenyl ring. Reagents 
bearing electron withdrawing group on the phenyl ring are expected to be more 
reactive than the unsubstituted phenoxymaleimide 101. Indeed, the experimental 
results indicate this trend with the nitro substituted phenoxymaleimide 103 being 
faster than 101. There is not much difference between compounds 104 and 101, 
suggesting that the methyl ester does not exert a strong enough electron 
withdrawing effect. 
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Fig. 18. Reactivity of selected phenoxymaleimides towards Grb2 (L11C) SH2 
 The reaction between maleimide 103 and Grb2 SH2 (L111C) 26 was 
monitored over 2 h with a maximum yield of 74% being reached. The rate of 
reaction was significantly decreased, which could indicate a certain degree of 
degradation of the reagent or that the reagent was not present in stoichiometric 
amount. In an attempt to improve the yield of the transformation, the amount of 
phenoxymaleimide 101 was increased to 10 eq.. Gratifyingly, the reaction reached 
completion within 10 min.  
 In conclusion, alkoxymaleimides and phenoxymaleimides are less reactive 
than bromomaleimides. They have a different reactivity profile arising from the 
electronic effects of the substituents and the leaving group ability difference (pKa 
(PhOH) = 10 while pKa (MeOH) = 15). Alkoxymaleimides lead mainly to addition 
products such as Grb2-alkoxysuccinimide adduct 115 (M = 14312) while 
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phenoxymaleimides undergo the addition-elimination sequence giving Grb2-
thiomaleimide conjugate 113 (M = 12280) only. Thiosuccinimide type products, 
similar to the ones obtained when maleimide is added to a thiol, are more resistant 
in thiol rich envirnments therefore their use is preffered if the conjugate is subjected 
to such conditions. The use of the less reactive phenoxymaleimide can be of use in 
the context of selective labelling of the most reactive cysteine only, on a protein 
substrate bearing at least two cysteines, with enough difference in reactivity. Such 
differences in the reactivity of cysteine residues have been reported in the literature 
by Moody et al.194 and are the basis for dual modification of proteins strategies. Fast 
and efficient conversion to the maleimide labelled Grb2 SH2 (L111C) 26 was 
achieved when using a excess (10 eq.) of phenoxymaleimide 101.  
II.2.5 Reactivity of aminomaleimides towards Grb2 SH2 (L111C) 
 The amino group has a strong electron donating effect by mesomerism 
which deactivates the maleimide ring towards nucleophilic attack. We were 
interested to check the degree of deactivation, therefore the reactivity of 
aminomaleimides 92 - 94 towards cysteine in Grb2 SH2 (L111C) 26 was 
investigated.  
 Treatment of Grb2 SH2 (L111C) 26 with 100 eq. of 92, 93 or 94 did not lead 
to any reaction after 2 h at 0 °C suggesting that, under these conditions, the 
reagents are completely unreactive towards cysteine (Scheme 72). In conclusion, 
aminomaleimides are unsuitable for cysteine labelling. This is due to the strong 
deactivation induced by the amino substituents. 
 
Scheme 72. Reaction of aminomaleimides 92 - 94 with Grb2 SH2 (L111C)  
II.2.6 Reactivity of benzoatemaleimide 82 towards Grb2 SH2 (L111C) 
 As opposed to amino groups, the benzoate group has electron an 
withdrawing effect both by induction and mesomerism. This is expected to activate 
the ring towards nucleophilic attack. 
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The reaction between 1 eq. of benzoatemaleimides 82 and Grb2 SH2 
(L111C) 26 was performed and monitored by LC-MS over 2 h. Scheme 73 shows 
the composition of the reaction mixture after 2 h: 61% of unreacted Grb2 SH2 
(L111C) 26, 12% of N-methyl Grb2 thiomaleimide conjugate 113 and 27% of an 
unidentified product with a mass of M = 14307. Benzoate maleimide is therefore 
unsuitable for cysteine labelling as it leads to the formation of a side-product. The 
conversion could be increased by using excess reagent but that might increase the 
yield of the side product as well. Further investigation is required.  
 
Scheme 73. Reaction of Grb2 SH2 (L111C) with benzoatemaleimide 82 
II.2.7 Reactivity of selenomaleimide 79 towards Grb2 SH2 (L111C) 
 Similar with the work with the other reagents, the reaction between Grb2 
SH2 (L111C) and 1 eq. selenomaleimide 79 was performed and then monitored by 
LC-MS over 1 h. The reaction mixture after 1 h contained 20% unreacted Grb2 SH2 
(L111C) 26, 54% the expected Grb2-N-methyl thiomaleimide conjugate 113 and 
26% of product 117 with a mass M = 14321, for which we suggest the structure 
shown below (Scheme 74). The formation of compounds such as 117 is 
documented in the literature and is due to the strong oxidising capacity of the 
selenide ion. This preliminary result shows the low potential of using this reagent for 
the cysteine labelling. 
 
Scheme 74. Labelling of Grb2 SH2 (L111C) with selenomaleimide 79 
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II.2.8 Reactivity of thiosulfoxymaleimides towards somatostatin 
 Having shown that the dithiomaleimides such as 63 can be efficiently 
employed for disulphide bridging, it was envisaged that the replacement of one of 
the thiophenol substituents with the more electron withdrawing sulfoxy group would 
increase the rate of reaction with reduced disulphides whilst preserving the bridging 
ability of the reagent. In order to assess the utility of this class of reagents, 
disubstituted maleimides 68 and 69 were reacted with somatostatin 29, the 
previously employed model system in the Baker group.  
 The first step of the stepwise bridging protocol involves the reduction of the 
disulphide bond in somatostatin. This is achieved by treating somatostatin 29 with 
1.5 eq. of TCEP at pH 6.4 (50 mM phosphate buffer, 20% CH3CN, 2.5 % DMF) for 1 
h. In order to probe the completion of the reduction of the disulphide bond, an 
aliquot of the reduced peptide solution 118 is reacted with with 5 eq. of the 
commercially available dibromomaleimide 25 for 5 min (Scheme 75).  
 
Scheme 75. Reduction and reduction-probing steps 
As the LC-MS spectrum of this mixture showed only the bridged 
somatostatin 119 (M = 1734), confirming completion of the reduction step, the 
addition of 1 eq. of disubstituted maleimide 68 was performed (Fig. 19). LC-MS 
analysis of the reaction mixture after 5 min shows that the mixture consisted of 
unreacted somatostatin 29 (M = 1640) and bridged product 120 (M = 1748) in a 1 : 2 
molar ratio. Approximately the same ratio was obtained when 2 eq. of 68 were 
employed. It is also important to highlight that the reactions did not proceed any 
further after 5 min, which is presumably due to the instability of these reagents in 
water, in a similar fashion to sulfoxymaleimides 66 and 67. When 6 eq. of maleimide 
68 were used, conversion was 90%, proving the potential utility of these reagents to 
act as disulphide bridging reagents.  
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Fig. 19. Stepwise bridging of somatostatin using thiosulfoxymaleimides 68 - 69 
 In conclusion, except for some very small peaks, bridging reaction of 
somatostatin with 6 eq. of maleimide 68 is sufficiently clean. On the other hand, 
reaction between reagent 69 and somatostatin 29 led to a complex mixture 
consisting of the expected bridged product (M = 1648) and three other unidentified 
side products (M = 1756, M = 1982 and M = 2090). In this case, the reduced peptide 
was fully used up within the first 5 min. This reactivity pattern makes compound 15 
unsuitable for disulphide bridging. 
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II.2.9 Reactivity of diphenoxymaleimides towards somatostatin 
The reaction between 1 eq. of diphenoxymaleimide 100 and somatostatin 29 
was investigated (Fig. 20). Gratifyingly, the reaction lead to the maleimide bridged 
somatostatin conjugate 120 (M = 1748). However, the conversion after 1 h was only 
34%, much lower than with dibromomaleimide 65, which gave full conversion in just 
10 min with the same number of equivalents.83 To speed up the reaction, the 
number of eq. of diphenoxymaleimide 100 was increased to 10 and 100 respectively 
in which cases the reaction reached completion within 1 h and 10 min respectively. 
 
 
Fig. 20. Bridging of somatostatin with diphenoxymaleimide 100 
 Reagent 100 was shown to be compatible with the in situ protocol, which 
consists in adding the reducing agent immediately after the labelling reagent had 
been mixed with the peptide, so that the disulphide bond reacts as soon as it is 
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reduced. With 3 eq. of TCEP and 100 eq. of diphenoxymaleimide 100, the 
conversion reached after just 10 min was 92 %. 
The assumption that reduced somatostatin 118 undergoes oxidation, 
preventing the reaction from reaching completion is supported by the fact that the 
conversion increased when the amount of TCEP was increased from 1.5 to 3 eq 
(Fig. 20). This also suggests that there is no significant cross-reactivity between 100 
and the reducing agent TCEP. 
It was hypothesised that the reactivity and water solubility of 
phenoxymaleimides can be tuned by adding substituents on the phenyl rings.  
 
 
Fig. 21. Reactivity profile towards somatostatin of diphenoxymaleimide 100 compared to analogues 
105 and 107 
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Electron withdrawing substituents (COOMe, NO2) are expected to speed up 
the bridging as they would activate the double bond towards nucleophilic attack, 
while electron donating substituents (OMe) are expected to have the opposite effect. 
To illustrate this, di(para-methoxy)phenoxymaleimide 105 (Fig. 21),and, at the other 
end of the spectrum, di(para-methylester)phenoxymaleimide 107 were synthesised. 
Indeed, experimental results confirm the expected reactivity trend (Fig. 21). 
These results prove that the diphenoxymaleimides are slower bridging 
reagents compared to dibromomaleimide. The reason for this is the electron 
donating effect of the phenoxy groups deactivates the double bond towards 
nucleophlilic attack by increasing the electron charge density. This makes these 
reagents potentially useful for the selective labelling of the most reactive disulphide 
bond residues in proteins. They are especially recommended in cases where the in 
situ protocol is preferred, as results indicate no cross-reactivity with TCEP. 
II.2.10 Reactivity of halophenoxymaleimides towards somatostatin and 
Grb2 SH2 (L111C) 
 This class of compounds is interesting due to their potential to act as 
disulphide bond labelling reagents but also to illustrate the influence of the 
substituents on the double bond on the regioselectivity of the thiol attack. 
 To investigate the regioselectivity of the thiol addition to substituted 
maeimides, Grb2 SH2 (L111C) 26 was treated with 1 eq. of 99 and the reaction was 
monitored by LC-MS over 45 min. After this time, the reaction mixture contained 
unreacted Grb2 SH2 (L111C) 26 (70%), the rest being a species with M = 14359 
that corresponds to structure 121 (Fig. 22). The formation of a sole protein 
conjugate suggests a clear selectivity for phenoxy displacement over bromine.  
 
Fig. 22. Reaction of Grb2 SH2 (L111C) with halophenoxymaleimide 99 
The proposed mechanism is as follows: firstly, the thiolate attacks the α-
position on the double bond, which is the carbon with the lowest electron density to 
give intermediate 122; this is followed by elimination of the phenoxy group, to give 
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product 121 (Scheme 76). This shows that it is the electronic effect of the leaving 
groups and not the leaving group ability (pKa) that dictates which of the two 
substituents is displaced by thiol. 
 
Scheme 76. Postulated mechanism for the formation of conjugate 121 
 Next, the potential utility of these reagents to act as disulphide bridging 
reagents was explored. Using the stepwise protocol reaction conditions, the labelling 
of somatostatin 29 with 1 eq. iodophenoxymaleimide 108 was complete within 1 
min, which makes it the fastest disubstituted maleimide tested so far (Scheme 77). 
Reagent 108 performed less well in the in situ protocol (1.5 eq. of TCEP, 1 eq. 
iodophenoxymaleimide 108) where the conversion was 73%, after 40 min, which 
could indicate a certain degree of cross-reactivity of such reagents with TCEP. 
 
Scheme 77. Stepwise bridging of somatostatin with iodophenoxymaleimide 108 
 To further asses the reactivity of these reagents, a competition experiment 
with dibromomaleimide was designed (Scheme 78). The experiment is based on the 
fact that the two reagents have a different substituent on the nitrogen atom, giving 
somatostatin conjugates with different masses. When a mixture of 1 eq. of 
iodophenoxymaleimide 108 and 1 eq. of dibromomaleimide 25 was treated with 1 
eq. of somatostatin 29, a 40 : 60 mixture of N-methyl maleimide bridged 
somatostatin adduct 120 (M = 1748) and maleimide bridged somatostatin conjugate 
119 (M = 1734) was obtained. This shows that reagent 108 is slightly less reactive 
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towards somatostatin 29 compared to dibromomaleimide 25. This feature could 
become more obvious on a less reactive substrate.  
 
Scheme 78. Competition experiment between reagents 108 and 25 for bridging somatostatin 
 Reaction of 1 eq. of iodophenoxymaleimide 108 with Grb2 SH2 (L111C) 26 
gave conjugate 123 proves that the attack of the thiol takes place α to the oxygen 
part of the phenoxy group, as expected considering the strong mesomeric effect of 
the oxygen part of the phenoxy group. 
In order to evaluate the contribution of the iodine substituent in the reactivity 
of 108, the corresponding bromomaleimide analogue 109 was synthesised and then 
the reactivity of the two reagents was assessed using Grb2 SH2 (L111C) 26 as 
model system. Fig. 23 shows that 108 is marginally faster than 109, which suggests 
that the iodine has a weaker deactivating effect on the β-carbon atom compared to 
bromine. This is in accordance with the trend of increasing strength of the 
mesomeric effect in the order I < Br, which is proportional to the orbital overlap 
between the orbital of the carbon and the halogen atom. 
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Fig. 23. Comparison between the reactivity of compounds 108 and 109 towards Grb2 SH2 (L111C)  
The same experiments were repeated using iodophenoxymaleimide 106. In 
the stepwise protocol complete labelling of somatostatin 29 was achieved in 1 min 
(Scheme 79). Following the in situ protocol (1.5 eq. of TCEP, 1 eq. 
iodophenoxymaleimide 106) a maximum conversion of 61% was achieved after 55 
min. A 93% conversion was achieved by increasing the amount of TCEP to 3 eq.. 
This supports the assumption that the lower conversions in the experiment carried 
out with 1.5 eq. TCEP are due to the reoxidation of somatostatin rather than cross-
reactivity between the labelling reagent and TCEP. 
 
Scheme 79. Stepwise bridging of somatostatin with iodophenoxymaleimide 106 
In conclusion, halophenoxymaleimides are very fast disulphide bridging 
reagents, very similar in reactivity to the dibromomaleimide, as suggested by the 
competition experiments. The conversions are very high both in the in situ and 
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stepwise protocols, indicating a negligible cross-reactivity between the 
halophenoxymaleimides and TCEP. They are also very useful compounds as they 
allow the study of the regioselectivity of the thiol addition to the disubstituted 
maleimide. 
II.2.11 Reactivity of bromochloromaleimide 91 
The asymmetric dihalomaleimide 91 represents an interesting substrate for 
the study of the regioselectivity of the thiol addition to substituted maleimides. The 
reaction between 1 eq. of bromochloromaleimide 91 was performed, under standard 
conditions and the reaction mixture was analysed by LC-MS over 1 h. Fig. 24 shows 
the abundance of the products present in the reaction mixture.  
 
 
Fig. 24. Labelling of Grb2 SH2 (L111C) with bromochloromaleimide 91 
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The first observation that can be made is that the reaction does not reach 
completion in the time-frame investigated, with around 23% of the unreacted Grb2 
SH2 (L111C) protein being detected in the reaction mixture after 1 h. This can be 
due to an error in the measurement of exactly 1 eq. of reagent. The other 
observation is that the reaction does lead to two different products, 121 and 124, 
indicating that the attack of the thiol takes place at both positions on the double 
bond. 
Additionally, the experimental results indicate that product 121 is formed 
preferentally over product 124, the final abundances in the reaction mixture after 10 
min being 50% for 121 and 25% for 124. The reaction was monitored for another 50 
min, with no significant improvement in the conversion. 
To explain the formation of conjugate 121 as a major product, it is essential 
to consider the the electronic effects of the two substituents: chlorine and bromine 
are both electron withdrawing by induction (I-) and electron donating by conjugation 
(M+), (Fig. 25). Both effects activate the α-position to the halogen towards 
nucleophilic attack. Based on the variation of the strength of these effects as 
depicted in Fig. 25, it was predicted that the preffered attack will be at the α-carbon 
atom with respect to the chloro substituent. Formation of product 121 as the major 
product confirms that it is the electronic effect of the substituents and not the leaving 
group ability that is key for the regioselectivity of the reaction.  
 
Fig. 25. Electronic effects of bromine and chlorine and the thiol addition to bromochloromaleimide 91 
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II.3 Kinetic study  
II.3.1 Purpose 
The kinetic study was performed with the aim of quantifying and comparing 
the reactivity of various monosubstituted maleimides towards the free cysteine 
groups in proteins. So far, the standard method employed by our group has been to 
monitor the reaction between the maleimide under investigation and Grb2 SH2 
(L111C) by LC-MS.139 This method allows the comparison between different 
reagents and gives a qualitative indication of reaction rate, but lacks accuracy. 
Additionally, the monosubstituted halomaleimides (iodomaleimide 88, 
bromomaleimide 57 and chloromaleimide 86) labelled Grb2 SH2 (L111C) very 
quickly, the only time point where a difference could be detected being after 1 min. 
The need for an assay with better time resolution became clear. A kinetic study was 
consequently designed to enable a more quantitative comparison between the 
reagents tested by finding the rate equation for the addition of cysteine to 
monosubstituted maleimides. 
II.3.2 Selection of the method and preliminary tests 
The chosen method to monitor the reaction was UV-spectroscopy. 
Thiomaleimides show an absorbance maximum around 350 nm, therefore it was 
decided to see whether this could be exploited.177 It was envisaged that the reaction 
progress could be monitored by the increase in the absorbance of the peak 
corresponding to the thiomaleimide product. For this to be possible, the two starting 
materials (the maleimide and the thiol) must not absorb in the same region as the 
product and the reaction must yield thiomaleimide only.  
Initial tests were conducted using bromomaleimide 57, which does not 
absorb above 300 nm. The UV-spectra of Grb2 SH2 (L111C) 26 was recorded. 
Unfortunately, the protein showed a significant absorbance in the region of interest, 
350 nm. We then focused on finding a small molecule thiol and selected 2-
mercaptoethanol, mainly due to its water solubility. As it did not absorb around 350 
nm, it became the reagent of choice. The reaction between bromomaleimide 57 and 
2-mercaptoethanol was performed in pH 6 buffer, containing 20% CH3CN to ensure 
the solubility for all reagents. Gratifyingly the UV-spectrum of the reaction mixture 
after 1 h, showed a peak with an absorbance maximum at 360 nm, that was 
attributed to the thiomaleimide product 125 (Scheme 80).  
95 
 
 
Scheme 80. Reaction of maleimide 57 with 2-mercaptoethanol 
 As the initial results were promising, it was important to make sure that the 
other maleimide analogues obeyed the condition stated above; thus the UV-spectra 
of bromomaleimide 57, chloromaleimide 86, iodomaleimide 88, phenoxymaleimide 
101 and 4-nitro phenoxymaleimide 103 were recorded under the reaction conditions. 
Fig. 26 shows that except for the 4-nitro phenoxymaleimide 103, the rest of the 
analogues that we selected for this kinetic study do not present a significant 
absorbance at 360 nm. 
 
 
Figure 26. UV-absorbance spectra of substituted maleimides and 2-mercaptoethanol  
(67 μM in phosphate buffer pH 6, 20% CH3CN) 
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II.3.3 Results obtained with 2-mercaptoethanol as model system 
 Several parameters (pH, temperature, concentration of reagents, setup) 
were varied in order to determine the optimal reaction conditions. The optimised 
concentration of the two reagents is 167 μM in phosphate buffer pH 6 (20% 
CH3CN). Reactions were done at room temperature. 
 A calibration curve was plotted using different concentrations of 2-
mercaptoethanolmaleimide 125 synthesised in the lab (Fig. 27).  
 
Fig. 27. Calibration curve for mercaptoethanolmaleimide 125 (concentrations between 40 μM and 150 
μM in phosphate buffer 20% CH3CN) 
The linear equation shown below will allow the correlation of the absorbance 
peak at 360 nm (x) to the concentration of thiomaleimide formed (y) and is essential 
for signalling the end-point of the reaction. 
𝑦 = 0.0032 ∙ 𝑥 − 0.009       (Equation 1) 
 The reaction between 57 and 2-mercaptoethanol was performed under the 
optimised conditions and the absorbance peak at 360 nm was monitored over 10 
min (Fig. 28).  
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Fig. 28. Experimental data for the reaction of bromomaleimide 57 and 2-mercaptoethanol to the model 
system 
 Experimental data was corrected by substracting the signal given by the 
background from the experimental values of the absorbance: 
𝐴𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑=𝐴360 − 𝐴𝑏𝑘 , where A360 = absorbance of the sample at 360 nm 
                                               Abk = absorbance of the solvent at 360 nm 
Then the difference between the final (t = 10 min) and the initial (t0 = 0 min) 
absorbance at 360 nm, ΔA, was calculated which, was introduced in Equation 1 to 
generate the corresponding thiomalemide concentration. This corresponds to a 
conversion of 95%. The next step was fitting for the experimental data with a 
theoretical model. The rate equations for first and second order reactions were 
tested but they did not fit the experimental curve. Further attempts to determine the 
order of the reaction (i.e. the method of pseudo first order conditions) were not 
possible in our case as the system did not allow use of excess thiol, as this would 
convert the product into a dithiosuccinimide which could not detected by UV-
spectroscopy. 
We then tested the other maleimides, under the same conditions: 
concentration of the two reagents was 167 μM in pH 6 phosphate buffer (20% 
CH3CN) and room temperature. The reactions with iodomaleimide 88 and 
chloromaleimide 86 were monitored over the same period of time, 10 min, whereas 
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the phenoxymaleimide 101 proved to be a much slower reagent therefore the 
progress of the reaction was monitored over 60 min (Fig. 29). The reaction curves 
reached a plateau at the time when the acquisition was stopped so it is assumed 
that either reached completion or an equilibrium point. 
 
 
Fig. 29. Comparison between the reaction profiles of monosubstituted maleimide analogues  
with 2-mercaptoethanol 
 The same analysis of the experimental data was performed for the other 
analogues (Table 4).  
Maleimide ΔAbs 
Yield 
thiomaleimide 
125 (%) 
Δ Abs 
corrected 
Corrected yield 
thiomaleimide 125 
corrected (%) 
57 0.507 95 - - 
86 0.469 88 0.462 86 
88 0.232 43 0.287 54 
101 0.153 31 0.192 36 
Table 2. Conversions of the reactions of selected substituted maleimides with 2-mercaptoethanol 
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 The influence of the maleimide on the absorbption at 360 nm was considered 
and corrected values for the conversion were obtained. The difference is most 
obvious in the case of iodomaleimide 88 which is the analogue with the highest 
absorbance at 360 nm. 
In conclusion, experimental results show an unexpected feature of these 
reactions: they do not reach completion. The phenoxymaleimide 101 was expected 
to be a slow reagent from the way it reacted with Grb2 SH2 (L111C). Results based 
on UV-absorbance data confirm this but the fact that the yield with respect to the 
thiomaleimide is low (~30%) and that it does not seem to increase if left to react for 
longer could be due to the oxidation of the 2-mercaptoethanol or degradation of the 
labelling reagent via hydrolysis.  
 A more surprising result is the one for the reaction between iodomaleimide 
88 and 2-mercaptoethanol, which was expected to be the fastest reaction. However 
the amount of thiomaleimide 125 formed was very small (~50%), which indicates 
that some side reactions are taking place. The distinguishing factor for this reaction 
from the other two involving the bromo- and chloromaleimide respectively is that the 
iodide is the most nucleophilic. Side reactions could therefore involve addition of the 
iodide onto the thiomaleimide product, leading to a iodothiosucinimide. 
In conclusion, 2-mercaptoethanol is not a suitable model system as the 
reactions with the different maleimides do not reach completion. This is in direct 
contrast with the results obtained for the Grb2 SH2 (L111C) 26, where LC-MS 
results indicate the reactions have gone to completion. The reasoning that was 
found for this difference in reactivity is that 2-mercaptorethanol is a small molecule 
and therefore it is more reactive (i.e. due to steric factors, electronic effects) 
compared to a protein such as Grb2 SH2 (L111C) 26. A new model system was 
required and after a screening of several thiol containing molecules, reduced 
gluthathione became the reagent of choice as it showed no absorbtion around 360 
nm and was readily available.  
II.3.4 Results obtained with gluthathione as model system 
After an initial screening of optimal conditions (pH, concentration, amount of 
organic solvent), 75 μL of reduced GSH (300 μM in pH 6 50 mM phosphate buffer) 
were added to 75 μL bromomaleimide 57 (300 μM in 50 mM phosphate buffer pH 6, 
20% CH3CN) and the reaction mixture was left to stand for 1 h at room temperature. 
Fig. 30 shows the UV spectra of the starting material and the reaction mixture after 1 
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h. A clearly visible peak with a maximum at 360 nm was observed, alongside the 
disappearance of the peaks characteristic to the starting materials. 
 
Fig. 30. UV absorbance spectra of the starting materials and of the reaction mixture of 57 (300 μM) 
with GSH (300 μM) in phosphate buffer pH 6 (10% CH3CN) after 1 h and background correction 
 As with the experiments with 2-mercaptoethanol, the yield of the 
thiomaleimide product was corrected after recording the UV spectra of the 
maleimide partner. Next, the reactions between GSH and the three halomaleimides 
were performed and monitored by the evolution of the peak at 360 nm. As can be 
seen from Fig. 31, the reaction progresses up to a maximum value of the 
absorbance and then instead of the expected plateau, is followed by a descending 
curve. This tendency is most significant for the iodo derivative 88. Same as before, 
the explanation for the disappearance of the product is attributed to the side 
reactions promoted by the iodide on the product (e.g. addition of the halide ion to the 
resulting thiomaleimide). The yields for all three of the reactions were calculated and 
are given in Table 3. A corrected version of the yields, that considers the influence 
of the maleimides on the product peak, is also provided. 
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Fig. 31. Reaction profiles between GSH and the various maleimide analogues at 150 μM in phosphate 
buffer pH 6 10% CH3CN 
 From this moment on, the analysis of data was based on the assumption that 
at the time point where the peak at 360 nm was at its maximum, the reaction 
reached completion. The reaction between bromomaleimide 57 and GSH was taken 
as a reference and it was assumed to be quantitative. 
Maleimide ΔAbs 
Yield thiomaleimide 
126 (%) 
ΔAbs 
corrected 
Yield thiomaleimide 126 
after correction (%) 
57 0.387 100 - - 
86 0.339 87 0.342 89 
88 0.298 77 0.392 100 
Table 3. Conversions for the reactions between halomaleimides and GSH 
 Reaction profiles were similar to the ones obtained with 2-mercaptoethanol. 
Our attempts to fit the experimental data to a simple rate equation were 
unsuccessful. This suggests that the system is characterised by a complex rate 
equation. The data obtained is in accordance with the LC-MS data on Grb2 SH2 
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(L111C) protein: phenoxymaleimide 101 is significantly slower than halomaleimides 
57, 86, 88 and that chloromaleimide 86 is slower than bromomaleimide 57.  
As mentioned above, the reaction of maleimides with GSH cannot be 
accurately monitored by LC-MS because of the low molecular weights involved. It 
was decided to attempt to use 1H-NMR to analyse the reaction mixtures for the 
chloro- and bromomaleimide and in this way explain the disappearance of the 
product and why the reaction with chloromaleimide 86 does not reach completion. 
 The reactions were carried out at a concentration of 1.67 mM in 150 μM 
phosphate buffer pH 6 containing 10 % CD3CN. The high concentration was 
necessary to ensure a good quality 1H-NMR spectrum for product 126. The samples 
were prepared by mixing the reaction mixture with deuterium oxide in a 9 : 1 volume 
ratio the spectrum was obtained on a 400 MHz NMR spectrometer, using a Water 
suppression tool and having 80 scans. The 1H-NMR spectra for the reactions of the 
two halomaleimides signalled the glutathionethiomaleimide conjugate 126 based the 
peak at 6.56 ppm (Scheme 81). 
 
Scheme 81. Reaction between bromomaleimide 57/chloromaleimide 86 and GSH 
However, due to the signal to noise ratio, it was not possible to eliminate the 
possibility of side product formation, making the experiment inconclusive. The pH 
screen (pH 4 to 6) was performed in the attempt to slow down the reaction and also 
see if the intermediate succinimide can be detected but no signs of this intermediate 
were observed. 
II.4 Succinimide bridging of disulphide bonds 
While the utility of disubstituted maleimides such as dibromomaleimide and 
dithiophenolmaleimide in disulphide labelling has been extensively explored, the use 
of monosubstituted maleimides has not been studied. The reaction between a 
reduced disulphide bond and a monosubstituted maleimide is expected to lead a 
dithiosuccinimide bridge as route b in Scheme 82, as opposed to disubstituted 
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maleimides such as dibromomaleimide and dithiomaleimide which lead to a 
maleimide bridge as in route a in Scheme 82. Such dithiosuccinimides are expected 
to have different properties to dithiomaleimides (e.g. different reactivity with thiols, 
hydrolytic stability etc.) and could serve as a complementary approach to disulphide 
bridging. 
 
Scheme 82. Reactivity of disubstituted (route a) and monosubstituted (route b) maleimides towards a 
reduced disulphide 
However, previous experiments conducted by L. Tedaldi, have shown that 
when 2.2 eq. of bromomaleimide 22 were reacted with reduced somatostatin 118, 
the product of the reaction was exclusively the bis-labelled peptide 127 (M = 1834), 
(Scheme 83).177 This suggests that the rate of addition of a second molecule of 
bromomaleimide 22 is higher than the rate of the intramolecular thiol attack on the 
thiomaleimide. 
 
Scheme 83. Reaction between reduced somatostatin and bromomaleimide 22 
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Having shown that phenoxymaleimides display a lower reactivity towards 
cysteine groups in peptides and proteins, we envisaged that this new class of 
reagents would also display a different reactivity pattern towards disulphide bonds 
compared to the highly reactive bromomaleimides. 
To test this hypothesis, reduced somatostatin 118 was treated with various 
amounts of bromomaleimide 57 and phenoxymaleimide 101 respectively (Fig. 32).  
 
X Eq. Time (min) Yield 128 (%) Yield 129 (%) 
Br 1.5 10 70 30 
OPh 1.5 10 100 0 
Br 2.5 60 22 78 
OPh 2.5 60 100 0 
OPh 10 60 100 0 
Fig. 32. LC-MS based analysis of reactions between monosubstituted maleimides 57 and 101 and 
reduced somatostatin  
When 1.5 eq. of each of the reagents were used, the reaction with 
bromomaleimide 57 led to a mixture of succinimide bridged conjugate 128 (M = 
1750) and bis-labelled adduct 129 (M = 1862) in a 7 : 3 molar ratio, while the 
reaction with phenoxymaleimide lead only to the succinimide bridged conjugate 128. 
The reactions were repeated in the presence of a larger excess of reagent (2.5 eq.). 
In the case of the bromomaleimide reaction, the same product mixture was obtained 
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but this time the distribution of the product was inverted: 78% bis-labelled conjugate 
129 and 22% succinimide bridged adduct 128. Increasing the amount of 
phenoxymaleimide 101 to 2.5 eq. and 10 eq. led to no change in the reaction 
outcome, the only product detected being the succinimide bridged conjugate 128 
(Fig. 32). 
These results indicate that the bromomaleimide 57 prefers to add to the two 
cysteines rather than undergo the intramolecular cyclisation leading to the 
succinimide bridged adduct 128. Phenoxymaleimide 101, being less reactive, reacts 
with one of the two cysteine groups and then the double bond of the maleimide is 
attacked by the second cysteine in a conjugate addition type reaction. The 
experimental results show that the intermolecular second addition of a 
phenoxymaleimide molecule to the free cysteine leading to 129 is slower than the 
intramolecular cyclisation leading to the succinimide bridged product 128.  
To support this first set of results, a competition experiment between 
bromomaleimide 22 and phenoxymaleimide 101 was designed (Fig. 33). First an 
equimolar mixture of 22 and 101 (1.5 eq of each, 1 : 1 molar ratio) was treated with 
reduced somatostatin 118 and then the reaction was repeated starting from a 1 : 5 
molar mixture of 22 and 101 (1.5 eq. of 22 and 7.5 eq. of 101). The different 
functionalisation of the nitrogen atom chosen allowed the identification of the 
maleimide that had reacted. In both cases, a mixture of the succinimide bridged 
adduct 130 (M = 1736) and the bis-labelled adduct 127 (M = 1834) was obtained 
and based on their masses, it was possible to conclude that the products are 
derived from the bromomaleimide addition only.  
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22 (eq.) 101 (eq.) Time (h) Yield 130 (%) Yield 127 (%) 
1.5 1.5 0.08 56 46 
1.5 1.5 16 20 80 
1.5 7.5 0.08 51 49 
1.5 7.5 16 17 83 
Fig. 33. Competition experiments between bromomaleimide 22 and phenoxymaleimide 101 
The easiest way to test for the presence of free thiols, and therefore confirm 
the completion of the succinimide bridging is to add a reactive electrophile, known to 
react with thiols, such as maleimide. The succinimide bridged somatostatin 
conjugate 128 was treated with 1 eq. maleimide. LC-MS after 5 min of incubation at 
room temperature showed no sign of any reaction, indicating the absence of free 
thiols in the system (Scheme 84). 
 
Scheme 84. Reaction of succinimide bridged somatostatin conjugate 128 with maleimide  
In conclusion, by using reagents of tuned reactivity, succinimide bridging of 
the reduced disulphide bond in somatostatin was achieved. At this point it is 
important to highlight the fact that as opposed to maleimide bridging, which affords a 
single product 131, succinimide bridging affords 132 as a diastereoisomeric mixture 
of products (Fig. 34). In order to best make use of this strategy in biological systems, 
a very clear understanding of its structural properties will be required. From the 
small molecule work conducted so far, we anticipate that the trans isomers will be 
favoured but further investigation has not yet been conducted. 
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Fig. 34. Maleimide bridged biomolecule 131 and succinimide bridged biomolecule 132 
Having demonstrated that N-methyl phenoxymaleimide displays a high 
selectivity for succinimide bridging over the double addition, the next step was to 
test the scope of this bioconjugation approach and to prove its utility. For the latter 
aim, we set out to synthesise some useful N-functionalised phenoxymaleimides. The 
synthetic strategies employed are detailed in the next section.  
II.4.1 Synthesis of N-functionalised phenoxymaleimides 
Commonly employed protein tags are PEG chains, used mainly to enhance 
in vivo stability and water solubility of compounds, and fluorophores, for visualisation 
purposes. We therefore decided to functionalise the nitrogen atom of 
phenoxymaleimide with a fluorophore and a mini-PEG chain respectively. 
Rhodamine B was the fluorophore of choice as it has very good properties for 
imaging: broad fluorescence in the red spectrum of visible light, high quantum yield, 
and good photostability.195 Aromatic substituents on the nitrogen atom are known to 
induce changes in the electron distribution across the maleimide ring and therefore 
increase the reagent’s susceptibility to hydrolysis; consequently a representative of 
N-aryl phenoxymaleimides was targeted. 
The targeted compounds were 133 - 135 (Scheme 85); the original synthetic 
plan involved firstly the nitrogen functionalisation of bromomaleimide and a 
subsequent conjugate addition reaction with phenol. The bromomaleimide would be 
obtained via either a condensation reaction between the bromomaleic anhydride 
and the appropriate amine (Scheme 85, route a), starting from the activated N-
methoxycarbonyl bromomaleimide, by addition of the amine (Scheme 85, route b) or 
from the already functionalised maleimide, by bromination and subsequent 
dehydrobromination (Scheme 85, route c). 
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Scheme 85. Retrosynthetic routes for the synthesis of N-functionalised phenoxymaleimides 
A one step procedure starting from the phenoxymaleic anhydride 136 is not 
possible as it is anticipated that its synthesis would be highly disfavoured. This is 
due to the expected high selectivity of phenol (hard nucleophile) for the attack on the 
carbonyl groups (hard electrophile) of the bromomaleic anhydride rather than on the 
double bond (soft electrophile), (Scheme 86). 
 
Scheme 86. Reaction between phenol and bromomaleic anhydride 
Following the route described in Scheme 85c, N-phenyl phenoxymaleimide 
135 was synthesised in two steps starting from commercially available N-phenyl 
maleimide 137. The bromination of 137 was performed under standard conditions, 
while the dehydrobromination was achieved using the acid-catalysed mechanism 
described in Chapter II.1. The conjugate addition of phenol to the N-phenyl 
bromomaleimide 138 was successful but afforded the desired product 139 in a 
modest yield (36%), (Scheme 87). The low yield is associated with repeated column 
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chromatography to obtain pure product and also to the formation of side products, 
as indicated by the TLC of the reaction mixture.  
 
Scheme 87. Synthesis of N-phenyl phenoxymaleimide 139 
For the preparation of an N-PEGylated analogue it was decided to use a 3 
unit PEG chain, which has the advantage of being homogenous and therefore 
enables 1H-NMR analysis of the product. The 3 unit PEG amine 140 was prepared 
in three steps with an overall yield of 41%, according to a literature procedure 
(Scheme 88).196 The commercially available PEG chain 141 was reacted with tosyl 
chloride, to give the activated tosylated analogue 142. The SN2 displacement with 
sodium azide required heating for an extended time period and excess reagent due 
to the weak nucleophilicity of the sodium azide. In the end, the desired PEG-amine 
140 was obtained via a Staudinger reduction, using triphenylphosphine. 
 
Scheme 88. Synthesis of PEG amine 140 
With the PEG-amine 140 in hand, the synthesis of the N-PEG 
phenoxymaleimide 133 was straightforward, starting from the activated N-
methoxycarbonyl bromomaleimide 144 (Scheme 89).  
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Scheme 89. Synthesis of N-PEG phenoxymaleimide 133 
This synthetic route was developed in the Baker group and represents a mild 
method for the synthesis of N-functionalised bromomaleimides, avoiding the harsh 
conditions required by the two other routes (routes a and c in Scheme 85).197 This 
route is particularly useful when the amine contains sensitive functionalities. Another 
advantage of this route is the ease of synthesising the N-methoxycarbonyl 
bromomaleimide 144; this is obtained in quantitative yield from bromomaleimide 22 
by addition of methyl chloroformate in the presence of N-methyl morpholine. The 
product is not stable during flash chromatography on silica gel but this kind of 
purification is not required, as after the extraction with CH2Cl2 the product is free of 
impurities. The nucleophilic displacement with the amine to give N-PEG 
bromomaleimide 145 proceeded with a yield of 44% and lastly, the bromide was 
displaced by phenol, under the standard conditions detailed in Chapter II.1. 
The final targeted phenoxymaleimide was the N-rhodamine labelled 
derivative 134. Having a literature precedent for the synthesis of the N-rhodamine 
labelled bromomaleimide 147,149 it was decided to prepare 147 and then attempt the 
conjugate addition with phenol (Scheme 90). Rhodamine-bromomaleimide 
derivative 147 was generated by condensation of the bromomaleic anhydride with 
intermediate 149. The low yield in the final step is associated with difficulties in 
purification.  
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Scheme 90. Synthesis of N-rhodamine bromomaleimide 147 
Unfortunately, the conjugate addition with phenol on bromomaleimide 147 
was unsuccessful and the starting material was fully recovered (Scheme 91).  
 
Scheme 91. Conjugate addition of phenol to bromomaleimide 147 
The next strategy that was explored was the route involving the carbamate 
chemistry, which required N-methoxycarbonyl phenoxymaleimide 151 to be 
synthesised. Unfortunately, the addition of phenol to N-methoxycarbonyl 
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bromomaleimide 144 did not lead to the desired product 151 (Scheme 92). This is 
likely due to the competing addition of the phenoxide, a hard nucleophile, to the 
carbonyls. 
 
Scheme 92. Conjugate addition of phenol to N-methoxycarbonyl bromomaleimide 144 
This led to the necessity of synthesising phenoxymaleimide 152 followed by 
its activatation with methyl chloroformate (Scheme 93). Initial attempts to displace 
the bromide in 22 with phenol led to a complex mixture of products, likely caused by 
the oligomerisation initiated by deprotonation of the imide. The problem was solved 
by performing the reaction at a high concentration of phenol (17 mM) and increasing 
the temperature to 40 °C. Under these conditions, the carbamate could then be 
installed in an excellent yield (95%). 
 
Scheme 93. Synthesis of N-methoxycarbonyl phenoxymaleimide 151 
Unfortunately, the reaction between 151 and the rhodamine-amine derivative 
149 was unsuccessful (Scheme 94). The reaction was performed in the presence of 
DBU as a base, which was required to free the amine in 149. This result was 
however not very surprising as previous results within the Baker group198 indicated 
the N-methoxycarbonyl substituted maleimides tend to react less readily with bulky 
amines.  
 
Scheme 94. Reaction between phenoxymaleimide 151 and rhodamine amine 149 
113 
 
It was then decided to attempt the labelling of phenoxymaleimide with 
rhodamine using the Huisgens [3+2] cycloaddition reaction. The alkyne functionality 
required for the click reaction was easily installed on the nitrogen atom of the 
phenoxymaleimide, by reacting the N-methoxycarbonyl phenoxymaleimide 151 with 
propargyl amine (Scheme 95). A literature search provided a highly efficient route 
towards azido-rhodamine derivative 154,199 starting from rhodamine B and 
azidoethanol 155,200 which in turn is synthesised by nucleophilic displacement with 
sodium azide from commercially available chloroethanol (Scheme 96). With both the 
alkyne and azide components in hand, the click reaction was attempted using an 
adapted literature protocol,201 and gratifyingly yielded the desired N-rhodamine 
labelled phenoxymaleimide 156 in a good yield (62%).  
 
Scheme 95. Convergent synthesis of N-rhodamine phenoxymaleimide 156 
II.4.2 Synthesis of water soluble phenoxymaleimides 
Water solubility is a key feature of protein labelling reagents as it contributes 
to the preservation of the stability of the biomolecule by allowing the transformation 
to take place in buffer. The aim was to synthesise a water soluble 
phenoxymaleimide derivative. The typical way of increasing the water solubility of an 
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organic compound is by decorating it with hydrophilic groups such as carboxylic 
acids (COOH), PEG chains ((OCH2CH2)n) or sulfonates ((SO3)2-). 
The following work is the result of a collaboration with Masters’s student 
Patrick Mayer. It was decided to install the hydrophilic tag on the phenyl ring in order 
to retain the three points of attachment of phenoxymaleimide for further conjugation. 
We first set out to test the influence on the water solubility of a carboxylic group and 
a mini-PEG chain respectively.  
Following the synthetic route developed by Masters’s student P. Mayer, the 
water soluble phenoxymaleimide 157 was prepared in a 6.9% overall yield, 2.9% 
higher than the one previously reported.202 The synthesis involves the synthesis of 
the protected carboxylic acid phenoxymaleimide 158 under standard conditions via 
conjugate addition of phenol 159 to bromomaleimide (55%). Phenol 159 was 
prepared according to a literature procedure (Scheme 96).203 Compound 158 was 
then subjected to standard deprotection conditions (32 eq. TFA, 19 eq. thioanisole, 
4 h, CH2Cl2)204 to give the desired p-carboxylic acid phenoxymaleimide 102 in a 
satisfactory yield (61%). The synthesis was completed by a HBTU/HOBt amide 
coupling with the already prepared PEG-amine 140. 
 
Scheme 96. Synthesis of water-soluble phenoxymaleimides 157  
The water solubility of the tested reagents was measured by Patrick Mayer in 
pH 6.4 buffer (50 mM sodium phosphate), as this was the pH used for the disulphide 
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bridging of somatostatin. Phenoxymaleimide 157 displayed a solubility of 1.20 
mmol/mL which was compatible with the succinimide bridging protocol used so far. 
II.4.3 In situ succininimide bridging of disulphide bonds 
In analogy to the maleimide bridging of disulphide bonds developed within 
our group, we were interested to see whether the succinimide bridging could be 
performed in situ. This means that the reducing agent is added to a mixture of the 
peptide and the labelling reagent so that as soon as the disulphide bond is reduced 
it reacts with the labelling reagent. In this way, the time the disulphide bond stays in 
its reduced form is minimised.  
To test this, a sample of somatostatin 29 (200 µM, 50 mM sodium phosphate 
buffer, pH 6.4, 40% CH3CN, 2.5% DMF) was mixed with phenoxymaleimide 101 
(1.5 eq.) and TCEP (1.5 eq.) was added to the resulting mixture (Scheme 97). LC-
MS analysis after 2 h at room temperature indicated full conversion of native 
somatostatin 29 to the succininimide bridged product 128. 
 
Scheme 97. In situ succinimide bridging of somatostatin  
Phenoxymaleimides are the first of the reagents tested so far within the 
library to display no cross-reactivity with TCEP. Therefore they are ideal reagents for 
the in situ protocol. 
II.4.4 Scope of the stepwise succinimide bridging of disulphide bonds 
Having demonstrated that the reaction between reduced somatostatin and 
phenoxymaleimide (1.5 - 10 eq.) leads rapidly and quantitatively to the succinimide 
bridged peptide, we wanted to explore the scope of this strategy regarding to the 
protein substrate and also prove its utility in the area of protein modification by using 
reagents bearing useful tags (e.g. fluorophores, PEG chains).  
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Firstly, the successful bridging of somatostatin with N-functionalised 
phenoxymaleimides was shown.  
The two reagents investigated were the N-pegylayed and rhodamine labelled 
phenoxymaleimides 133 and 156. The pegylation proceeded smoothly both 
stepwise and in situ, with equimolar amounts of the reducing and labelling reagents 
(1.5 eq. each), (Scheme 98). 
 
Scheme 98. PEGylation of somatostatin  
Next, labelling with the N-rhodamine labelled phenoxymaleimide 156 was 
achieved. The transformation required developing an optimized protocol consisting 
of the addition of phenoxymaleimide 156 (1.2 eq.) to reduced somatostatin followed 
by addition of an additional portion of TCEP (0.6 eq.) after 30 min of incubation at 
room temperature (Scheme 99). 
 
Scheme 99. Stepwise succinimide bridging of somatostatin with N-rhodamine phenoxymaleimide 156 
Another peptide studied within the group is the peptide octreotide, which is 
the clinical analogue of somatostatin, marketed by Roche and mainly used for the 
treatment of acromegaly.205 Octreotide 163 is a 8-amino acid peptide and is supplied 
as the acetate salt. Masters student Hanno Kossen showed that indeed, the 
succininimide bridging of octreotide can be achieved under very similar conditions  
to the ones described for somatostatin (Scheme 100).206 
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Scheme 100. Succinimide bridging of octreotide with phenoxymalemide 103 
The next step was to investigate the applicability of this method on large 
proteins. Antibody fragments are now highly valued for their utility in 
therapeutics207,208 (e.g. synthesis of antibody-drug conjugates, tumor imaging) and 
therefore their labelling with useful functionalities (e.g. drugs, fluorophores, PEG 
chains) would bebeneficial. The model systems chosen were Trastuzumab Fab, 
Rituximab Fab and the shMFE disulphide-stabilised variable fragment (ds-scFv), 
each containing a single disulphide bond.  
Rituximab (Rituxan ®, Genentech) is a chimeric monoclonal antibody that 
targets the human CD20 cell surface antigen.209 It has received FDA approval to be 
used as a therapeutic reagent for non-Hodgkin’s lymphoma and rheumatoid arthritis. 
Trastuzumab (Herceptin) is a monoclonal IgG1 antibody that binds to HER2/neu 
receptor and has received FDA approval for the treatment of certain breast and 
gastric cancers.210 The disulphide bond of interest in Fab fragments is between the 
heavy and light chains and is distal to the antigen-binding site. The ds-scFv 
fragment used has been developed by the group of Prof. Chester (UCL Cancer 
Institute) and targets the carcinoembrionic antigen (CEA). The two domains are 
linked by a artificially inserted peptide linker and a disulphide bond, for extra 
stability.211 This particular interdomain disulphide bond is our target for the 
succinimide bridging. 
Rituximab Fab was provided by Dr. Felix Schumacher187 in the Baker group 
at UCL and the anti-CEA ds-scFv by Dr. Berend Tolner in the Chester group at UCL 
Cancer Institute. Trastuzumab Fab was prepared by pepsin and papain digest, 
following a literature protocol.212 
Rituximab Fab 165 was successfully pegylated with phenoxymaleimide 146 
(Scheme 101). The two step procedure, also referred to as the “stepwise protocol”, 
begins with the reduction of the protein using TCEP (30 eq.). After completion of the 
reduction step (which can be checked by LC-MS), the protein was buffer swapped 
into PBS (pH 7.4) containing EDTA (1 mM), to remove the unreacted reducing agent 
and avoid reoxidation of the disulphide bond. The labelling reagent 146 (5 eq.) was 
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then added and the resulting mixture was incubated for 1 h at room temperature. 
This afforded the succinimide bridged Rituximab Fab 166 as the sole product of the 
reaction. 
 
Scheme 101. Stepwise succinimide bridging of Rituximab Fab with phenoxymaleimide 146 
Similarly, Herceptin (Trastuzumab) Fab 167 was successfully labelled using 
phenoxymaleimide 101 (Scheme 102). The main difference in the protocol 
compared with that for Rituximab Fab 165 is in the reduction step, which was 
performed in this case in pH 8 borate buffer and at 37 °C with just 2 eq. of TCEP. No 
purification between steps was necessary hence the labelling reagent 101 (2 eq.) 
was added immediately after the reduction had been confirmed by LC-MS. This 
protocol is referred to as “sequential bridging”. 
 
Scheme 102. Sequential succinimide bridging of Trastuzumab Fab with phenoxymaleimide 101 
Finally, the disulphide bond stabilised scFv (ds-scFv) 33 was labelled with 
101 and 146. The bridging protocol was adapted from the one reported by Dr. 
Schumacher in the Baker group.187 The bridging was performed in situ and consists 
of the addition of the labelling regent (5 eq. in the case of 101 and 25 eq. in the case 
of 146) and of reducing agent, benzeneselenol (15 eq. for the reaction involving 101 
and 50 eq. for the reaction involving 146) simultaneously (Scheme 103). The 
increased amounts of labelling and reducing reagents required when 
phenoxymaleimide 146 was used can be correlated to the larger size of this reagent 
compared to the N-methylated analogue 101 and to the fact that the disulphide bond 
is not very solvent-exposed. This is in accordance with the observations of Dr. 
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Schumacher in the Baker group who observed the lack of reactivity of the ds-scFv 
towards TCEP as a result of the steric bulk of TCEP. 
 
Scheme 103. Succinimide bridging of ds-scFv  
To highlight the utility of phenoxymaleimides, the reaction between ds-scFv 
33 and bromomaleimide 57 was performed under the same conditions. This reaction 
afforded just unreacted starting material, due to the cross-reactivity between 
bromomaleimide and benzeneselenol. 
II.4.5 Organic solvent free succinimide labelling of somatostatin 
As mentioned before, water soluble reagents for protein labelling are highly 
sought after due to the concern that the addition of organic solvents to proteins can 
disturb their tertiary structures and therefore interfere with their biological activity. 
Phenoxymaleimide 157 was designed as a water soluble representative of this class 
of compounds, and it was shown to have a solubility of 10 mM in pH 6.4 50 mM 
phosphate buffer, at room temperature. It was chosen to be the ideal candidate for 
attempting the succinimide bridging of somatostatin 29 under organic solvent free 
conditions. Consequently, a solution of somatostatin (200 μM, pH 6.4 50 mM 
phosphate buffer) was mixed with phenoxymaleimide 157 (1.5 eq., 10 mM stock 
solution in the same buffer) and the water soluble reducing agent TCEP added 
(Scheme 104). LC-MS analysis of the reaction mixture indicated completion of the 
reaction after 4 h of incubation at room temperature.  
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Scheme 104. In situ organic solvent-free succinimide bridging of somatostatin 
This is the first example of a completely organic free disulphide bridging 
reaction involving substituted maleimides. 
II.4.6 Stability of the succinimide bridged conjugates towards thiols 
The stability of protein conjugates towards thiols is of significant importance 
especially in the case of protein drug conjugates which must survive plasma 
conditions in order to reach the targeted site. Body plasma contains several species 
with free thiol groups such as free cysteine, homocysteine, reduced glutathione and 
albumin,213 while the intracellular environment is particularly rich in glutathione, 
which can reach concentrations of up to 11 mM.214 
The stability of succinimide bridged conjugates towards thiols was assessed 
in parallel to the corresponding maleimide bridged constructs. As mentioned in the 
introduction chapter, the maleimide bridge undergoes cleavage in the presence of 
excess thiols such as 2-mercaptoethanol or glutathione.139 However, when 
hydrolysed, the resulting maleamic acid conjugates are no longer susceptible to thiol 
attack.141 
For the following experiments, somatostatin 29 and ds-scFv 33 were used as 
model systems.  
First, somatostatin conjugates 128 and 120 were prepared as 200 µM 
solutions in pH 6.4 phosphate buffer containing 40% CH3CN and 2.5% DMF, 
according to the general procedures for the stepwise bridging of somatostatin with 
phenoxymaleimides and dibromomaleimide respectively (Experimental section). 
Then a large excess (100 eq.) of 2-mercaptoethanol was added and the resulting 
solutions kept on ice for 13 h. Fig. 35 shows the percentage of cleavage to the 
reduced peptide undergone by the two constructs over time. The maleimide bridged 
conjugate 120, expected to undergo rapid cleavage in the presence of such a large 
excess of thiol, did indeed lose the maleimide tag (80% degradation) within the first 
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hour. In the same time, the succinimide bridged somatostatin conjugate 128 was 
stable. Even after 13 h, LC-MS analysis of the sample containing succinimide 
bridged somatostatin conjugate 128 indicated that just 13% of 128 underwent 
cleavage. The small difference between the 1 h and the 13 h time points for 
conjugate 128 can be explained by the oxidation of the 2-mercaptoethanol, over 
time, to the corresponding disulphide. 
The same experiment was carried out using reduced glutathione. This is of 
particular significance, considering the abundance of glutathione in the body. Fig. 35 
shows the extent of cleavage of conjugates 120 and 128 when placed in a medium 
with a high concentration of thiol. This is consistent with the previous set of results. 
In this case however, the succinimide bridged somatostatin 128 does not undergo 
any degradation, even after 13 h on ice. This can be explained by the fact that 
glutathione, being more bulky, is slightly less reactive than 2-mercaptoethanol.  
 
Thiol Time (h) 
Cleaved to reduced 
somatostatin 118 (%) 
128 120 
2-Mercaptoethanol  
1 0 80 
13 13 85 
Glutathione  
1 0 16 
13 0 80 
 
Fig. 35. LC-MS based thiol stability analysis of somatostatin conjugates 128 and 120 
The thiol stability of the maleimide bridged ds-scFv 171 has been studied 
and reported by Schumacher et al.;146 a direct comparison with the corresponding 
succinimide analogue was desirable. For this, the succinimide bridged construct 169 
was synthesised. In his study, Dr. Schumacher reported complete cleavage of the 
maleimide bridge after 48 h at ambient temperature in the presence of a large 
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excess (100 eq.) of glutathione or 2-mercaptoethanol (Fig. 36). On the other hand, 
the succinimide bridged construct 169 was completely stable even after the 48 h 
incubation.  
 
Thiol (100 eq.) Time (h) 
Cleaved to reduced 
somatostatin 118 (%) 
169 171 
2-mercaptoethanol  
48 
0 100 
Glutathione 0 100 
Fig. 36. LC-MS based thiol stability analysis of ds-scFv conjugates 169 and 171 
In conclusion, for substrates containing a less accessible disulphide bond, 
such as ds-scFv 33 explored in this work, the succinimide tag is likely to have a 
longer in vivo half-life compared to the maleimide tag. The two approaches have 
complimentary applications; while the quick cleavage under high thiol concentrations 
of the maleimide tag can be used for drug-release into cells, the succinimide version 
will provide a slower or negligible release, depending on the time frame considered. 
The succinimide bridging can potentially be used for applications where 
irreversibility of labelling is desired, such as fluorescent tagging for visualisation 
purposes. 
Encouraged by these results, the next experiment was designed to assess 
the stability of the two somatostatin conjugates 128 and 120 under cytoplasm 
mimicking conditions. Conjugates 128 and 120 were prepared as before and then 
dialysed into 20 mM HEPES buffer (100 mM KCl, 1 mM MgCl2, 1 mM EDTA, pH 
7.4). The concentration of the peptide conjugates was adjusted to 100 μM and the 
resulting reaction mixtures were incubated at 37 °C for 21 h in the presence of 1 mM 
reduced glutathione. As we can see from Fig. 37, the succinimide bridged construct 
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128 is indeed more stable than the maleimide bridged analogue 120. After 21 h, 
there was no more 129 and around 27% 128 (results not shown on the graph). 
However, this set of results shows that at 37 °C, the relevant temperature for in vivo 
applications, even the succinimide bridge undergoes cleavage of the tag.  
 
Fig. 37. Stability of somatostatin conjugates 128 and 120 under cytoplasm mimicking conditions  
To explain the reactivity of the succinimide bridged construct 128 in the 
presence of excess thiol, we propose the mechanism depicted in Scheme 105. 
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Scheme 105. Postulated mechanism for the cleavage of the succinimide bridge in conjugate 128 in the 
presence of excess thiol 
We postulate that conjugate 128 is in equilibrium with the product of the retro-
Michael addition, conjugate 173. The equilibrium is shifted to the side of the 
succinimide bridged product but in the presence of excess thiol, conjugate 128 will 
be completely consumed. This is because intermediate 173 reacts with thiols in a 
conjugate addition type reaction, undergoing cleavage of the maleimide tag. This is 
in accordance with previous reports within the group.139 
An elegant way to completely inhibit the reaction of the succinimide bridged 
construct with thiols could be hydrolysis of the succinimide ring (Scheme 106). By 
hydryolysing the maleimide ring, the pKa of the α-protons to the carbonyls would 
increase, preventing the retro-Michael addition which preceeds the loss of the 
maleimide tag. This hypothesis was inspired by the method developped within our 
group to render the maleimide bridged conjugates inactive to thiols.141 
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Scheme 106. Strategy for rendering the succinimide bridged constructs thiol stable 
Therefore the next step was to investigate ways to achieve controlled 
hydrolysis of the succinimide ring. For this we decided to focus on N-phenyl 
phenoxymaleimides which are known to be more susceptible to hydrolysis than the 
N-alkyl analogues.215 Once again, these experiments were performed in parallel with 
the investigation of the maleimide bridging strategy, so that the two approaches can 
be more accurately compared. 
For this we prepared conjugates 174 and 175, according to the general 
procedure for bridging somatostatin with phenoxymaleimides and 
dibromomaleimides respectively, and then dialysed them into pH 8 phosphate buffer 
(50 mM sodium phosphate) for 12 h at 0 oC. The N-phenyl dibromomaleimide 176, 
necessary for the synthesis of conjugate 175 was prepared according to a literature 
procedure.189 The concentration of the peptide conjugates was adjusted to 100 μM 
and an aliquot taken and analysed by LC-MS. The remaining reaction mixtures were 
incubated at 37 °C for 1 h and then analysed by LC-MS (Fig. 38). Hydrolysis of both 
conjugates happens during dialysis. The succinimide bridged conjugate 175 is 
slightly more stable than the maleimide bridged conjugate 176 but after 1 h at 37 °C 
both constructs are almost fully hydrolysed. In conclusion, the succinimide bridge 
has a similar hydrolytic stability to the maleimide bridge and both constructs undergo 
quick hydrolysis at pH 8. 
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Conjugate 
% Hydrolysed 
after dialysis after 1 h @ 37 °C 
174 75 91 
175 92 95 
Fig. 38. LC-MS based hydrolytic stabilities of somatostatin conjugates 174 and 175 
The hydrolysed samples of succinimide bridged conjugate 174 and 
maleimide bridged conjugate 175 were then subjected to a large excess of thiol, 100 
eq. of 2-mercaptoethanol and incubated at 37 °C for 21 h. Gratifyingly, LC-MS 
analysis showed no reaction had occurred. 
The influence of the nature of the substituent on the nitrogen atom was 
assessed by comparing the hydrolytic stability of 174 and 128. Conjugates 174 and 
128 were prepared, according to the general procedures for the succinimide 
bridging with phenoxymaleimide, and then dialysed into pH 8 phosphate buffer for 
12 h at 0 °C. The concentration of both peptide conjugates was adjusted to 100 μM 
and an aliquot was taken and analysed by LC-MS. The remaining reaction mixtures 
were incubated at 37 °C for 1 h and then analysed by LC-MS. Fig. 39 shows the 
percentages of hydrolysed conjugates. The difference between the two conjugates 
was very significant: while 25% of 174 underwent hydrolysis during dialysis, 128 
was fully stable. Even after 1 h of incubation at 37 °C, most of 128 (70%) is present 
in the reaction mixture while by this time most of 174 (91%) had hydrolysed. 
However, after 16 h, even the succinimide bridged conjugate 128 is fully hydrolysed. 
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Conjugate 
% Hydrolysed 
after dialysis after 1 h @ 37 °C after 16 h @ 37 °C 
174 75 91 98 
128 0 30 96 
Fig. 39. LC-MS based hydrolytic stabilities of somatostatin constructs 174 and 128 
 These results highlight the strength of this approach in tuning the properties 
of bioconjugates. It was shown that both the nature of the substituent on the 
nitrogen atom and the nature of the bridge between the cysteine groups can alter 
the hydrolytic stability of the conjugates. By controlling these parameters, we can 
choose the optimal strategy for different applications, depending on its 
requirements. 
II.5 Differential dual labelling of disulphide bonds 
Going back to the mechanism depicted in Scheme 105, we envisaged that 
the product of the Michael addition, 173 could be trapped with a carefully chosen 
electrophile. This could be of interest as it could lead to a method to incorporate two 
labels onto a biomolecule. Such a reagent should display a high reactivity and thiol 
selectivity. One such electrophile is bromomaleimide. 
To test this, conjugate 128 was treated with a slight excess of 
bromomaleimide 22 (5 eq.) and the resulting mixture was incubated overnight at 
room temperature (Scheme 107). The different functionalisation on the nitrogen 
atom of the reagent allows easier interpretation of the LC-MS data. Gratifyingly, LC-
MS of the reaction mixture showed one product only, the dual labelled conjugate 
177. At this stage it is important to say that the structure of 177 is based on its mass 
which indicates that it containes two different maleimide labels, confirming the 
addition of bromomaleimide 22 to intermediate 173. It is natural to envisage the 
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formatio of the two possible regioisomers, as the retro-Michael addition is not 
expected to be selective. The LC trace offers no indication on the presence of one 
or two species as there is just one peak that corresponds to the mass of 177. More 
details on this will be given later on. 
The key species in this transformation is intermediate 173. The conjugate 
addition of bromomaleimide on the free thiol in 173 is expected to be the fast step 
while the formation of 173 is the rate-limiting step. As mentioned before, the 
equilibrium between 128 and 173 is shifted to the product side due to the constant 
consumption of 173. The phosphate ions present in the buffer system act as a base. 
 
Scheme 107.Dual labelling of somatostatin with bromomaleimide 22 
The transformation was attempted, under the same conditions with another 
thiol selective electrophile, the commonly employed maleimide. Once again, a sole 
clean product, 178, was obtained (Scheme 108). This time, the conjugate contains 
one maleimide and one succinimide tag. 
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Scheme 108. Dual labelling of somatostatin with maleimide  
The fact that the use of a highly reactive electrophile is critical for the 
success of the transformation is highlighted by the experiment depicted in Scheme 
109. Succinimide bridged somatostatin conjugate 128 is stable, even after 2 days of 
incubation at room temperature, in the presence of excess of the less electrophilic 
phenoxymaleimide 101 (9 eq.).  
 
Scheme 109. Stability of conjugate 128 in the presence of excess phenoxymaleimide 101 
This is mainly because the addition of a phenoxymaleimide molecule to 
intermediate 173 is significantly slower than the intramolecular cyclisation 
regenerating the succinimide bridged conjugate 128.  
As shown earlier, when a thiol is added to a mixture of bromomaleimide and 
phenoxymaleimide, the former species is the only one reacting, even in the 
presence of excess phenoxymaleimide (Fig. 33). This shows potential for 
developing a one-pot dual modification strategy, without purification between the two 
steps. 
With these results in hand, we set out to optimise the protocol in terms of 
reaction time and amount of reagent used. We used the reaction between 
succinimide bridged somatostatin conjugate 128 and bromomaleimide 22 as the 
model system. A temperature increase was expected to speed up the reaction and 
therefore it was decided to carry out the reaction at 37 °C. The amount of 
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bromomaleimide used vas varied (5 - 1.5 eq.) and gratifyingly, full conversion was 
achieved within 2 h with only 1.5 eq. of reagent 22 (Scheme 110). The use of the 
minimum amount of labelling reagent is desired as this is prepared in a DMF stock 
and a high content of organic solvent can act as a denaturant and alter the 
conformation of the peptide. No intermediate purification was performed. 
 
 
Scheme 110. Optimisation of the dual labelling of somatostatin with bromomaleimide 22 
As mentioned in the introduction, methods for the differential dual 
functionalisation of biomolecules are highly desirable in the areas of proteomics and 
therapeutics. To show the potential of our approach to access various dual 
functionalised peptides, we constructed conjugates 177 and 180 - 182. We highlight 
here conjugate 182, bearing two different fluorophores that form a FRET pair and 
conjugate 180, bearing a PEG chain and a fluorophore. Labelling with a FRET pair 
is a commonly employed method to study conformational changes of a protein 
during folding and unfolding or during binding to another protein or small molecule. 
PEGylation of a biomolecule also labelled with a fluorophore could prospectively 
increase the in vivo stability of the conjugate which could be useful in imaging 
studies. 
All dual labelled conjugates shown below have been prepared in a single pot 
starting from already prepared succinimide bridged somatostatin conjugates 128, 
161 and 162 (200 µM in pH 6.4 50 mM sodium phosphate containing 40% 
acetonitrile, 2.5% DMF) (Fig. 40). The succinimide bridged somatostatin was used 
without purification. The bromomaleimide solutions used were 100x more 
concentrated than the peptide solution, thus allowing the minimum addition of DMF 
to the reaction. N-Fluorescein bromomaleimide 179 was prepared according to a 
literature procedure.177 
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R1 
Conjugate 
code 
R2 
Reagent 
code 
Reagent (eq.) Product 
Me 128 H 22 1.5 177 
PEG 161 Fluorescein 179 4 180 
PEG 161 Me 57 3 181 
Linker-
Rhodamine 
162 Fluorescein 179 4 182 
Fig. 40. Scope of the dual labelling of somatostatin 
In conclusion, a series of novel bioconjugates of somatostatin were 
prepared. The protocol is easy, involves minimal amounts of reagents and can be 
carried out without intermediate purification.  
An important issue that remains to be addressed is the regioselectivity of the 
dual labelling; that is, whether the retro-Michael addition is selective or not. If not, 
the product of the addition of the second labelling reagent is a mixture of the two 
possible regioisomers (Scheme 111).  
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Scheme 111. Possible products of the 2nd step of the dual modification strategy 
In order to investigate the selectivity of the Michael addition, dual labelled 
somatostatin 181 was synthesised and then subjected to trypsin digest. The 
optimized conditions are 10 : 1 molar ratio between peptide conjugate and trypsin, 
pH 8.1 buffer (100 mM ammonium acetate, 1 mM calcium chloride) at 37 °C for 15 
h. Trypsin is a commonly employed enzyme for peptide mapping that cleaves 
peptides on the C-terminal side of lysine and arginine residues. Looking at the 
structure of the dual labeled somatostatin conjugate 181, there will be two points of 
cleavage, leading to three fragments (F1, F2, F3). Fig. 41 contains the expected 
masses of the possible products, also taking into account the possibility that the 
maleimide rings undergo hydrolysis. 
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R1 Ring hydrolysed Mass F1 R2 Ring hydrolysed Mass F3 Mass F2 
PEG No 618 PEG No 799 
740 
PEG Yes 637 PEG Yes 817 
CH3 No 486 CH3 No 666 
CH3 Yes 504 CH3 Yes 684 
Fig. 41. Possible fragments after trypsin digest of dual labelled conjugate 181 
The mass trace of the peptide sample after digest is shown below (Fig. 42), 
the retention time for this being 2.54 min, under the same LC-MS conditions 
described in the Experimental section. The peak corresponding to the middle 
fragment F2 is clearly identified (M+H+ = 741). There are also peaks at 799 and 817 
which correspond to F3, labelled with N-pegylated maleimide, both non-hydrolysed 
(M = 799) and hydrolysed (M = 817).  Two peaks corresponding to F1, labelled with 
N-pegylated maleimide, both non-hydrolysed (M = 618) and hydrolysed (M = 637) 
have been also identified. These peaks have a smaller intensity but this might be 
due to the difference in the ionisation ability of the three fragments. Peaks with 
masses corresponding to fragments labelled with the N-methyl maleimide have not 
been detected in the mass trace but the information available indicated the lack of 
regioselectivity leading to a mixture of the two possible regioisomers as the product 
of the dual modification strategy. Their ratio is expected to be dependent on the pKa 
of the cysteines connected by the succinimide bridge and possibly the steric 
hindrance induced by the neighbouring amino acids, therefore we can envisage that 
the regioselectivity varies from protein to protein. 
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Fig. 42. MS trace of the trypsin digested dual labelled somatostatin conjugate 181 
To illustrate that the methodology is applicable to other peptides we next 
decided to investigate the peptide octreotide 163. The dual labelling of the 
succinimide bridged octreotide conjugate 164 was first attempted using the 
optimised conditions for somatostatin: 1.5 eq. of bromomaleimide 22 and incubation 
at 37 °C (Fig. 43, Entry 2). This time, however, LC-MS trace indicated that after 2 h 
the reaction mixture consisted of unreacted starting material 164 (M = 1130) and 
two other species. These two species have the same mass (M = 1225) which 
corresponds to the addition of 22 to the starting material 164 but the significant 
difference in the retention time indicates a different site of labelling. We postulate 
that the two products obtained correspond to the structures 183a and/or 183b and 
184, and that product 184 is the result of a competing lysine labelling reaction (Fig. 
43). This assumption is supported by the fact that the fact that products 183 and 184 
have different retention times in the LC trace: 183 was eluted at 1.27 min and 184 at 
1.37 min. Another alternative for the side-reaction is the labelling of the N-terminus 
however, this is acetylated therefore unreactive. 
An optimisation study was consequently performed, with the aim of achieving 
full conversion to product 183a and/or 183b. The conditions employed are 
summarised in Fig. 43, together with information on the presence (Y) or absence (N) 
of each possible product in the reaction mixture.  
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Entry 
22 
(eq.) 
Temperature 
(°C) 
pH Time (h) 164 
183  
(a or b) 
184 
1 1.5 22 6.4 24 Y N N 
2 1.5 37 6.4 2 Y N N 
3 3 37 6.4 2 Y Y Y 
4 5 37 6.4 1.5 Y Y Y 
5 5 37 6.4 4 Y Y Y 
6 5 37 6.4 18 Y Y Y 
7 5 37 5 18 Y Y N 
8 5 37 7 18 Y Y Y 
9 5 37 8 18 Y Y Y 
 
Fig. 43. Optimisation study for the dual labelling of octreotide 
Unfortunately none of the tested conditions led to a clean product. Full 
conversion was not achieved, even with 5 eq. of labelling reagent. The side product 
184 is formed in considerable amount with respect to the desired product indicating 
that the two competing reactions - Michael addition at cysteine and lysine - proceed 
at similar rates. The slower rate of the cysteine modification suggests that the retro-
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Michael addition is much slower on octreotide than on somatostatin. As soon as the 
amount of labelling reagent 22 was increased to 3 eq. the desired product 183 was 
formed, but unfortunately together with side-product 184. It is noteworthy to highlight 
the fact that when the reaction mixture in Entry 3 (Fig. 43) was analysed by LC-MS 
after 7 days of incubation at room temperature a product that corresponds to the 
incorporation of three maleimide tags (M = 1320) was observed. We suggest that 
the structure of product 185 (Fig. 44). 
 
Fig. 44. Postulated structure of side product 185 
The pH screen illustrated the fact that the two competing reactions are 
influenced in the same way:  
(a) a low pH (5) stops the lysines from reacting with bromomaleimide but 
significantly reduces the rate of the retro-Michael addition; even after 18 h at 
37 °C, the conversion was very low, making the protocol not viable; 
(b) the product mixture obtained when the reaction was performed at pH 7 was 
very similar to the one obtained at pH 6; in both cases, the two products are 
obtained in comparable amounts, together with unreacted starting material; 
(c) an increase in the pH (8) speeds up both reactions, therefore the ratio 
between the two products is preserved. In this case, though, hydrolysis of the 
maleimides rings also takes place and this completely inhibits the retro-
Michael addition, leading to an overall decrease of the percentage of desired 
product in the reaction mixture.  
With no other solutions in hand for stopping the labelling reagent from 
reacting with the lysine group on octreotide, we decided to try different labelling 
reagents that would hopefully display a higher selectivity for thiols compared to 
lysines. Dr. Vijay Chudasama in the Caddick group at UCL reported on the use of 
substituted pyridazinediones 186 and 187 for cysteine labelling and some available 
analogues were tested.216 Another reagent investigated by Dr. Chudasama was the 
amide 188, which was shown to act as a low reactivity conjugate acceptor with high 
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selectivity for thiols. We also tested maleimide (Fig. 45). All reactions have been 
performed at in pH 6.4, 50 mM phosphate buffer containing 40% CH3CN and 2.5% 
DMF at 37 °C. 
 
Fig. 45. Structures of cysteine labelling reagents tested 
Unfortunately, all of the reagents tested failed to satisfy our requirements; in 
all cases when a reaction occurred (Entries 1, 7 and 8, Fig.46) the desired product 
189a or/and 189b was obtained together with the lysine modified product 190. 
Except for maleimide, which is known to be highly reactive, the other reagents 
displayed significantly lower reactivity so that high amounts of reagents (100 - 300 
eq.) were necessary to promote the reaction.  
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Entry Reagent (eq.) Time (h) 163 189 190 
1 Maleimide (5) 2 Y Y Y 
2 186 (1.5) 2 Y N N 
3 187 (1.5) 2 Y N N 
4 188 (1.5) 2 Y N N 
5 188 (200) 19 Y N N 
6 187 (100) 19 Y Y N 
7 187 (100) 130 Y Y Y 
8 187 (300) 72 Y Y Y 
Fig. 46. Scope of the dual labelling of octreotide 
Lastly, we investigated the utility of using phenoxymaleimide 101, as this is 
less reactive than bromomaleimide and maleimide and more reactive than the 
pyridazinediones shown in Fig. 47. For this, PEG-succinimide bridged octreotide 
conjugate 191 was treated with N-methyl phenoxymaleimide 101 (15 eq.) and the 
reaction mixture was incubated at 37 °C for 30 h. The mass trace of the reaction 
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mixture at the end of the reaction indicated that the conversion of the reaction was 
unsatisfactory and that in addition to unreacted starting material 191 (eluted at 2.74 
min, M = 1263), the product mixture contained both the desired product 192 (eluted 
at 2.38 min, M = 1371) and the lysine modified product 193 (eluted at 3.12 min, M = 
1371).  
 
Fig. 47. 2nd step of dual labelling of octreotide using phenoxymaleimide 101 
Another strategy was to use the bromopyridazinedione to create a 6-
membered saturated ring bridge, similar to how phenoxymaleimide was used. In this 
way the pKa of the α-protons next to the carbonyl groups in the ring would be 
altered, leading to a change in the rate of the retro-Michael addition. Various 
amounts (1.5 - 10 eq.) of bromopyridazinedione 187 were added to reduced 
octreotide 194 (200 μM in pH 6.4 50 mM phosphate buffer, 40% CH3CN, 2.5% 
DMF) and the reaction was monitored by LC-MS over 1 h (Fig. 48, Entries 1-3). The 
reaction was maintained at room temperature. Unfortunately, all attempts to obtain a 
clean bridged octreotide conjugate failed. The reaction either did not proceed or 
gave a mixture of the desired bridged peptide conjugate 195 (M = 1187) and the bis-
labelled product 196 (M = 1356). This was surprising given the fact that previous 
data indicated that bromopyridazinedione is less reactive than the 
phenoxymaleimide. It seems that the rate of addition of the second molecule of 
labelling reagent 187 is of the same order of magnitude as the intramolecular 
cyclisation leading to the desired product. An even less reactive labelling reagent 
was needed, and in analogy with the scale of reactivity between bromo and 
phenoxymaleimides, a novel pyridazinedione analogue was designed: 
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phenoxypyridazinedione 197 (Scheme 112). This was obtained by conjugate 
addition of phenol to bromopyridazinedione 187, under the optimised conditions for 
the addition of phenol to bromomaleimide (Chapter II.1).  
 
Scheme 112. Synthesis of phenoxypyridazinedione 197 
Indeed, this reagent was significantly less reactive. Quantities as high as 500 
eq. and a temperature of 37 °C were employed to achieve full conversion of the 
reduced octreotide 194 but unfortunately the product mixture contained both the 
mono-labelled 195 (M = 1188) and the bis-labelled peptide 196 (M = 1356) 
conjugates (Fig. 48, Entry 5-6). 
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Entry X Reagent (eq.) Temperature (°C) Time (h) 194 195 196 
1 Br 187 (1.5) 22 1 Y N N 
2 Br 187 (5) 22 1 Y Y Y 
3 Br 187 (10) 22 1 Y Y Y 
4 OPh 197 (5) 22 24 Y N N 
5 OPh 197 (100) 37 23 Y Y Y 
6 OPh 197 (500) 37 23 N Y Y 
Fig. 48. Scope of the addition of substituted pyridazine diones to reduced octreotide 
Another strategy that was investigated for tackling the competing lysine 
modification is depicted in Scheme 113. This new approach focuses on the retro-
Michael addition product 173 rather than on optimising the conditions of the second 
step or the labelling reagent used. We postulate that by reducing the maleimide in 
173 to the corresponding succinimide, the intramolecular cyclisation will be inhibited, 
making the thiol fully available for the reaction with the labelling reagent (e.g. 
bromomaleimide). This thiol labelling is expected to be far faster than the lysine 
modification, ensuring the formation of the desired dual labelled product 199 in high 
yields. 
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Scheme 113. Strategy for inhibiting the lysine modification side-reaction 
As it was readily available, somatostatin 29 was used as a model system 
and the reducing agents investigated were dithiothreitol and TCEP. 
Firstly DTT 7 was investigated. As depicted in Scheme 114, when DTT 7 is 
added to the succinimide bridged somatostatin 128, the reducing agent is expected 
to react with the product of the retro-Michael addition reaction, 173 by attacking the 
double bond in the maleimide ring. The next step would consist of the cyclisation of 
DTT 7 to give the 6-membered ring containing an internal disulphide bond and an 
intermediate enolate that could either abstract a proton to give product 198 
(Scheme114, route a) or undergo cleavage of the maleimide tag to give reduced 
143 
 
somatostatin 118 (Scheme 114, route b). The addition of excess maleimide is a 
simple and efficient way of quantifying the products present in the product mixture.  
 
Scheme 114. Possible reaction routes for the addition of DTT to x 
A series of DTT 7 concentrations (10 - 100 eq.) were screened. The reaction 
mixtures were incubated for 2 h at 37 °C and the results are shown in Table 4.  
DTT 7 (eq.) Temperature (oC) Time (h) 128 (%) 201 (%) 202 (%) 
10 37 2 18 47 28 
25 37 2 12 65 23 
50 37 2 11 63 26 
100 37 2 0 72 28 
Table 4. Testing the reduction of 173 with DTT 7 (10 - 100 eq.)  
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The major product was in all cases 201, the product derived from reduced 
somatostatin 118 (M = 1834) (Scheme 115, route b). The desired product 202 (M = 
1849) was also formed but as the minor product. Furthermore, the higher the 
concentration of DTT, the more cleavage occurs. We then decided to investigate the 
reactions over a shorter period of time (15 min and 30 min time points) using a small 
excess of reducing agent (5 and 10 eq.), (Table 5). Unfortunately, the major product 
in this case is the unreacted starting material 128 (M = 1750). Both products 201 
and 202 appear to form under these reaction conditions and it seems difficult to 
favour the formation of one over the other. 
DTT 7 (eq.) Temperature (oC) Time (min) 128 (%) 201 (%) 202 (%) 
5 
37 15 62 13 25 
37 30 56 25 19 
10 
37 15 66 10 24 
37 30 60 20 20 
Table 5. Testing the reduction of 173 with DTT (5 and 10 eq.) 
The use of TCEP was also investigated. Excess TCEP (65 eq.) was added 
to a sample of succinimide bridged somatostatin 128 and then incubated at room 
temperature for 6 h. According to the same principle as the previous experiment, 
maleimide (100 eq.) was added to quench the reaction. LC-MS analysis of the final 
reaction mixture indicated that no reaction had occurred.  
In conclusion, efforts to prevent the lysine labelling during the second step of 
the dual modification of octreotide by reducing the maleimide ring in intermediate 
173 proved unsuccessful. The competing lysine labelling seems to be favoured by 
the same factors as the retro-Michael addition (increased temperature, pH, 
increased reactivity of the labelling agents) therefore a new approach should be 
found to inhibit it. 
To explore the scope of the dual labelling with respect to the protein 
substrate, we decided to test it on a larger protein. The ds-scFv 33 was the model 
system of choice as the disulphide bond is artificially inserted therefore not essential 
for retention of the biological activity of the protein. 
The temperature (22 °C or 37 °C) and the amount of the bromomaleimide 22 
(5 - 50 eq.) were varied in order to find the optimal reaction conditions to produce 
the highest conversion to a product whose mass corresponds to structure 203 (Fig. 
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49). It is important to highlight that the selectivity of the retro-Michael addition has 
not been investigated in the case of the ds-scFv substrate therefore the identity of 
product 203 in terms of regioselectivity is not confirmed. All reactions were 
performed after the ds-scFv succinimide bridged conjugate 169 was separated from 
the small molecules in the first step (reducing agent and labelling reagent) by 
ultracentrifugation and after the concentration was readjusted to 70 µM. 
 
Entry 
22 
(eq.) 
Temperature 
(°C) 
Time 
(h) 
Comments on the product mixture 
1 20 22 24 
Unreacted 169 (M = 26850), part of a 
complex mixture 
2 5 37 2 
Unreacted 169 (major product) + 203 (M = 
26945) + unidentified species (M = 27010) 
3 10 37 5.5 
Main products: species with M = 26992 (2 
maleimides, 1 hydrolysed + Na), another 
species with M = 27115 (3 maleimides, 2 
rings hydrolysed + Na), part of a complex 
mixture 
4 50 37 2.5 
203 (M = 26945) is the main product but 
still some unreacted 169 (M = 26850) + 
other minor unidentified products 
5 50 37 3.5 
Complex mixture, contains degradation 
products 
Fig. 49. Optimisation of the 2nd step of the dual labelling of ds-scFv conjugate 169 
When the transformation was performed at room temperature and 20 eq. of 
bromomaleimide 22 were used, no reaction occurred even after 24 h. This indicated 
that the reaction is much slower than in the case of octreotide and somatostatin, so 
it was decided to raise the temperature to 37 °C. When 5 eq. of bromomaleimide 22 
were employed, the reaction mixture after 2 h consisted of unreacted starting 
material 169 (M = 26850), a species whose mass (M = 26945) corresponds to that 
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of the desired product 203 and an unidentified species (M = 27010). It was then 
decided to use more bromomaleimide 22 (10 eq.) and leave the reaction for longer 
(5.5 h) but in this case the LC-MS showed a complex mixture, indicating a significant 
amount of degradation. We postulate that in this case the maleimide rings undergo 
hydrolysis, leading to product 204 (M = 26992) and also that lysine modification 
takes place, leading to a product 205 whose mass (M = 27115) corresponds to the 
incorporation of three maleimide rings, two of them showing as the Na carboxylate 
salts (Fig. 50). It is important to highlight the fact that the site of hydrolysis is not 
determined therefore the structures below should not be taken as definite; the 
structures for 204 and 205 therefore only correspond to one of the possible isomers. 
 
Fig. 50. Postulated structures for the products in Fig. 49  
The difficulty in achieving the required transformation is correlated to the fact 
that the disulphide bond in this protein is quite buried in the tertiary structure and 
therefore it is less prone to react. To test this hypothesis, we decided to investigate 
the use of a denaturant, in our case guanidinium chloride. Denaturants are 
chemicals that interfere with the intramolecular interactions mediated by non-
covalent forces (i.e. hydrogen bonds, van der Waals forces, and hydrophobic 
effects) in the protein.217 At 6 M GndCl concentration all proteins are completely 
denatured (and hence unfolded). Our interest was in achieving a partial unfolding 
which would expose the disulphide of interest, so we screened several 
concentrations of GndCl.  
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GndCl (M) Comments on the product mixture 
0 Complex mixture (mostly unreacted 169) 
1 Complex mixture (203 together with unidentified species with 
masses M = 27015 and M = 27106) 
2 203 is the sole product 
3 Complex mixture (203 together with 33, unidentified species M = 
27358 and M = 28609 and degradation products) 
Fig. 51. Effect of guanidinium chloride addition on the 2nd step of the dual labelling of ds-scFv 
conjugate 169 
The cleanest reaction mixture was obtained at 2 M GndCl, after 3 h of 
incubation at 37 °C and with 50 eq. bromomaleimide 22 (Fig. 51). The major peak in 
the LC-MS spectrum corresponds to the bis-labelled ds-scFv conjugate 203 (M = 
26949). 
We then applied these optimised conditions to the reactions depicted in 
Schemes 116 and 117. In both cases the conversion was 100% but the formation of 
the desired product was accompanied by unwanted side-reactions. When the bis-
PEG-ylation was attempted, a species with a mass of 39 units higher than the one of 
the bis-labelled product was observed (Scheme 115). We suspect that one of the 
maleimide rings hydrolysed to give a 7 : 3 mixture of product 206 and 207, based on 
the LC-MS trace. The site of hydrolysis could not be determined, therefore the 
structure proposed for compound 207 is only of one of the two possible isomers. 
Additionally, there is no information whether compound 206 was obtained as a 
single regioisomer or together with its regioisomer, with the maleimide rings with 
swapped positions. For simplicity, only one structure is shown. 
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Scheme 115. 2nd step of the dual labelling of ds-scFv using N-PEG bromomaleimide 145 
When 50 eq. of N-Rhodamine bromomaleimide 147 were added to the 
succinimide bridged conjugate 170, a product with a mass corresponding to the 
addition of two N-Rhodamine maleimide tags was obtained in a 4 : 6 ratio together 
with the desired product 208 (Scheme 116). No information on the regioselectivity of 
the retro-Michael addition is available therefore the possibility of conjugate 208 
existing as a mixture of the two possible regioisomers should not be neglected. 
Based on the results obtained when investigating the reactivity of octreotide, we 
postulate that the side product could be the result of lysine-modification and 
therefore corresponds to product 209. 
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Scheme 116. 2nd step of the dual labelling of ds-scFv using N-Rhodamine bromomaleimide 147 
In conclusion, the dual labelling strategy of ds-scFv 33 suffers from the same 
limitations as when octreotide 163 was investigated: slow kinetics of the retro-
Michael addition requiring excess labelling reagent, increased temperature and 
addition of a denaturant (only in the case of ds-scFv) which favour the addition of 
the labelling reagent to a lysine residue. In all these transformations, the optimised 
protocol led to the desired dual labelled product as the major product hence the 
strategy could still be used, provided the lysine-modified side-product can be 
separated. The success of the dual labelling depends on the accessibility of the 
disulphide and on how essential it is in the tertiary structure of the protein. The effect 
on the protein activity is in fact another aspect that needs to be considered when 
choosing the labelling strategy. In our case, the disulphide bond remains broken, 
therefore activity of the protein could be severely altered. We envisage that our 
approach could be most useful for the labelling of engineered disulphides. In this 
instance, they could also be designed to be solvent accessible and near aminoacids 
residues that would stabilize the resulting thiolate, hence potentially favouring the 
Michael addition.218 
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III Conclusions 
In conclusion, the present work details the synthesis of a library of novel 
mono- and disubstituted maleimides (~30 analogues) with the aim of establishing 
the influence of the substituent(s) on the double bond on the reactivity of these 
reagents with cysteine and also developing reagents with tuned properties. A faster, 
more reliable and suitable for scale-up synthesis of bromomaleimide was 
established. The rest of the analogues were obtained mainly via conjugate addition 
reactions with appropriately chosen nucleophiles starting from bromomaleimide or 
the commercially available dibromomaleimide. Sulfoxymaleimides were obtained via 
oxidation of the corresponding thiomaleimides. Various attempts to further oxidize 
the sulfoxymaleimides to the sulfonylmaleimides were unsuccessful. 
The utility of the novel monosubstitued analogues as protein labelling 
reagents was then tested on a model protein- the single cysteine mutant of the Grb2 
SH2 domain protein.  
It was shown that by varying the leaving groups on the maleimide core, a 
range of novel cysteine labelling reagents could be produced with tuneable 
properties (Fig. 52). Among the monosubstituted analogues, sulfoxymaleimides are 
the most reactive however, excess reagent is required due to their degradation in 
aqueous systems. The halomaleimides are all very fast and efficient labelling 
reagents, with similar reactivity profiles. At the other end of the spectrum, 
phenoxymaleimides display reduced reactivity. Fine tuning could be achieved by 
installing different groups on the phenyl ring. The main advantages of 
phenoxymaleimides are their ideal compatibility with the in situ protocol and the fact 
that the reagent can be rendered water soluble by installing a short PEG chain on 
the phenyl ring. Methoxymaleimides are even less reactive compared to 
phenoxymaleimides and lead to a mixture of the protein thiomaleimide conjugates 
as the minor product and the the protein methoxythiosuccinimide as the major 
product. Aminomaleimides proved unreactive towards the cysteine in the Grb2 SH2 
(L111C), despite using excess reagent. 
Additionally, a kinetic study was designed in order to provide a more 
quantitative comparison between the reactivities of halomaleimides and cysteine. 
Glutathione addition to chloro-, bromo-, iodo- and phenoxymaleimide, leading to 
thiomaleimide 126 was monitored by UV-spectroscopy, based on the absorption of 
the thiomaleimide product.  
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Fig. 52. Reactivity scale of selected monosubstituted maleimides 
When reacted with reduced somatostatin 118, phenoxymaleimides led to the 
succinimide bridged product only as opposed to bromomaleimide which led to a 
mixture of a bis-addiction product and the succinimide bridged product (Scheme 
117). This enables phenoxymaleimides to be employed in succinimide bridging, 
offering a novel strategy for labelling of disulphide containing biomolecules (shown 
on two peptides (somatostatin 26 and octreotide 163) and three antibody fragments 
(ds-scFv 33, Rituximab Fab 165 and Trantuzumab Fab 167). This strategy is fast, 
efficient and perfectly compatible with the in situ protocol. The use of the water 
soluble phenoxymaleimide synthesized allowed the transformation to occur under 
organic solvent free conditions. 
 
Scheme 117. Phenoxymaleimide addition to reduced somatostatin 
Furthermore, the succinimide bridge was shown to be reversible and that the 
intermediate could be trapped with a suitable chosen electrophile such as 
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bromomaleimide or maleimide. This discovery led to the development of a one-pot 
dual labelling strategy of both peptides and proteins. The dual labelling works well 
on somatostatin, as supported by various dual labelled somatostatin conjugates 
prepared (Scheme 118). It was shown using somatostatin as substrate, that the 
retro-Michael addition is not regioselective and that in fact, the dual modified 
products are mixture of the two possible regioisomers. For the sake of simplicity, 
Scheme 118 shows only one of the two possible regioisomers. 
The strategy was also tested on the ds-scFv 33, for which an optimized 
protocol was established involving addition of 2 M guanidinium chloride to partially 
unfold the protein and therefore enhance the reactivity of the disulphide by 
increasing its solvent exposure. In the case of octreotide, the addition of the second 
label led to the formation of the dual labelled conjugate together with a side-product, 
assumed to be the product of a competing lysine modification. Attempts to stop the 
formation of the side-product were unsuccessful.  
 
Scheme 118. Dual labelling of somatostatin 
Regarding the activity of the protein after dual labelling, it is assumed that 
that might be severely affected as the disulphide bond remains broken. Accordingly, 
the strategy might be most suitable for artificially inserted disulphides or for 
disulphides that are not crucial for maintaining the biomolecule’s activity.  
A series of novel disubstituted maleimides was also synthesised and 
investigated as potential disulphide bridging reagents using somatostatin 29 as 
model system (Fig. 53). Diphenoxymaleimides are significantly slower compared to 
dibromo- or dithiophenolmaleimide but the reactions can be accelerated by adding 
excess reagent. This class of reagents is the first to display no cross-reactivity with 
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the reducing agent TCEP, therefore are ideal for the in situ protocol. 
Sulphoxythiomaleimides afforded the bridged somatostatin conjugate when used in 
excess (6 eq.) but suffered from the same aqueous instability as the 
sulfoxymaleimides. Halophenoxymaleimides on the other hand proved to be highly 
reactive, affording full conversion to the maleimide bridged peptide in just 1 min. 
Competition experiments with dibromomaleimide indicated that these reagents 
might be the fastest so far for disulphide bridging. Initial tests indicate less 
satisfactory conversions during the in situ protocol, which might suggest a certain 
degree of cross-reactivity between halophenoxymaleimides and TCEP but further 
investigation is required. 
 
Fig. 53. Review of selected disubstituted maleimides as reagents for disulphide bridging 
Finally, the regioselectivity of the thiol addition to the substituted maleimides 
was briefly explored. The product analysis of the reactions between the cysteine in 
Grb2 SH2 (L111C) 26 and substrates such as the halophenoxymaleimides and 
bromochloromaleimide 91 strongly suggests that the position of attack is governed 
by the electronic properties of the substituent (Scheme 119). Electron donating 
substituents will activate the α position towards nucleophilic attack via a mesomeric 
effect while electron withdrawing substituents will activate the β-position via the 
same mechanism. 
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Scheme 119. Exclusive α-thiol attack with respect to the oxygen in the phenoxy group 
IV Future plans 
Future work on this project could consist of further investigation of the cross-
reactivity of halophenoxymaleimides with TCEP to establish if these reagents are 
compatible with the in situ protocol. Potentially their high reactivity could be useful in 
cases when the disulphide bridging is particularly difficult (e.g. when the disulphide 
is less explosed). By trapping the two resultant thiols very quickly, these reagents 
have the potential of reducing the risk of disulphide scrambling. To prove this, the 
model systems should contain more than one disulphide bond. Such systems, like 
insulin (3 disulphides) and tertiapin Q (2 disulphides) are currently under 
investigation in our group. The work of Dr. Felix Schumacher on insulin indicates 
that the scrambling of the protein during disulphide bridging is not only dependant 
on the labelling reagent but also the reducing reagent and the protocol used (e.g. 
stepwise or in situ). Aditionally, each protocol needs to be optimized for each protein 
target. The selective disulphide bridging in proteins bearing more than one 
disulphide bond whilst retaining biological activity would indeed be a major 
advancement in the field of bioconjugation, as many therapeutical proteins contain 
more than one disulphide (e.g. nanobodies®,219 Fab fragments220). 
Diphenoxymaleimides, due to their lower reactivity could afford selective 
labelling in systems containing multiple disulphides of varied reactivity. 
The efficiency of succinimide bridging with phenoxymaleimides could 
potentially find applications in the context of antibody-drug conjugates. 
Dithiosuccinimides have been shown to be less susceptible to thiol attack compared 
to dithiomaleimides and this could be a very useful attribute in the context of 
antibody-drug conjugates where the requirements for plasma stability are very 
stringent. 
Furthermore, the retention of the biomolecule’s activity after succinimide 
bridging should be tested, especially considering that the product is a 
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diastereoisomeric mixture. This aspect is paramount in the design of protein 
therapeutics. 
Regarding the dual labelling strategy, its utility could be demonstrated on a 
protein substrate bearing an artificially inserted disulphide. In this way, the activity of 
the protein is not expected to be affected.  
The competing lysine modification remains a drawback of the strategy. From 
the data gathered so far, it seems that the extent of lysine modification is dependant 
on the protein and presumably also on the position of the disulphide on the protein. 
The inhibition of the lysine modification might be achieved by a more thourough 
understanding of the influence of the disulphide bond rather than by changing the 
reaction conditions and the labelling reagent. This is even more important if the 
targeted disulphide is artificially inserted and so its position on the protein could be 
varied. 
To conclude the work on the position of the thiol attack a mechanistic study 
is required. As seen in Scheme 120, the product of the thiol addition to 
bromomaleimide is the same regardless if the thiol attacks the carbon bearing the 
bromo substitutent (route A) or  the other carbon involved in the double bond (route 
B). 
 
Scheme 120. Possible mechanisms for the conjugate addition of the thiolate anion to bromomaleimide 
The basis of the mechanistic study is 13C-labelled bromomaleimide, for which 
a synthetic plan has been proposed (Scheme 121). The synthetic route starts with 
the carboxylation of ethyl propiolate, using 13C-labelled carbon dioxide. This reaction 
is well documented in the literature.221 The next step is a hydrobromination reaction, 
using butylpyridinium bromide.222 The hydrobromination could lead to 4 possible 
products, the Z and E isomers of the two possible regioisomers. The products 
shown for this step are the desired products as they would allow cyclisation under 
standard conditions,223 giving the bromomaleimic anhydride. The final step consists 
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of the condensation between methylamine and the bromomaleic anhydride, which is 
expected to be a high yielding reaction.177 
 
Scheme 121. Proposed synthetic route for the preparation of 13C-labelled bromomaleimide 
 
V Experimental Section 
V.1 Materials 
All commercially available chemicals were used as received without further 
purification. 
Lyophilised Somatostatin was purchased from Sigma Aldrich and Octreotide 
acetate was purchased from Source Bioscience.The anti-CEA ds-scFv shMFE23211 
antibody fragment was kindly provided by Dr Berend Tolner (UCL Cancer Institute) 
and the Grb 2 (L111C) SH2139 adaptor protein was kindly provided by Dr Rachel 
Morgan (UCL Chemistry). Clinical grade Rituximab antibody (MabThera) was 
purchased from Roche. Trastuzumab (Herceptin® 150 mg, Genentech) was 
purchased from Roche. 
All buffer solutions were prepared with double-deionised water and filter-
sterilised. 
V.2 General Methods 
All reactions were carried out at room temperature (19 - 22 °C), under argon, 
unless otherwise stated.  
1H NMR spectra were recorded on Bruker AMX600 (600 MHz) and AMX500 
(500 MHz) instruments at room temperature. The chemical shifts are expressed in 
parts per million (ppm) referenced to the residual solvent peaks. Data is reported as 
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follows: δ, chemical shift; integration, multiplicity (recorded as br (broad); s (singlet); 
d (doublet); t (triplet); q (quartet); qn (quintet), dd (doublet of doublets), dt (doublet of 
triplets), ddd (doublet of dublet of doublets), sext (sextet) and m (multiplet)), coupling 
constants (J in Hertz, Hz) and assignment. 13C-NMR spectra were recorded on the 
same instruments at 150 MHz and 125 Hz respectively. The chemical shifts are 
expressed in parts per million (ppm), referenced to the residual solvent peaks. For 
NMR experiments, CDCl3 denotes deuterated (d) chloroform, DMSO-d6 denotes 
deuterated (d6) dimethylsulfoxide and CD3OD denotes deuterated (d4) methanol. 
Infrared spectra were obtained on a Perkin Elmer Spectrum 100 FTIR 
Spectrometer operating in ATR mode. Data is reported as follows: wavenumber (cm-
1), intensity (recorded as br (broad), s (strong), m (medium) or w (weak)). Melting 
points were measured with a Gallenkamp and are uncorrected. In vacuo is used to 
describe solvent evaporation by Büchi rotary evaporation between 20 - 60 °C. High 
and low resolution mass spectrometry was performed using a VG70 SE operating in 
modes ES, EI, FAB or CI depending on the sample. All reactions were monitored by 
thin layer chromatography (TLC), using TLC plates pre-coated with silica gel 60 F254 
on aluminium (Merck KGaA). Chemical staining using KMnO4 was employed for 
visualisation under UV (254 or 365 nm). Normal phase silica gel 60 (0.04-0.063 mm, 
230-400 mesh) (BDH) and sand (VWR) were used for flash chromatography. 
Somatostatin, octreotide, anti-CEA ds-scfv antibody fragment and their 
conjugates were analysed by LC-MS using a Waters Acquity UPLC connected to 
Waters Acquity Single Quad Detector [column: Acquity UPLC BEH C18 1.7 µm 2.1 x 
50 mm; wavelength 254 nm; mobile phase 95 : 5 water (0.1% formic acid) : CH3CN 
(0.1% formic acid), gradient over 4 min to 5 : 95 water (0.1 % formic acid) : CH3CN 
(0.1 % formic acid); flow rate 0.6 mL/ min; MS mode ES+/-; scan range (m/z) = 95 - 
2090 Da; scan time 0.25 s]. Data was obtained in continuum mode. Sample 
volumes were between 10 - 30 µL. The electron spray source of the MS was 
operated with a capillary voltage of 3.5 kV and a cone voltage of 20 - 200 V. 
Nitrogen was used as the nebulizer and desolvation gas at a total flow of 600 L/h. 
Total mass spectra for protein samples were recontructed from the ion series using 
the MaxEnt 1 algorithm pre-installed on the MassLynx software. 
Rituximab and Herceptin Fabs were analysed by LC-MS using a Thermo 
Scientific uPLC connected to MSQ Plus Single Quad Detector (SQD) [Column: 
Hypersil Gold C4, 1.9 μm 2.1 x 50 mm; wavelength: 254 nm; mobile phase: 99 : 1 
water: CH3CN (0.1% formic acid), gradient over 4 min to 1: 9 water : CH3CN (0.1% 
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formic acid).; flow rate: 0.3 mL/min; MS Mode: ES+; scan range: (m/z) = 500 - 2000; 
scan time: 1.5 s]. Data obtained in continuum mode. The electrospray source of the 
MS was operated with a capillary voltage of 3.5 kV and a cone voltage of 50 V. 
Nitrogen was used as the nebulizer and desolvation gas at a total flow of 600 L/h. 
Ion series were generated by integration of the total ion chromatogram (TIC) over 
the 3.5 - 5.0 min range. Total mass spectra for protein samples were reconstructed 
from the ion series using the pre-installed ProMass software. 
The retention times of protein and peptide samples is given based on the 
gradient detailed above. 
Protein concentrations and UV-absorbances were obtained on a Carry BIO 
100 UV-Vis spectrophotometer (Varian) equivuipped with a temperature controlled 
12x sample holder in quartz cuvettes (1 cm path length, volume 75 µL) at room 
temperature, unless otherwise stated. Samples were baseline corrected. 
Glycine-SDS-PAGE was performed following standard lab procedures.12% 
gels were used, with a 4% gel as the stacking gel. A broad range MW marker (10 
kDa-250 kDa, BioLabs) was used as protein ladder. Samples were mixed in 1 : 1 
volume ratio with the running buffer (1 M Tris-HCl, pH 6.8, 30% w/v glycerol, 10% 
w/v SDS, Coomassie G-250). Coomassie G-250 was used for staining. 
Reactions involving somatostatin and octreotide were performed on a 100 - 
700 µL scale in 1.5 mL Eppendorf tubes while reactions involving Fab fragments 
and Grb2 SH2 (L111C) were performed on a 10 - 100 µL scale. Reactions with a 
total volume lower than 50 µL, were performed in 100 µL Eppendorf tubes.  
Buffer swapping of protein solutions was performed using Vivaspin 500 
(Santorius) Vivaspin 6 mL (Santorius) filters, both with 10 kDa MWCO. 
V.3 Synthesised compounds 
57. 3-Bromo-1-methyl-pyrrole-2,5-dione138 
 
 
To N-methylmaleimide (2.87 g, 25.0 mmol) in CHCl3 (125 mL), bromine (2.60 mL, 
55.5 mmol) was added dropwise and the resulting mixture was refluxed for 2 h. 
The solvent was removed in vacuo and the resulting solid was dissolved in EtOAc 
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(30 mL) and washed with 15% aq. Na2S2O3 (20 mL). The product was extracted 
with EtOAc (3 x 30 mL), dried (MgSO4) and filtered. The solvent was evaporated 
in vacuo to afford 6.39 g of N-methyl 2,3-dibromosuccinimide as yellow crystals. 
The succinimide product was dissolved in AcOH (150 mL), then sodium acetate 
(5.94 g, 71.6 mmol) was added and the reaction mixture was refluxed for 2.5 h. 
The reaction mixture was left to cool down to room temperature and then the 
solvent was evaporated in vacuo. The crude mixture was dissolved in EtOAc (50 
mL) and washed with sat. aq. Na2CO3 (3 x 25 mL). The organic phase was dried 
(MgSO4), filtered and the solvent evaporated in vacuo. Purification by flash 
chromatography (PE : EtOAc, gradient elution from 80 : 20 to 60 : 40) afforded 
the title compound 57 as white crystals (2.86 g, 15.1 mmol) in 65% yield.  
 
δH (600 MHz, CDCl3) 6.88 (1H, s, CH-2), 3.07 (3H, s, CH3-5); δC (150 MHz, 
CDCl3) 168.7 (C=O), 165.5 (C=O), 132.0 (CH), 131.5 (C), 24.7 (CH3); IR 3105 
(w), 2947 (w), 1776 (m), 1704 (s), 1588 (s), 14 93 (s), 1388 (m), 1231 (m), 969 
(s), 706 (s); MS (CI+) m/z, (relative intensity): 192 ([81M+H]+, 100), 190 ([79M+H]+, 
100). Exact mass calcd. for [C5H4NO279Br]++H: 189.9504. Measured: 189.9501 
(CI+); m.p.: 100 °C (lit. m.p.138: 88 - 89 °C). 
 
58. 3,4-dibromo-pyrrolidine-2,5-dione138 
 
 
To maleimide (2.00 g, 20.0 mmol) in CHCl3 (15 mL) bromine (1.16 mL, 20.0 mmol) 
in CHCl3 (15 mL) was added dropwise. The reaction mixture was refluxed for 3 h 
and then allowed to cool to room temperature over 1 h. The solid yellow precipitate 
was filtered and washed with cold CHCl3 (2 x 35 mL) to afford the title compound 58 
as a white solid (3.85 g, 14.9 mmol) in 75% yield. 
 
δH (500 MHz, CDCl3)  8.34 (1H, br s, NH), 4.73 (2H, s, 2 x CH-2); δC (125 MHz, 
CDCl3) 169.8 (2 x C=O), 42.8 (2 x CH); IR 2945 (w), 1789 (m), 1708 (s), 1373 (s), 
1170 (s); MS (ES+) m/z, (relative intensity): 259 ([81,81M+H]+, 28), 257 ([79,81M+H]+, 
29), 255 ([79,79M+H]+, 30); m.p.: 89 - 92 °C (lit. m.p.: 125 - 125.3 °C). 
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The stereochemistry of compound 58 was investigated. Based on molecular 
modelling (PC Model v 8.5) the calculated 3JHH for the anti isomer (corresponding to 
a torsional angle of 119°) is 2.2 Hz, exactly the same value that was measured 
when analysing the 13C satellites in the 1H-NMR spectrum. This demonstrates that 
the 2,3-dibromosuccinimide 58 was obtained as the anti isomer. 
 
22. 3-Bromo-pyrrole-2,5-dione138  
 
 
Dibromosuccinimide 58 (965 mg, 3.75 mmol) and sodium acetate trihydrate (1.54 g, 
11.3 mmol) were dissolved in AcOH (23 mL). The reaction mixture was refluxed for 
1.5 h, then allowed to cool to room temperature and then the solvent was 
evaporated in vacuo. The crude mixture was redissolved in EtOAc (50 mL) and 
washed with sat. aq. Na2CO3 (3 x 10 mL). The organic phase were dried (MgSO4), 
filtered and the solvent was evaporated in vacuo. Purification by flash 
chromatography (PE : EtOAc, gradient elution from 80 : 20 to 60 : 40) afforded the 
title compound 22 as white crystals (568 mg, 3.22 mmol) in 86% yield. 
 
δH (500 MHz, CDCl3)  7.70 (1H, br s, NH), 6.89 (1H, d, J = 1.5 Hz, CH-2); δC (150 
MHz, CDCl3) 168.0 (C=O), 164.9 (C=O), 132.9 (CH), 132.3 (C); IR 3236 (m), 1782 
(m), 1763 (m), 1716 (s), 1577 (m), 871 (m), 718 (m); MS (EI+) m/z, (relative 
intensity): 177 ([81M]+, 95), 175 ([79M]+, 95), 134 (97), 132 (98), 106 (70), 104(70). 
Exact mass calcd. for [C4H2NO279Br]+: 174.92634. Measured: 174.92649 (EI+); m.p.: 
149 °C (lit. m.p.138: 149 - 151 °C). 
 
59. 3-Hexylthio-pyrrole-2,5-dione177 
 
 
To a solution of bromomaleimide 22 (276 mg, 1.58 mmol) and sodium acetate 
trihydrate (215 mg, 1.58 mmol) in MeOH (45 mL) n-hexanethiol (250 μL, 1.72 mmol) 
in MeOH (300 mL) was added dropwise over 1 h with vigorous stirring. After a 
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further 20 min the solvent was removed in vacuo. Purification by flash 
chromatography (PE : EtOAc, gradient elution from 90 : 20 to 70 : 30) afforded the 
title compound 59 as a yellow solid (337 mg, 1.58 mmol) in 85% yield. 
 
δH (600 MHz, CDCl3) 6.04 (1H, s, CH-2), 2.91 (2H, t, J = 7.3 Hz, CH2-5), 1.75 (2H, 
qn, J = 7.5 Hz, CH2-6), 1.45 (2H, qn, J = 7.4 Hz, CH2-7), 1.33-1.27 (4H, m, CH2-8 
and 9), 0.90 (3H, t, J = 7.0 Hz, CH3-10); δC (150 MHz, CDCl3) 169.0 (C=O), 167.7 
(C=O), 152.8 (C), 118.2 (CH), 32.1 (CH2), 31.3 (CH2), 28.6 (CH2), 27.7 (CH2), 22.6 
(CH2), 14.1 (CH3); IR 3183 (w), 2956 (s), 2931 (m), 1742 (s), 1676 (s), 1549 (m), 
1470 (m), 1390 (s), 1364 (s), 1153 (s), 770 (m); m.p.: 104 °C (lit. m.p.177: 99 - 101 
°C). 
 
60. 3-Hexylthio-1-methyl-pyrrole-2,5-dione177 
 
 
To a solution of 57 (300 mg, 1.58 mmol) and sodium acetate trihydrate (215 mg, 
1.58 mmol) in MeOH (45 mL) n-hexanethiol (250 μL, 1.72 mmol) in MeOH (300 mL) 
was added dropwise over 1 h. After a further 15 min the solvent was removed in 
vacuo. Purification by flash chromatography (PE : EtOAc, gradient elution from 90 : 
10 to 70 : 30) afforded the title compound 60 as a yellow solid (308 mg, 1.35 mmol) 
in 86% yield.  
 
δH (600 MHz, CDCl3) 6.04 (1H, s, CH-2), 2.90 (2H, t, J = 7.3 Hz, CH2-6), 3.01 (3H, s, 
CH3-5), 1.74 (2H, qn, J = 7.5 Hz, CH2-7), 1.47-1.42 (2H, m, CH2-8), 1.33-1.29 (4H, 
m, CH2-9 and 10), 0.91-0.88 (3H, m, CH3-11); δC (150 MHz, CDCl3) 169.9 (C=O), 
168.2 (C=O), 151.8 (C), 117.3 (CH), 31.9 (CH2), 31.3 (CH2), 28.6 (CH2), 27.7 (CH2), 
24.1 (CH3), 22.6 (CH2), 14.1 (CH3); IR 3177 (m), 2930 (m), 1796 (m), 1742 (s), 1548 
(m), 1342 (m), 1033 (m), 832 (m); MS (CI+) m/z (relative intensity): 228 ([M+H]+, 
100), 194 (30). Exact mass calcd. for [C11H17NO2S]++H: 228.1058. Measured: 
228.1051 (CI+); m.p.: 63 °C (lit. m.p.177: 62 - 65 °C). 
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61. 1-Methyl-3-phenylthio-pyrrole-2,5-dione 
 
 
To a solution of thiophenol (269 μL, 2.63 mmol) in MeOH (280 mL) was added 
sodium acetate (215.9 mg, 2.63 mmol). The reaction mixture was cooled to -60 °C 
and bromomaleimide 57 (500 mg, 2.63 mmol) in MeOH (280 mL) was added 
dropwise over 45 min with vigorous stirring while maintaining the temperature 
between -60 and -50 °C. The reaction mixture was removed from the cooling bath 
and was stirred for a further 10 min before the solvent was removed in vacuo. 
Purification by flash chromatography (PE : EtOAc, gradient elution from 95 : 5 to 93 : 
7) afforded the title compound 61 as a yellow oil (353 mg, 1.61 mmol) in 61% yield. 
 
δH (600 MHz, CDCl3) 7.55-7.54 (2H, m, 2 x CH-Ar), 7.49-7.47 (3H, m, 3 x CH-Ar), 
5.65 (1H, s, CH-3), 3.02 (3H, s, CH3-1); δC (150 MHz, CDCl3) 169.7 (C=O), 168.1 
(C=O), 152.7 (C), 134. 5 (2 x CH), 130.5 (CH), 130.3 (2 x CH), 127.4 (C), 118.9 
(CH), 24.7 (CH3); IR 2947 (w), 1770 (m), 1698 (s), 1561 (m), 1440 (m), 1385 (m), 
971 (m); MS (EI+) m/z (relative intensity): 219 ([M]+, 27), 134 (100), 90 (23). Exact 
mass calcd. for [C11H9NO2S]+: 219.0348. Measured: 219.0345 (EI+).  
 
63. 1-Methyl-3,4-bis(phenylthio)-pyrrole-2,5-dione 
 
 
A solution of thiophenol (256 μL, 3.35 mmol) in MeOH (3 mL) was added dropwise 
to a solution of N-methyl 2,3-dibromomaleimide (400 mg, 1.47 mmol) and sodium 
acetate (370 mg, 3.35 mmol) in MeOH (28 mL). The reaction mixture was stirred at 
room temperature for 15 min before the solvent was evaporated in vacuo. 
Purification by flash chromatography (PE : EtOAc, gradient elution from 94 : 6 to 90 : 
10) afforded title compound 63 as a yellow solid (399 mg, 1.22 mmol) in 85% yield. 
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δH (600 MHz, CDCl3) 7.30-7.29 (2H, m, 2 x CH-Ar), 7.27-7.24 (4H, m, 4 x CH-Ar), 
7.22-7.20 (4H, m, 4 x CH-Ar), 3.01 (3H, s, CH3-1); δC (150 MHz, CDCl3) 167.0 (2 x 
C=O), 135.9 (2 x C), 132.0 (4 x CH), 129.1 (4 x CH), 128.5 (2 x CH and 2 x C), 24.8 
(CH3); IR 1706 (s), 1440 (m), 1382 (m); MS (EI+) m/z, (relative intensity): 327 ([M]+, 
23), 180 (13), 111 (53), 107 (34); Exact mass calcd. for [C17H13NO2S2]+: 327.0382. 
Measured: 327.0384 (EI+); m.p.: 94 - 95 °C. 
 
64. 3,4-bis(Hexylthio)-1-methyl-pyrrole-2,5-dione 
 
 
A solution of n-hexanethiol (491 μL, 3.35 mmol) in MeOH (5 mL) was added slowly 
to a solution of N-methyl 2,3-dibromomaleimide (400 mg, 1.47 mmol) and sodium 
acetate (275 mg, 3.35 mmol) in MeOH (29 mL). The reaction mixture was stirred for 
15 min at room temperature and then the solvent was evaporated in vacuo. 
Purification by flash chromatography (PE : Et2O, 99 : 1) afforded title compound 64 
as a yellow oil (170 mg, 0.49 mmol) in 34% yield. 
 
δH (600 MHz, CDCl3) 3.26 (4H, t, J = 7.5 Hz, 2 x CH2-4), 3.00 (3H, s, CH3-1), 1.63 
(4H, qn, J = 7.5 Hz, 2 x CH2-5), 1.41 (4H, qn, J = 7.4, Hz, 2 x CH2-6), 1.31-1.25 (8H, 
m, 2 x CH2-7 and 2 x CH2-8), 0.88 (6H, t, J = 7.0 Hz, 2 x CH3-9); δC (150 MHz, 
CDCl3) 166.9 (2 x C=O), 136.0 (2 x C), 32.0 (2 x CH2), 31.4 (2 x CH2), 30.6 (2 x 
CH2), 28.3 (2 x CH2), 24.5 (CH3), 22.6 (2 x CH2), 14.1 (2 x CH3); IR 2925 (w), 1721 
(s), 1637 (s), 1439 (m), 1148 (m); MS (EI+) m/z (relative intensity): 343 ([M]+, 100), 
226 (26), 175 (22). Exact mass calcd. for [C17H29NO2S2]+: 343.1634. Measured: 
343.1638 (EI+). 
 
66. 3-Hexylsulfinyl-1-methyl-pyrrole-2,5-dione 
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To a solution of thiomaleimide 60 (300 mg, 1.32 mmol) in CH2Cl2 (30 ml) at -10 °C a 
solution of m-CPBA (235 mg, 1.32 mmol) in CH2Cl2 (15 ml) was added over 30 min. 
A further portion of m-CPBA (70.4 mg, 0.39 mmol) in CH2Cl2 (3 mL) was added after 
3 h. Another portion of m-CPBA (47.0 mg, 0.26 mmol) in CH2Cl2 (1 mL) was added 
after 5 h. After a total of 6 h the reaction mixture was washed with 10% aq. NaHCO3 
(2 x 25 mL), dried (MgSO4), filtered and the solvent evaporated in vacuo to afford 
the title compound 66 as a pale yellow waxy solid (321 mg, 1.32 mmol) in 100% 
yield. 
 
δH (600 MHz, CDCl3) 7.13 (1H, s, CH-2), 3.20 (1H, ddd, J = 7.3, 6.0, 4.3 Hz, CHH-
6), 3.06 (3H, s, CH3-5), 3.05-3.01 (1H, m, CHH-6), 1.99-1.91 (1H, m, CHH-7), 1.73-
1.66 (1H, m, CHH-7), 1.51-1.43 (2H, m, CH2), 1.34-1.30 (4H, m, 2 x CH2), 0.91-0.88 
(3H, m, CH3-11); δC (150 MHz, CDCl3) 167.0 (C=O), 166.5 (C=O), 154.7 (C), 133.8 
(CH), 53.4 (CH2), 31.2 (CH2), 28.3 (CH2), 24.4 (CH3), 22.5 (CH2), 22.0 (CH2), 14.1 
(CH3); IR 1708 (s), 1442 (m), 1383 (m); MS (CI+) m/z (relative intensity): 244 
([M+H]+, 100), 117 (12). Exact mass calcd. for [C11H17NO3S]++H: 244.1001. 
Measured: 244.1002 (CI+); m.p.: 33 - 35 °C. 
 
68. 1-Methyl-3-phenylsulfinyl-4-phenylthio-pyrrole-2,5-dione 
 
 
To a solution of dithiomaleimide 63 (100 mg, 0.30 mmol) in CH2Cl2 (7 mL) was 
added m-CPBA (105 mg, 0.61 mmol) in CH2Cl2 (3.5 mL) over 30 min at -10°C. The 
reaction mixture was allowed to warm to room temperature over 1.5 h. After this 
time, the solution was washed with 10% aq. Na2CO3 (5 mL), brine (5 mL), dried 
(MgSO4), filtered and the solvent evaporated in vacuo. Purification by flash 
chromatography (PE : EtOAc, gradient elution from 90 : 10 to 70 : 30) afforded the 
title compound 68 as a yellow oil (48.7 mg, 0.14 mmol) in a 46% yield. 
 
δH (600 MHz, CDCl3) 7.68-7.65 (4H, m, 4 x CH-Ar), 7.53-7.49 (4H, m, 4 x CH-Ar), 
7.48-7.45 (2H, m, 2 x CH-Ar), 2.88 (3H, s, CH3-1); δC (150 MHz, CDCl3) 167.7 
(C=O), 167.6 (C=O), 150.0 (C), 141.6 (C), 134.8 (2 x CH-Ar), 133.2 (C), 131.5 (CH), 
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131.3 (CH), 130.3 (2 x CH), 129.5 (2 x CH), 126.6 (C), 124.8 (2 x CH), 24.6 (CH3); 
IR 1775 (w), 1707 (s), 1532 (w), 1442 (m), 1380 (m); MS (CI+) m/z (relative 
intensity): 344 ([M+H]+, 100), 327 (14), 295 (27). Exact mass calcd. for 
[C17H13NO3S2]++H: 344.0415. Measured: 344.0419 (CI+). 
 
69. 3-Hexylsulfinyl-4-hexylthio-1-methyl-pyrrole-2,5-dione 
 
 
To a solution of dithiomaleimide 64 (128 mg, 0.37 mmol) in CH2Cl2 (9 mL) was 
added m-CPBA (146 mg, 0.82 mmol) in CH2Cl2 (5 mL) over 30 min at -15°C. The 
reaction mixture was allowed to warm to room temperature over 45 min. After this 
time, the mixture was washed with 10% aq. Na2CO3 (5 mL), brine (5 mL), dried 
(MgSO4), filtered and the solvent was evaporated in vacuo. Purification by flash 
chromatography (PE : EtOAc, gradient elution from 85 : 15 to 70 : 30) afforded the 
title compound 69 as a yellow oil (50.7 mg, 0.14 mmol) in 38% yield. 
 
δH (600 MHz, CDCl3) 3.44 (2H, td, J = 11.5 , 3.5 Hz, CH2-17), 3.39-3.34 (1H, ddd, J 
= 15.2, 9.6, 5.6 Hz, CHH-6), 3.18-3.13 (1H, ddd, J = 16.2, 9.7, 6.4 Hz, CHH-6), 3.03 
(3H, s, CH3-1), 1.82-1.73 (2H, m, CH2-7), 1.70 (2H, qn, J = 7.7 Hz, CH2-16), 1.49-
1.41 (4H, m, CH2-8 and CH2-15), 1.33-1.28 (8H, m, CH2-9, CH2-10, CH2-13, CH2-
14), 0.89 (6H, t, J = 6.9 Hz, CH3-11 and CH3-12); δC (150 MHz, CDCl3) 165.4 (C=O), 
165.1 (C=O), 151.6 (C), 130.5 (C), 52.6 (CH2), 32.3 (CH2), 31.5 (CH2), 31.3 (CH2), 
29.9 (CH2), 28.46 (CH2), 28.43 (CH2), 24.6 (CH3), 22.8 (CH2), 22.6 (CH2), 22.5 
(CH2), 14.1 (CH3), 14.0 (CH3); IR 2952 (m), 2926 (m), 1704 (s), 1526 (w), 1434 (m), 
1379 (m), 1051 (m); MS (EI+) m/z (relative intensity): 359 ([M]+, 15), 342 (46) 275 
(48), 175 (100), 116 (78). Exact mass calcd. for [C17H19NO3S2]+: 359.1583. 
Measured: 359.1577 (EI+). 
 
70. 3-Phenylsulfonyl-pyrrolidine-2,5-dione180 
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To a solution of maleimide (500 mg, 5.15 mmol) in water (10 mL) monopotassium 
phosphate buffer (10% (w/v) aq., 84 mL, 6.18 mmol) and sodium benzenesulfinate 
(950 mg, 5.67 mmol) were added. The resulting mixture was stirred at room 
temperature for 2 h, during which time a white solid precipitated. The solid was 
filtered and dried in vacuo to give the title compound 70 as a white solid (1.20 g, 
5.01 mmol) in 98% yield. 
 
δH (600 MHz, CDCl3) 8.03 (1H, br s, NH), 7.96-7.94 (2H, m, 2 x CH-5), 7.78-7.75 
(1H, m, CH-7), 7.65-7.62 (2H, m, 2 x CH-6), 4.36 (1H, dd, J = 9.7, 3.9 Hz, CH-3), 
3.41 (1H, dd, J = 19.2, 3.8 Hz, CHH-2), 3.12 (1H, dd, J = 19.2, 9.8 Hz, CHH-2); δC 
(150 MHz, CDCl3) 172.3 (C=O), 167.9 (C=O), 136.4 (C), 135.2 (CH), 129.6 (2 x 
CH), 129.5 (2 x CH), 64.5 (CH), 31.0 (CH2); IR 3342 (w), 1792 (m), 1714 (s), 1311 
(m), 1150 (m); MS (EI+) m/z (relative intensity): 239 ([M]+, 4), 175 (55), 141 (85), 85 
(100). Exact mass calcd. for [C10H9NO4S]+: 239.0247. Measured: 239.0248 (EI+); 
m.p.: 152 °C (lit. m.p.180: 156 - 158 °C). 
 
71. 1-Methyl-3-phenylsulfonyl-pyrrolidine-2,5-dione 
 
 
To a solution of N-methylmaleimide (111 mg, 1.00 mmol) in water (1.8 mL) 
monopotassium phosphate buffer (10% (w/v) aqueous, 1.5 mL, 1.10 mmol) and 
sodium benzenesulfinate (201 mg, 1.20 mmol) were added. The mixture was stirred 
at room temperature for 1.5 h. Firstly a white solid precipitated, but in time the 
reaction mixture turned pink and a waxy solid was formed. The reaction mixture was 
extracted with CH2Cl2 (3 x 10 mL), the combined organic layers were washed with 
brine (5 mL), dried (MgSO4), filtered and the solvent was evaporated in vacuo to 
afford the title compound 71 as a white solid (228 mg, 0.90 mmol) in a 90% yield. 
 
δH (600 Hz, CDCl3) 7.94-7.93 (2H, m, 2 x CH-7), 7.75 (1H, tt, J = 7.5, 1.3 Hz, CH-9), 
7.65-7.62 (2H, m, 2 x CH-8), 4.33 (1H, dd, J = 9.6, 3.8 Hz, CH-2), 3.36 (1H, dd, J = 
19.0, 3.8 Hz, CHH-1), 3.07 (1H, dd, J = 19.0, 9.6 Hz, CHH-1), 2.97 (3H, s, CH3-4); 
δC (150 Hz, CDCl3) 172.9 (C=O), 168.6 (C=O), 136.6 (C), 135.1 (CH), 129.6 (2 x 
CH), 129.5 (2 x CH), 63.4 (CH), 31.0 (CH2), 25.6 (CH3); IR 2950 (w), 1784 (w), 1702 
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(s), 1436 (m), 1382 (m), 1323 (m), 1311 (m), 1286 (m), 1150 (s), 1117 (m); MS (EI+) 
m/z (relative intensity): 252 ([M]+, 100). Exact mass calcd. for [C11H11NO4S]+: 
252.0331. Measured: 252.0334 (EI+); m.p.: 147 - 149 °C. 
 
62. (3r,4r)-1-Methyl-3,4-bis(phenylthio)pyrrolidine-2,5-dione  
 
 
A solution of thiophenol (269 μL, 2.63 mmol) in MeOH (100 mL) was added over 15 
min to a solution of bromomaleimide 57 (250 mg, 1.31 mmol) and sodium acetate 
(179 mg, 1.31 mmol) in MeOH (70 mL). The reaction mixture was stirred at room 
temperature for 18 h and then the solvent was removed in vacuo. Water (10 mL) 
was added and then the product was extracted with EtOAc (3 x 10 mL), washed with 
brine (10 mL), dried (MgSO4) and filtered. The solvent was evaporated in vacuo to 
afford the title compound 62 as a yellow solid (410 mg, 1.24 mmol) in 95% yield. 
 
δH (600 MHz, CDCl3) 7.45-7.44 (4H, m, 4 x CH-Ar), 7.38-7.35 (2H, m, 2 x CH-5), 
7.33-7.30 (4H, m, 4 x CH-Ar), 3.90 (2H, s, 2 x CH-3), 2.74 (3H, s, CH3-1); δC (150 
MHz, CDCl3)* 173.4 (2 x C=O), 134.9 (4 x CH), 129.8 (2 x CH), 129.6 (4 x CH), 51.8 
(2 x CH), 25.4 (CH3); IR 2970 (w), 1737 (s), 1714 (s), 1438 (m), 1365 (m), 1228 (m), 
1217 (m), 745 (w); MS (EI+) m/z, (relative intensity): 329 ([M]+, 3), 220 (14), 109 
(100). Exact mass calcd. for [C17H15NO2S2]+: 329.05387. Measured: 329.05426 
(EI+); m.p.: 94 - 96 °C. 
* 2 C missing due to overlap 
 
The stereochemistry of compound x was investigated. Based on molecular 
modelling (PC Model v 8.5) 3JHH for the anti isomer (corresponding to a torsional 
angle of 118°) is 3.2 Hz, whereas for the syn isomer 3JHH (corresponding to a 
torsional angle of 5°) is 11.1 Hz. From the 13C satellites in the 1H-NMR spectrum, 
3JHH = 3.2 Hz which demonstrates that compound 62 was obtained as the anti 
isomer. 
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76. 3-Methoxy-1-methyl-4-phenylsulfonyl-pyrrolidine-2,5-dione 
 
 
To a solution of dithiosuccinimide 62 (20.0 mg, 0.06 mmol) in MeOH (7.5 mL) was 
added Oxone® (221.3 mg, 0.36 mmol) in water (2.5 mL) and the resulting mixture 
was stirred at room temperature for 12 h. After this time, the solvent was evaporated 
in vacuo. Purification by flash chromatography (PE : EtOAc, gradient elution from 70 
: 30 to 50 : 50) afforded the title compound 76 as a transparent oil (3.80 mg, 0.01 
mmol) in 22% yield. 
 
δH (600 MHz, CDCl3) 7.98-7.97 (2H, m, 2 x CH-Ar), 7.77-7.75 (1H, m, CH-Ar), 7.66-
7.62 (2H, m, 2 x CH-Ar), 4.71 (1H, d, J = 3.5 Hz, CH-4 or CH-5), 4.17 (1H, d, J = 3.5 
Hz, CH-4 or CH-5), 3.69 (3H, s, CH3-10), 3.00 (3H, s, CH3-1); δC (150 MHz, CDCl3) 
172.2 (C=O), 166.5 (C=O),137.1 (C), 135.2 (CH), 129.5 (2 x CH), 129.4 (2 x CH), 
75.4 (CH), 69.9 (CH), 60.4 (CH3), 24.2 (CH3); IR 2923 (w), 1710 (s), 1434 (m), 
13412 (m), 1151 (s); MS (CI+) m/z (relative intensity): 284 ([M+H]+, 100), 251 (20). 
Exact mass calcd. for [C12H13NO5S]++H: 284.0593. Measured: 284.0588 (CI+). 
 
From molecular modelling of compound 76; the deheadral angle is 130 °C in the 
trans isomer and 20 °C in the cis isomer. These two angles correspond to 4.5 Hz 
and 10 Hz respectively. The J coupling is 3.5 Hz for the dublet in compound 76, 
indicating the trans isomer. 
 
78. 3-hydroxy-1-methyl-4-phenylsulfonyl-pyrrolidine-2,5-dione 
 
 
To a solution of dithiosuccinimide 62 (20.0 mg, 0.06 mmol) in t-BuOH (7.5 mL) was 
added Oxone® (221 mg, 0.36 mmol) in water (2.5 mL) and the resulting mixture was 
stirred at room temperature for 12 h. After this time, the solvent was evaporated in 
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vacuo. Purification by flash chromatography (PE : EtOAc, gradient elution from 70 : 
30 to 50 : 50) afforded the title compound 78 as a transparent oil (4.80 mg, 0.02 
mmol) in 30% yield. 
 
δH (600 MHz, CDCl3) 8.00-7.99 (2H, m, 2 x CH-Ar), 7.80-7.78 (1H, m, CH-Ar), 7.69-
7.67 (2H, m, 2 x CH-Ar), 4.94 (1H, d, J = 3.5 Hz, CH-4), 2.98 (3H, s, CH3-1);  (150 
MHz, CDCl3) 175.9 (C=O), 168.2 (C=O),139.2 (C), 135.9 (CH), 130.5 (2 x CH), 
130.4 (2 x CH), 71.6 (CD), 68.9 (CH), 60.3 (CH3), 25.4 (CH3); IR 1713 (s), 1448 (m), 
1311 (m), 1152 (s); MS (CI+) m/z (relative intensity): 270 ([M+H]+, 50), 205 (100). 
Exact mass calcd. for [C11H11NSO5]++H: 270.0436. Measured: 270.0438 (CI+). 
 
79. 1-Methyl-3-phenylselanyl-pyrrole-2,5-dione 
 
 
To a degassed solution of benzeneselenol (604 μL, 2.52 mmol) in MeOH (220 mL) 
was added sodium acetate (172 mg, 2.10 mmol) and the reaction mixture was 
cooled to -60°C. A solution of bromomaleimide 57 (200 mg, 1.05 mmol) in MeOH 
(220 mL) was added dropwise over 45 min with vigorous stirring while maintaining 
the temperature between -60 and -50 °C. The reaction mixture was allowed to warm 
to room temperature over 15 min and then the solvent was removed in vacuo. 
Purification by flash chromatography (PE : EtOAc, gradient elution from 90 : 10 to 70 
: 30) afforded of the title compound 79 as a yellow oil (514 mg, 1.93 mmol) in 92% 
yield. 
 
δH (600 MHz, CDCl3) 7.63-7.62 (2H, m, 2 x CH-Ar), 7.49-7.46 (1H, m, CH-8), 7.22-
7.20 (2H, m, 2 x CH-Ar), 5.88 (1H, s, CH-3), 3.02 (3H, s, CH3-1); δC (150 MHz, 
CDCl3) 169.9 (C=O), 169.2 (C=O), 150.6 (C), 135.9 (2 x CH), 130.4 (2 x CH), 130.2 
(CH), 124.7 (CH), 123.9 (C), 24.2 (CH3); IR 1765 (w), 1701 (s), 1556 (w), 1440 (m), 
1384 (m); MS (EI+) m/z (relative intensity): 267 ([M]+, 84), 209 (32), 182 (83), 102 
(100). Exact mass calcd. for [C11H9NO2Se]+: 266.9793. Measured: 266.9802 (EI+). 
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80. 1-Methyl-3,4-bis(phenylselanyl)-pyrrole-2,5-dione 
 
 
A degassed solution of benzeneselenol (425 μL, 3.89 mmol) in MeOH (3 mL) was 
added dropwise to a solution of N-methyl 2,3-dibromomaleimide (400 mg, 1.47 
mmol) and sodium acetate (320 mg, 3.90 mmol) in MeOH (47 mL). After 1 h, a 
second portion of sodium acetate (121 mg, 1.47 mmol) and benzeneselenol (100 
μL, 0.91 mmol) in MeOH (0.5 mL) was added. After 2 h, a third portion of 
benzeneselenol (161 μL, 1.47 mmol) in MeOH (0.5 mL) was added and the reaction 
mixture was stirred for a further 10 min before the solvent was removed in vacuo. 
Purification by flash chromatography (PE : EtOAc, gradient elution from 95 : 5 to 92 : 
8) afforded the title compound 80 as a yellow solid (369 mg, 0.87 mmol) in 61% 
yield. 
 
δH (600 MHz, CDCl3) 7.49-7.47 (4H, m, 4 x CH-Ar), 7.36-7.33 (2H, m, 2 x CH-7), 
7.29-7.27 (4H, m, 4 x CH-Ar), 2.97 (3H, s, CH3-1); δC (150 MHz, CDCl3) 167.6 (2 x 
C=O), 138.5 (2 x C), 134.9 (4 x CH), 129.4 (4 x CH), 128.9 (2 x CH), 126.2 (2 x C), 
24.8 (CH3); IR 1717 (s), 1578 (w), 1439 (m), 1473 (w), 439 (m), 2243 (s); MS (EI+) 
m/z (relative intensity): 423 ([M]+, 25), 314 (16), 111 (32). Exact mass calcd. for 
[C17H13NO2Se2]+: 422.9271. Measured: 422.9278 (EI+); m.p.: 82 - 83 °C. 
 
82. 1-Methyl-pyrrole-2,5-dione-3-yl 3-chlorobenzoate 
 
 
To a solution of seleomaleimide 79 (64.8 mg, 0.24 mmol) in CH2Cl2 (5 mL) was 
added m-CPBA (43.3 mg, 0.24 mmol) in CH2Cl2 (3 mL) over 30 min at -15 °C. The 
reaction mixture was allowed to warm to room temperature and after 3 h a second 
portion of m-CPBA (21.6 mg, 0.12 mmol) in CH2Cl2 (1.0 mL) was added dropwise at 
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-15 °C. After a further 20 h a third portion of m-CPBA (13.0 mg, 0.07 mmol) in 
CH2Cl2 (0.5 mL) was added dropwise at -15 °C. After a total of 22 h, the reaction 
mixture was washed with 10% aq. Na2CO3 (5 mL), brine (5 mL), dried (MgSO4), 
filtered and the solvent was evaporated in vacuo. Purification by flash 
chromatography (PE : EtOAc, gradient elution from 90 : 10 to 70 : 30) afforded the 
title compound 82 as a white solid (7.40 mg, 0.03 mmol) in 11% yield. 
 
δH (600 MHz, CDCl3) 8.16 (1H, t, J = 1.7 Hz, CH-8), 8.09 (1H, ddd, J = 7.8, 1.2, 1.1 
Hz, CH-12), 7.67 (1H, ddd, J = 8.0, 1.1, 0.9 Hz, CH-10), 7.49 (1H, t, J = 7.9 Hz, CH-
11), 6.67 (1H, s, CH-5), 3.08 (3H, s, CH3-1); δC (150 MHz, CDCl3) 169.9 (C=O), 
165.6 (C=O), 161.1 (C=O), 149.6 (C), 135.4 (C), 135.1 (CH), 130.7 (CH), 130.4 
(CH), 129.0 (C), 128.9 (CH), 111.2 (CH), 24.1 (CH3); IR 3167 (m), 1750 (s), 1711 
(s), 1629 (m); MS (CI+) m/z, (relative intensity): 266 ([M+H]+, 41), 139 (100). Exact 
mass calcd. for [C12H8ClNO4]++H: 266.0220. Measured: 266.0219 (CI+); m.p. 123 - 
125 °C. 
 
85. 3-Chloro-pyrrole-2,5-dione224 
 
 
To a solution of bromomaleimide 22 (75.0 mg, 0.43 mmol) in MeOH (1 mL) was 
added tetrabutylammonium chloride (953 mg, 3.43 mmol) and the reaction mixture 
was refluxed. After 12 h, the solvent was removed in vacuo. Purification by flash 
chromatography (PE : EtOAc, gradient elution from 80 : 20 to 70 : 30) afforded the 
title compound 85 as a white solid (33.0 mg, 0.25 mmol) in 58% yield. 
 
δH (500 MHz, CDCl3) 7.46 (1H, br s, NH), 6.66 (1H, s, CH-2); δC (125 MHz, CDCl3) 
166.9 (C=O), 164.4 (C=O), 141.7 (C), 127.9 (CH); IR 3237 (m), 1720 (s), 1590 (m), 
1036 (w); MS (CI+) m/z, (relative intensity): 134 ([37M+H]+, 30), 132 ([35M+H]+, 100). 
Exact mass calcd. for [C4H3NO235Cl]++H: 131.9852. Measured: 131.9855 (CI+); 
m.p.: 130 °C (lit. m.p.225: 131 °C).  
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86. 3-Chloro-1-methyl-pyrrole-2,5-dione 
 
 
To a solution of bromomaleimide 57 (400 mg, 2.10 mmol) in MeOH (4 mL) 
tetrabutylammonium chloride (1.17 g, 4.20 mmol) was added and the reaction 
mixture was refluxed. After 4.5 h a second portion of tetrabutylammonium chloride 
(2.28 g, 8.20 mmol) was added and the reflux was continued. After a total of 7.5 h, 
the solvent was removed in vacuo. Purification by flash chromatography (PE : 
EtOAc, gradient elution from 95 : 5 to 75 : 25) afforded the title compound 86 as a 
white solid (272 mg, 1.86 mmol) in a 89% yield. 
 
δH (600 MHz, CDCl3) 6.64 (1H, s, CH-2), 3.07 (3H, s, CH3-5); δC (150 MHz, CDCl3) 
168.0 (C=O), 165.1 (C=O), 141.1 (C), 126.9 (CH); 24.6 (CH3); IR 3099 (w), 2924 
(br), 1704 (s), 1601 (m), 1442 (m), 977 (m); MS (EI+) m/z, (relative intensity): 147 
([37M]+, 30), 145 ([35M]+, 100),. Exact mass calcd. for [C5H4NO235Cl]+: 144.9925. 
Measured: 144.9928 (EI+); m.p.: 115 °C. 
 
88. 3-Iodo-1-methyl-pyrrole-2,5-dione 
 
 
A solution of sodium iodide (2.84 g, 18.9 mmol) and bromomaleimide 57(0.60 g, 
3.15 mmol) in acetone (3 mL) was refluxed for 7 h and then stirred at room 
temperature for 15 h. The solids were filtered and the filtrate was concentrated in 
vacuo. Purification by flash chromatography (PE : EtOAc, gradient elution from 90 : 
10 to 80 : 20) afforded the title compound 88 as a yellow solid (616 mg, 2.59 mmol) 
in 82% yield. 
 
δH (500 MHz, CDCl3) 7.18 (1H, s, CH-3), 3.09 (3H, s, CH3-1); δC (150 MHz, CDCl3) 
170.0 (C=O), 166.9 (C=O), 140.7 (CH), 107.3 (C), 24.9 (CH3); IR 2922 (w), 1702 (s); 
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MS (EI+) m/z (relative intensity): 237 ([M]+, 100), 152 (31); Exact mass calcd. for 
[C5H4NO2I]+: 236.9281. Measured: 236.9285; m.p.: 109 - 110 °C.  
 
89. 3,4-Diiodo-pyrrole-2,5-dione189 
 
 
A solution of 2,3-dibromomaleimide (1.00 g, 3.92 mmol) and sodium iodide (1.76 g, 
11.8 mmol) in AcOH (14 mL) was refluxed for 2 h and then water (11 mL) was 
added. The white precipitate was filtered, washed with water (10 mL) and dried in 
vacuo to afford the title compound 89 as a yellow solid (1.01 g, 2.90 mmol) in 74% 
yield.  
 
δC (150 MHz, CDCl3) 165.9 (2 x C=O), 118.5 (2 x C); IR 3242 (s), 1756 (m), 1709 
(s), 1545 (m), 1009 (s); MS (EI+) m/z, (relative intensity): 349 ([M]+, 100), 179 (27) . 
Exact mass calcd. for [C4HNO2I2]+: 348.8091; Measured: 348.8096 (EI+); m.p.: 245 - 
246 °C (lit. m.p.189: 254 - 255 °C). 
 
90. 3,4-Diiodo-1-methyl-pyrrole-2,5-dione 
 
 
A solution of N-methyl 2,3-dibromomaleimide (1.00 g, 3.72 mmol) and sodium iodide 
(1.67 g, 11.2 mmol) in AcOH (14 mL) was refluxed for 2 h and then water (11 mL) 
was added. The white precipitate was filtered, washed with water (20 mL) and dried 
in vacuo to afford the title compound 90 as a yellow solid (941 mg, 2.59 mmol) in 
70% yield.  
 
δH (600 MHz, CDCl3) 3.15 (3H, s, CH3-3); δC (150 MHz, CDCl3) 166.6 (2 x C=O), 
117.3 (2 x C), 26.1 (CH3); IR 1701 (s), 1553 (w), 1382 (m); MS (EI+) m/z, (relative 
intensity): 363 ([M]+, 8), 127 (100). Exact mass calcd. for [C5H3NO2I2]+: 362.8248; 
Measured: 362.8254 (EI+); m.p.: 250 °C. 
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91. 3-Bromo-4-chloro-1-methyl-pyrrole-2,5-dione 
 
 
To a solution of chloromaleimide 86 (75 mg, 0.51 mmol) in CHCl3 (0.4 mL) a 
solution of bromine (26.2 µL, 0.51 mmol) in CHCl3 (0.4 mL) was added dropwise 
and the resulting reaction mixture was refluxed for 2 h. After this time, another 
portion of bromine (13.1 µL, 0.5 mmol) in CHCl3 (0.5 mL) was added and the reflux 
continued for 1 h. Then, another portion of bromine (26.2 µL, 0.51 mmol) in CHCl3 
(0.5 mL) was added and the reflux continued. After a total of 5 h, the solvent was 
removed in vacuo. Purification by flash chromatography (PE : EtOAc, gradient 
elution from 90 : 10 to 80 : 20) afforded the title compound 91 as a white solid (36.0 
mg, 0.12 mmol) in 23% yield. 
 
δH (600 MHz, CDCl3) 3.12 (3H, s, CH3-5); δC (150 MHz, CDCl3) 163.64 (C=O), 
164.59 (C=O), 138.2 (C), 124.4 (C), 25.4 (CH3); IR 1719 (s), 1002 (m); MS (CI+) 
m/z, (relative intensity): 228 (25), 226 (100), 224 (76). Exact mass calcd. for 
[C5H379Br35ClNO2]+: 222.9030. Measured: 222.9037 (EI+); m.p.: 130 °C. 
 
92. 1-Methyl-3-propylamino-pyrrole-2,5-dione177  
 
 
To a solution of propylamine (75 μL, 1.09 mmol) and sodium acetate (92 mg, 1.12 
mmol) in MeOH (15 mL) bromomaleimide 92 (213 mg, 1.12 mmol) in MeOH (15 mL) 
was added dropwise and the solution was stirred at room temperature for 25 min. 
After this time, the solvent was evaporated in vacuo. Purification by flash 
chromatography (PE : EtOAc, gradient elution from 80 : 20 to 60 : 40) afforded the 
title compound 92 as a yellow solid (75.1 mg, 0.45 mmol) in 41% yield. 
 
δH (500 MHz, CDCl3) 5.37 (1H, br s, NH), 4.79 (1H, s, CH-2), 3.15-3.11 (2H, dt, J = 
6.9, 6.0 Hz, CH2-6), 2.97 (3H, s, CH3-5), 1.66 (2H, sext., J = 7.2 Hz, CH2-7), 0.98 
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(3H, t, J = 7.3 Hz, CH3-8); δC (150 MHz, CDCl3) 172.7 (C=O), 167.7 (C=O), 149.5 
(C), 83.9 (CH), 46.1 (CH2), 23.5 (CH3), 21.9 (CH2), 11.4 (CH3); IR 3317 (s), 1697 (s), 
1654 (s), 1453 (m); MS (EI+) m/z, (relative intensity): 168 ([M]+, 78), 139 (100). 
Exact mass calcd. for [C8H12N2O2]+: 168.0893. Measured: 168.0889 (EI+); m.p.: 85 - 
86 °C. 
 
93. 1-Methyl-3-phenylamino-pyrrole-2,5-dione 
 
 
To bromomaleimide 57 (100 mg, 0.53 mmol) in MeOH (1 mL) was added sodium 
acetate (43.9 mg, 0.53 mmol) and aniline (49.0 μL, 0.53 mmol). The reaction 
mixture was refluxed for 2 h and then the solvent was evaporated in vacuo. 
Purification by flash chromatography (PE : EtOAc, 75 : 25) afforded the title 
compound 93 as a yellow solid (40.1 mg, 0.20 mmol) in 51% yield. 
 
δH (600 MHz, CDCl3) 7.42-7.39 (2H, m, 2 x CH-Ar), 7.24 (1H, br s, NH), 7.17-7.14 
(3H, m, 3 x CH-Ar), 5.51 (1H, s, CH-2), 3.05 (3H, s, CH3-5); δC (150 MHz, CDCl3) 
172.9 (C=O), 168.4 (C=O), 142.6 (C), 138.5 (C), 129.9 (2 x CH), 124.6 (CH), 118.8 
(2 x CH-Ar), 89.2 (CH), 23.9 (CH3); IR 3292 (m), 1693 (s), 1614 (m), 1448 (m), 700 
(m); MS (EI+) m/z, (relative intensity): 203 ([M]+, 100), 94 (21). Exact mass calcd. for 
[C11H10N2O2]+: 202.0737. Measured: 202.0732 (EI+); m.p.: 190 °C. 
 
94. 3-Bromo-4-phenylamino-pyrrole-2,5-dione 
 
 
To a mixture of 2,3-dibromomaleimide (100 mg, 0.39 mmol) and sodium acetate 
(32.4 mg, 0.39 mmol) in EtOH (2 mL) was added aniline (31.7 μL, 0.39 mmol). The 
reaction mixture was refluxed for 2 h and then the solvent was evaporated in vacuo. 
Purification by flash chromatography (PE : EtOAc, 75 : 25) afforded the title 
compound 94 as an orange solid (104 mg, 0.39 mmo) in 68% yield. 
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δH (500 Hz, CDCl3) 7.42-7.38 (2H, m, 2 x CH-Ar), 7.29-7.26 (1H, m, CH-8), 7.22-
7.20 (2H, m, 2 x CH-Ar), 7.09 (1H, br s, NH); δC (150 Hz, CDCl3) 166.9 (C=O), 166.1 
(C=O), 140.5 (C), 134.9 (C), 128.9 (2 x CH), 126.8 (CH), 124.7 (2 x CH), 81.7 (C); 
IR 3282 (m), 1715 (s), 1641 (s), 1614 (m); MS (EI+) m/z, (relative intensity): 268 
([81M]+, 98), 266 ([79M]+, 98), 144 (100). Exact mass calcd. for [C10H779BrN2O2]+: 
265.9685. Measured: 265.9679 (EI+); m.p.: 172 °C. 
 
95. 3-Methoxy-1-methyl-pyrrole-2,5-dione226 
 
 
To a solution of bromomaleimide 57 (100 mg, 0.53 mmol) in MeOH (1.5 mL) was 
added sodium methoxide (42.6 mg, 0.78 mmol) and the resulting reaction mixture 
was stirred at room temperature for 10 min. The mixture was cooled to 0 - 4 °C, 
maintained at this temperature for a further 24 h and then the solvent was 
evaporated in vacuo. The crude mixture was redissolved in CH2Cl2 (10 mL) and 
washed with water (10 mL). The aqueous layer was extracted with CH2Cl2 (3 x 10 
mL) and the combined organic layers were dried (MgSO4), filtered and the solvent 
was evaporated in vacuo. Purification by flash chromatography (PE : EtOAc, 
gradient elution from 80 : 20 to 65 : 35) afforded the title compound 95 as a white 
solid (18.6 mg, 0.13 mmol) in 25% yield. 
 
δH (600 MHz, CDCl3) 5.40 (1H, s, CH-2), 3.93 (3H, s, CH3-6), 2.99 (3H, s, CH3-5); δC 
(150 Hz, CDCl3) 170.3 (C=O), 165.8 (C=O), 161.2 (C), 96.3 (CH), 58.9 (CH3), 23.6 
(CH3); IR 3112 (m), 1708 (s), 1634 (s), 1449 (s), 1324 (m), 957.1 (m), 818 (m); MS 
(EI+) m/z, (relative intensity): 141 ([M]+, 72), 112 (100). Exact mass calcd. for 
[C6H7NO3]+: 141.0420. Measured: 141.0426 (EI+); m.p.: 124 °C (lit. m.p.227: 129 - 
130 °C).  
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99. 3-Bromo-1-methyl-4-phenoxy-pyrrole-2,5-dione  
 
 
100. 1-Methyl-3,4-diphenoxy-pyrrole-2,5-dione 
  
 
A solution of phenol (147 mg, 1.56 mmol) in dry dioxane (2 mL) was added dropwise 
to a solution of potassium tert-butoxide (213 mg, 1.85 mmol) in dry dioxane (4 mL). 
18-crown-6 (491 mg, 1.85 mmol) was added and the reaction mixture was stirred at 
room temperature for 15 min. The resulting mixture was added to a solution of N-
methyl 2,3-dibromomaleimide (200 mg, 0.74 mmol) in dry dioxane (2.5 mL) over 30 
min, and the stirring continued at room temperature for 48 h. After this time, the 
solvent was evaporated in vacuo and the resulting crude was redissolved in EtOAc. 
The organic layer was washed with 1 M NaOH (3 x 5 mL), brine (5 mL), dried 
(MgSO4), filtered and the solvent evaporated in vacuo. Purification by flash 
chromatography (PE : EtOAc, 80 : 20) afforded 99 as a white solid (45.1 mg, 0.16 
mmol) in 22% yield. Further elution afforded 100 as a white solid (65.4 mg, 0.22 
mmol) in 30% yield. 
 
Compound 99: 
δH (600 MHz, CDCl3) 7.40-7.38 (2H, m, 2 x CH-Ar), 7.29-7.27 (1H, m, CH-9), 7.14-
7.12 (2H, m, 2 x CH-Ar), 3.09 (3H, s, CH3-1); δC (150 MHz, CDCl3) 165.4 (C=O), 
164.3 (C=O), 153.4 (C), 152.3 (C), 129.8 (2 x CH), 126.3 (CH), 119.7 (2 x CH), 98.3 
(C), 24.7 (CH3); IR 2927 (w), 1727 (s), 1649 (m), 1452 (m), 1197 (m); MS (CI+) m/z 
(relative intensity): 284 ([81M+H]+, 100), 282 ([79M+H]+, 100), 74 (14); Exact mass 
calcd. for [C11H8NO379Br]++H: 281.9766 (CI+). Measured: 281.9764 (CI+); m.p.: 124 
°C. 
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Compound 100: 
δH (600 MHz, CDCl3) 7.18-7.16 (4H, m, 4 x CH-Ar), 7.05-7.02 (2H, m, 2 x CH-7), 
6.84-6.82 (4H, m, 4 x CH-Ar), 3.08 (3H, s, CH3-1); δC (150 MHz, CDCl3) 165.6 (2 x 
C=O), 154.9 (2 x C), 133.3 (2 x C), 129.5 (4 x CH), 124.6 (2 x CH), 117.3 (4 x CH), 
23.8 (CH3); IR 2923 (w), 1717 (s), 1683 (m), 1488 (m), 1445 (m), 1334 (m), 1232 
(m), 1086 (m); MS (EI+) m/z (relative intensity): 295 ([M]+, 35), 119 (33). Exact mass 
calcd. for [C17H13NO4]+: 295.0839. Measured: 295.0841; m.p. 103 - 105 °C. 
 
97. 3-Bromo-4-phenoxy-pyrrole-2,5-dione 
 
98. 3,4-Diphenoxy-pyrrole-2,5-dione 
 
 
To a solution of phenol (244 mg, 2.59 mmol) in dry dioxane (2 mL) potassium tert-
butoxide (31 mg, 2.95 mmol) in dry dioxane (4 mL) was added dropwise and the 
resulting solution was stirred for 10 min at room temperature. The resulting mixture 
was added dropwise to a solution of 2,3-dibromomaleimide (300 mg, 1.18 mmol) in 
dry dioxane (2 mL) and the mixture stirred at room temperature for 59 h. After this 
time, the solvent was evaporated in vacuo. The crude mixture was redissolved in 
EtOAc (20 mL), washed with water (10 mL), brine (10 mL), dried (MgSO4), filtered 
and the solvent was evaporated in vacuo. Purification by flash chromatography (PE : 
Et2O, gradient elution from 90 : 10 to 50 : 50) afforded the title compound 97 as a 
white solid (88.5 mg, 0.33 mmol) in 28% yield. Further elution afforded the title 
compound 98 as a yellow solid (7.2 mg, 0.02 mmol) in 2% yield 
 
Compound 97: 
δH (600 MHz, CDCl3) 7.95 (1H, br s, NH), 7.40 (2H, t, J = 8.3 Hz, 2 x CH-Ar), 7.30-
7.27 (1H, m, CH-8), 7.15-7.13 (2H, m, 2 x CH-Ar); δC (150 MHz, CDCl3) 164.4 
(C=O), 163.5 (C=O), 153.2 (C), 152.4 (C), 129.9 (2 x CH), 126.4 (CH), 119.7 (2 x 
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CH), 99.4 (C); IR 3221 (br), 1719 (s), 1641 (s), 1488 (s), 1275 (s); MS (CI+) m/z, 
(relative intensity): 270 ([81M+H]+,97), 268 ([79M+H]+, 100). Exact mass calcd. for 
[C10H679BrNO3]++H: 267.9609. Measured: 267.9612 (CI+); m.p.: 130 °C. 
 
Compound 98: 
δH (600 MHz, CDCl3) 7.20-7.17 (4H, m, 4 x CH-Ar), 7.13 (1H, br s, NH), 7.06-7.03 
(2H, m, 2 x CH-6), 6.85-6.83 (4H, m, 4 x CH-Ar); δC (150 MHz, CDCl3) 164.4 (2 x 
C=O), 154.7 (2 x C), 133.9 (2 x C), 129.6 (4 x CH), 124.7 (2 x CH), 117.3 (4 x CH); 
IR 3276 (br), 1726 (s), 1590 (m), 1489 (s), 1339 (s), 1220 (m); MS (EI+) m/z, 
(relative intensity): 281 ([M]+, 75); Exact mass calcd. for [C16H11NO4]+: 281.0683. 
Measured: 281.0682 (EI+); m.p.: 128 °C. 
 
101. 1-Methyl-3-phenoxy-pyrrole-2,5-dione 
 
 
To a solution of phenol (207 mg, 2.20 mmol) in dry dioxane (1 mL) potassium tert-
butoxide (264 mg, 2.31 mmol) in dry dioxane (3 mL) was added dropwise and the 
solution was stirred for 15 min at room temperature. The resulting mixture was 
added dropwise to a solution of bromomaleimide 57 (400 mg, 2.10 mmol) in dry 
dioxane (1 mL) and the stirring was continued at room temperature for another 30 
min. After this time, the solvent was evaporated in vacuo. Water (10 mL) was added 
and the crude product was extracted with EtOAc (3 x 30 mL), washed with brine (10 
mL), dried (MgSO4), filtered and the organic solvent was evaporated in vacuo. 
Purification by flash chromatography (PE : EtOAc, gradient elution from 90 : 10 to 80 
: 20) afforded the title compound 101 as a white solid (321 mg, 1.58 mmol) in 75% 
yield. 
 
δH (600 MHz, CDCl3) 7.46-7.43 (2H, m, 2 x CH-Ar), 7.32-7.30 (1H, m, CH-9), 7.18-
7.18 (2H, 2 x CH-Ar), 5.27 (1H, s, CH-2), 3.05 (3H, s, CH3-5); δC (150 MHz, CDCl3) 
170.1 (C=O), 165.8 (C=O), 159.6 (C), 153.9 (C), 130.4 (2 x CH), 126.9 (CH), 119.9 
(2 x CH), 99.4 (CH), 23.7 (CH3); IR 1714 (s), 1637 (m), 1313 (m), 1220 (w); MS 
(EI+) m/z, (relative intensity): 203 ([M]+, 100), 94 (21). Exact mass calcd. for 
[C11H9NO3]+: 203.0577. Measured: 203.0579 (EI+); m.p.: 63 °C. 
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103. 1-Methyl-3-(4-nitrophenoxy)-pyrrole-2,5-dione 
 
 
To a solution of 4-nitrophenol (155 mg, 1.10 mmol) in dry dioxane (1 mL) a mixture 
of potassium tert-butoxide (132 mg, 1.16 mmol) in dry dioxane (4 mL) and 18-crown 
ether (306 mg, 1.16 mmol) was added dropwise and the solution was stirred for 15 
min. The resulting mixture was then added dropwise to a solution of 
bromomaleimide 57 (200 mg, 1.05 mmol) in dry dioxane (1 mL) and the stirring 
continued for another 20 h. After this time, the solvent was evaporated in vacuo. The 
resulting crude was redissolved in EtOAc (10 mL), washed with 1 M aq. NaOH (5 
mL), extracted with EtOAc (3 x 10 mL), dried (MgSO4), filtered and concentrated in 
vacuo. Purification by flash chromatography (PE : EtOAc, gradient elution from 90 : 
10 to 70 : 30) afforded the title compound 103 as a white solid (114 mg, 0.46 mmol) 
in 44% yield. 
 
δH (600 MHz, CDCl3) 8.37-8.35 (2H, m, 2 x CH-Ar), 7.39-7.37 (2H, m, 2 x CH-Ar), 
5.49 (1H, s, CH-2), 3.07 (3H, s, CH3-5); δC (150 MHz, CDCl3) 169.1 (C=O), 165.0 
(C=O), 158.2 (C), 157.6 (C), 145.9 (C), 126.4 (2 x CH), 120.7 (2 x CH), 101.5 (CH), 
23.9 (CH3); IR 1713 (s), 1635 (m), 1588 (m), 1522 (m), 1350 (m), 1231 (w); MS 
(EI+) m/z, (relative intensity): 248 ([M]+, 100), 150 (16). Exact mass calcd. for 
[C11H8N2O5]+: 248.0428. Measured: 248.0435 (EI+); m.p.: 123 - 124 °C. 
 
104. Methyl 4-(1-methyl-pyrrole-2,5-dione-3-yloxy)benzoate 
 
 
To a solution of methyl 4-hydroxybenzoate (170 mg, 1.10 mmol) in dry dioxane (1 
mL) a mixture of potassium tert-butoxide (132 mg, 1.16 mmol) and 18-crown-6 ether 
(306 mg, 1.16 mmol) in dry dioxane (4 mL) was added dropwise and the resulting 
solution was stirred for 15 min at room temperature. The resulting mixture was 
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added dropwise to a solution of bromomaleimide 57 (200 mg, 1.05 mmol) in dry 
dioxane (1 mL) and stirred at room temperature for 19 h. After this time, the solvent 
was evaporated in vacuo, washed with 1 M aq. NaOH, extracted with EtOAc (3 x 
30 mL), dried (MgSO4), filtered and the solvent was evaporated in vacuo. 
Purification by flash chromatography (PE : EtOAc, gradient elution from 90 : 10 to 70 
: 30) afforded the title compound 104 as yellow solid (196 mg, 0.75 mmol) in a 72% 
yield. 
 
δH (600 MHz, CDCl3) 8.15-8.13 (2H, m, 2 x CH-Ar), 7.27-7.25 (2H, m, 2 x CH-Ar), 
5.37 (1H, s, CH-2), 3.94 (3H, s, CH3-9), 3.06 (3H, s, CH3-11); δC (150 MHz, CDCl3) 
169.7 (C), 165.9 (C), 165.4 (C), 158.5 (C), 157.2 (C), 132.2 (2 x CH), 128.9 (C), 
119.9 (2 x CH), 100.3 (CH), 52.6 (CH3), 23.9 (CH3); IR 1731 (s), 1713 (s), 1638 (m), 
1600 (m), 1440 (m), 1285 (m), 1105 (m); MS (EI+) m/z, (relative intensity): 261 ([M]+, 
100), 86 (20). Exact mass calcd. for [C13H11NO5]+: 261.0632. Measured: 261.0636 
(EI+); m.p.: 149 °C. 
 
105. 3,4-bis(4-Methoxyphenoxy)-1-methyl-pyrrole-2,5-dione  
 
 
A solution of 4-methoxyphenol (199 mg, 1.59 mmol) in dry dioxane (1.9 mL) was 
added dropwise to a solution of potassium tert-butoxide (206 mg, 1.85 mmol) in dry 
dioxane (4.3 mL). The reaction mixture was stirred for 15 min then added to a 
solution of N-methyl 2,3-dibromomaleimide (200 mg, 0.74 mmol) in dry dioxane (2.5 
mL) over 30 min. The resulting mixture was stirred at room temperature for 20 h, 
then concentrated in vacuo and redissolved in EtOAc (30 mL). The organic layer 
was washed with 1 M NaOH (10 mL), with brine (10 mL), dried (MgSO4), filtered and 
the solvent was evaporated in vacuo. Purification by flash chromatography (PE : 
EtOAc, gradient elution from 95 : 5 to 40 : 60) afforded the title compound 105 as a 
yellow solid (33.1 mg, 0.10 mmol) in 13% yield. 
 
δH (600 MHz, CDCl3) 6.80-6.78 (4H, m, 4 x CH-Ar), 6.71-6.68 (4H, m, 4 x CH-Ar), 
3.76 (6H, s, 2 x CH3-7), 3.04 (3H, s, CH3-8); δC (150 MHz, CDCl3) 165.8 (2 x C=O), 
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156.5 (C), 148.9 (C), 133.5 (C), 118.4 (4 x CH), 114.4 (4 x CH), 55.7 (2 x CH3), 23.7 
(CH3); IR 2955 (w), 1717 (s), 1504 (s), 1227 (m); MS (EI+) m/z, (relative intensity): 
355 ([M]+, 100), 123 (83). Exact mass calcd. for [C19H17NO6]+: 355.1056. Measured: 
355.1056 (EI+); m.p.: 79 °C. 
 
106. 3-Iodo-1-methyl-4-(4-nitrophenoxy)-pyrrole-2,5-dione 
 
 
A solution of 4-nitrophenol (89.4 mg, 0.64 mmol) in dry dioxane (0.5 mL) was added 
dropwise to a solution of potassium tert-butoxide (89.4 mg, 0.72 mmol) and 18-
crown-6 ether (191 mg, 0.72 mmol) in dry dioxane (3 mL). The reaction mixture was 
stirred for 15 min then added over 30 min to a solution of diiodomaleimide 90 (200 
mg, 0.55 mmol) in dry dioxane (1 mL). The mixture was stirred at room temperature 
for 64 h, then concentrated in vacuo and redissolved in EtOAc (30 mL). The organic 
layer was washed with 1 M aq. NaOH (10 mL), brine (10 mL), dried (MgSO4), 
filtered and the solvent was evaporated in vacuo. Purification by flash 
chromatography (PE : EtOAc, gradient elution from 90 : 10 to 60 : 40) afforded the 
title compound 106 as a yellow solid (50.7 mg, 0.14 mmol) in 47% yield. 
 
δH (600 MHz, CDCl3) 8.31-8.29 (2H, m, 2 x CH-Ar), 7.24-7.22 (2H, m, 2 x CH-Ar), 
3.11 (3H, s, CH3-5); δC (150 MHz, CDCl3) 165.3 (C=O), 163.9 (C=O), 158.2 (C), 
158.1 (C), 145.2 (C), 125.9 (2 x CH), 119.5 (2 x CH), 79.1 (C), 25.2 (CH3); IR 1714 
(s), 1642 (m), 1586 (m), 1346 (m), 1274 (m); MS (EI+) m/z, (relative intensity): 374 
([M]+, 100), 168 (56). Exact mass calcd. for [C11H7O5N2I]+: 373.9394; Measured: 
373.9391 (EI+); m.p.: 117 °C. 
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107. Dimethyl 4,4'-(1-methyl-3,4 diyl(bis(oxy)bis(4,1-phenylene) dicarbonate) -
pyrrole-2,5-dione) x 
 
 
108. Methyl 4-(4-iodo-1-methyl-pyrrole-2,5-dione-3-yloxy)benzoate (43) 
 
 
A solution of methyl 4-hydroxybenzoate (186 mg, 1.21 mmol) in dry dioxane (1 mL) 
was added dropwise to a solution of potassium tert-butoxide (206 mg, 1.85 mmol) 
and 18-crown ether (363 mg, 1.37 mmol) in dry dioxane (4 mL). The reaction 
mixture was stirred at room temperature for 15 min then added to a solution of 
diiodomaleimide 90 (200 mg, 0.55 mmol) in dry dioxane (1 mL) over 30 min. The 
mixture was stirred at room temperature for 24 h, then concentrated in vacuo and 
dissolved in EtOAc (30 mL). The organic layer was washed with 1 M NaOH (10 mL), 
brine (10 mL), dried (MgSO4), filtered and the solvent was evaporated in vacuo. 
Purification by flash chromatography (PE : EtOAc, gradient elution from 90 : 10 to 60 
: 40) afforded the title compound 107 as a white solid (20.1 mg, 0.05 mmol) in 10% 
yield. Further elution gave the title compound 108 as a white solid (29.6 mg, 0.07 
mmol) in 13% yield. 
 
Compound 107: 
δH (600 MHz, CDCl3) 7.90-7.89 (4H, m, 4 x CH-Ar), 6.91-6.89 (4H, m, 4 x CH-Ar), 
3.89 (6H, s, 2 x CH3-8), 3.18 (3H, s, CH3-9); δC (150 MHz, CDCl3) 166.1 (2 x C=O), 
164.7 (2 x C=O), 157.9 (2 x C), 133.1 (2 x C), 131.5 (4 x CH), 126.8 (2 x C), 117.1 
(4 x CH), 52.4 (2 x CH3), 23.9 (CH3); IR 1715 (s), 1602 (m), 1436 (m), 1279 (s); MS 
(EI+) m/z, (relative intensity): 411 ([M]+, 100), 380 (50). Exact mass calcd. for 
[C21H17NO8]+: 411.0948. Measured: 411.0938 (EI+); m.p.: 120 °C. 
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Compound 108: 
δH (600 MHz, CDCl3) 8.12-8.10 (2H, m, 2 x CH-Ar), 7.19-7.16 (2H, m, 2 x CH-Ar), 
3.95 (3H, s, CH3-11), 3.12 (3H, s, CH3-5); δC (150 MHz, CDCl3) 166.1 (C=O), 165.9 
(C=O), 164.3 (C=O), 158.4 (C), 156.8 (C), 113.7 (2 x CH), 127.9 (C), 119.4 (2 x 
CH), 75.7 (C), 52.5 (CH3), 25.0 (CH3); IR 1715 (s), 1597 (m), 1436 (m), 1276 (s); MS 
(EI+) m/z, (relative intensity): 387 ([M]+, 100), 356 (23). Exact mass calcd. for 
[C13H10NO5I]+: 386.9598. Measured: 386.9599 (EI+); m.p.: 92 - 94 °C. 
 
109. Methyl 4-(4-bromo-1-methyl-pyrrole-2,5-dione-3-yloxy)benzoate 
 
 
A solution of methyl 4-hydroxybenzoate (124 mg, 0.81 mmol) in dry dioxane (1 mL) 
was added dropwise to a solution of potassium tert-butoxide (90.9 mg, 0.81 mmol) 
and 18-crown ether (213 mg, 0.81 mmol) in dry dioxane (4 mL). The reaction 
mixture was stirred for 15 min then added to a solution of N-methyl-2,3-
dibromomaleimide (200 mg, 0.74 mmol) in dry dioxane (1 mL) over 30 min. The 
mixture was stirred at room temperature for 10 h, then concentrated in vacuo and 
redissolved in EtOAc (30 mL). The organic layer was washed with 1 M aq. NaOH 
(10 mL), brine (10 mL), dried (MgSO4), filtered and the solvent was evaporated in 
vacuo. Purification by flash chromatography (PE : EtOAc, gradient elution from 80 : 
20 to 70 : 30) afforded the title compound 109 as a yellow solid (159 mg, 0.47 mmol) 
in 63% yield. 
 
δH (600 MHz, CDCl3) 8.10-8.07 (2H, m, 2 x CH-Ar), 7.17- 7.15 (2H, m, 2 x CH-Ar), 
3.92 (3H, s, CH3-11), 3.09 (3H, s, CH3-5); δC (150 MHz, CDCl3) 166.1 (C=O), 164.8 
(C=O), 163.9 (C=O), 156.9 (C), 151.7 (C), 131.7 (2 x CH), 127.9 (C), 119.1 (2 x CH-
Ar), 101.4 (C), 52.5 (CH3), 24.8 (CH3); IR 1719 (s), 1649 (m), 1599 (m), 1436 (m), 
1277 (s); MS (EI+) m/z, (relative intensity): 341 ([81M]+, 100), 339 ([79M]+, 100), 310 
(56), 308 (55). Exact mass calcd. for [C13H10NO579Br]+: 338.9737. Measured: 
338.9342 (EI+); m.p.: 132 - 133 °C. 
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110. (R)-Methyl 2-(tert-butoxycarbonylamino)-3-(1-methyl-pyrrole-2,5-dione-3-
ylthio)propanoate138 
 
 
To a solution of N-Boc-Cys-OMe (28.3 mg, 0.11 mmol) and sodium acetate (10.1 
mg, 0.12 mmol) in MeOH (2.7 mL) a solution of sulphoxymaleimide 66 (29.3 mg, 
0.12 mmol) in MeOH (2.7 mL) was added over 15 min. The reaction mixture turned 
pink, then green. The solvent was evaporated in vacuo. Purification by flash 
chromatography (PE : EtOAc, gradient elution from 70 : 30 to 40 : 60) afforded the 
title compound 110 as a white solid (18.0 mg, 0.06 mmol) in 52% yield. 
 
δH (600 MHz, CDCl3) 6.26 (s, 1H, CH-3), 5.37 (1H, d, J = 6.9 Hz, NH), 4.67 (2H, dd, 
J = 11.9, 6.7 Hz, CH-7), 3.79 (3H, s, CH3-9), 3.47 (1H, dd, J = 13.8, 5.1 Hz, CHH-6), 
3.35 (1H, dd, J = 13.8, 5.1 Hz, CHH-6), 3.00 (3H, s, CH3-1), 1.43 (9H, s, 3 x CH3-
12); δC (150 Hz, CDCl3) 170.2 (C=O), 169.5 (C=O), 167.9 (C=O), 155.1 (C=O), 
150.0 (C), 118.7 (CH), 81.0 (C), 53.3 (CH3), 52.8 (CH3), 33.9 (CH2), 28.4 (3 x CH3); 
IR 1703 (s), 1560 (w), 1441 (m), 1378 (w), 1253 (m); m.p.: 143 °C (lit. m.p.138: 101 - 
103 °C).  
 
116. 3-Hexylthio-3-methoxy-1-methyl-pyrrolidine-2,5-dione 
 
 
To a solution of methoxymaleimide 95 (6.3 mg, 0.04 mmol) and sodium acetate 
(7.30 mg, 0.09 mmol) in MeOH (6 mL) n-hexanethiol (63.0 μL, 0.45 mmol) in MeOH 
(4 mL) was added dropwise and the resulting mixture was stirred at room 
temperature. After 72 h of the solvent was evaporated in vacuo. Purification by flash 
chromatography (PE : EtOAc, gradient elution from 90 : 10 to 60 : 40) afforded the 
title compound 116 as a transparent oil (10.4 mg, 0.04 mmol) in 90% yield. 
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δH (600 MHz, CDCl3) 3.44 (3H, s, CH3-12), 3.02 (3H, s, CH3-5), 2.99 (1H, d, J = 17.9 
Hz, CHH-2), 2.81 (1H, ddd, J = 12.3, 8.2, 6.9 Hz, CHH-6), 2.74 (1H, ddd, J = 12.3, 
8.2, 6.9 Hz, CHH-6), 2.71 (1H, d, J = 17.8, CHH-2), 1.59-1.52 (2H, m, CH2-7), 1.39-
1.34 (2H,m, CH2-8), 1.31-1.24 (4H, m, CH2-9 and CH2-10), 0.87 (3H, t, J =7.0 Hz, 
CH3-11); δC (150 MHz, CDCl3) 173.1 (C=O), 172.1 (C=O), 87.8 (C), 51.8 (CH3), 42.1 
(CH2), 31.4 (CH2), 29.0 (CH2), 28.8 (CH2), 28.6 (CH2), 25.1 (CH3), 22.6 (CH2), 14.1 
(CH3), one CH2 missing due to overlap; IR 2927 (m), 1710 (s), 1434 (m), 1284 (m); 
MS (CI+) m/z (relative intensity): 260 ([M]+, 51), 228 (100). Exact mass calcd. for 
[C12H22NO3S]++H: 260.1320. Measured: 260.1316 (EI+). 
 
125. 3-(2-Hydroxyethylthio)-1-methyl-pyrrole-2,5-dione 
 
 
To a stirred solution of bromomaleimide 57 (100 mg, 0.53 mmol) and sodium 
acetate (93.2 mg, 0.53 mmol) in MeOH (60 mL) was added 2-mercaptoethanol 
(0.035 mL, 0.51 mmol) at room temperature. After 5 min, the solvent was 
evaporated in vacuo. Purification by flash chromatography (PE: EtOAc, gradient 
elution from 60 : 40 to 50 : 50) afforded the title compound 125 as a yellow solid (80 
mg, 0.43 mmol) in 84%.  
 
δH (500 MHz, CDCl3) 6.17 (1H, s, CH-2), 3.95 (2H, q, J = 5.9 Hz, CH-7), 3.16 (2H, t, 
J = 5.8 Hz, CH2-6), 3.02 (3H, s, CH3-5), 1.87 (1H, t, J = 5.7 Hz, OH); δC (150 MHz, 
CDCl3) 169.7 (C=O), 168.1 (C=O), 150.6 (C), 118.4 (CH), 60.2 (CH2), 34.5 (CH2), 
24.2 (CH3); IR 3446 (br), 1690 (s), 1555 (m), 1440 (m), 1384 (m), 973 (s); MS (EI+) 
m/z, (relative intensity): 187 ([M]+, 7), 187 (100). Exact mass calcd. for [C7H9NO3S]+: 
187.0298; Measured: 187.0300 (EI+); m.p.: 63 °C. 
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126. (R)-2-amino-5-((S)-1-(carboxymethylamino)-3-(1-methyl-pyrrole-2,5-dione-
3-ylthio)-1-oxopropan-2-ylamino)-5-oxopentanoic acid 
 
 
A solution of reduced glutathione (7.68 mg, 0.25 mmol) in 2.5 mL pH 6 buffer (50 
mM sodium phosphate) was added dropwise to a solution of bromomaleimide 57 
(4.75 mg, 0.25 mmol) in pH 6 buffer (50 mM sodium phosphate, 20% CH3CN). The 
reaction mixture was stirred at room temperature for 5 min. Part of the crude was 
purified by HP-LC (H2O : CH3CN = 95 : 5 to 5 : 95) to afford the title compound 126 
as yellow oil. 
 
δH (600 MHz, MeOD) 6.56 (1H, s, CH-15), 4.78 (1H, dd, J = 8.1, 5.9 Hz, CH-6), 4.03 
(1H, t, J = 6.3 Hz, CH-2), 3.95 (2H, s, CH2-8), 3.49 (1H, dd, J = 13.6 , 5.9, Hz, CHH-
10), 3.26 (1H, dd, J = 13.6, 8.2 Hz, CHH-10), 2.97 (3H, s, CH3-13), 2.57 (2H, t, J = 
6.9 Hz, CH2-4), 2.25-2.13 (2H, m, CH2-3); δC (150 MHz, CDCl3) 174.5 (C=O), 172.8 
(C=O), 171.9 (C=O), 171.5 (C=O), 171.3 (C=O), 169.5 (C=O), 151.2 (C), 120.0 
(CH), 53.4 (CH), 52.6 (CH), 41.8 (CH2), 33.8 (CH2), 32.2 (CH2), 26.9 (CH2), 24.1 
(CH3); MS (CI+) m/z, (relative intensity): 439 ([M+Na]+, 77), 287 (100). Exact mass 
calcd. for [C15H20N4O8S]++Na: 439.0897; Measured: 439.0900 (EI+). 
 
133. 1-(2-(2-(2-Methoxyethoxy)ethoxy)ethyl)-3-phenoxy-pyrrole-2,5-dione 
 
 
Method 1: A solution of PEG amine 140 (32.8 mg, 0.10 mmol) in CH2Cl2 (0.5 mL) 
was added to a solution of N-methoxycarbonyl phenoxymaleimide 151 (21.0 mg, 
0.08 mmol) in CH2Cl2 (0.5 mL) and the resulting mixture was stirred at room 
temperature for 15 h. After this time, the solvent was evaporated in vacuo. 
Purification by flash chromatography (CH2Cl2 : MeOH, gradient elution from 97 : 3 to 
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95 : 5) afforded the title compound 146 as a transparent oil (7.60 mg, 0.02 mmol) in 
25% yield. 
Method 2: To a solution of phenol (48.0 mg, 0.51 mmol) in dry dioxane (0.5 mL) 
potassium tert-butoxide (57.2 mg, 0.51 mmol) in dry dioxane (2.5 mL) was added 
dropwise. The resulting mixture was stirred for 15 min at room temperature and then 
added dropwise to a solution of N-PEG bromomaleimide 145 (85.8 mg, 0.26 mmol) 
in dry dioxane (1 mL). The mixture was stirred at room temperature for 1 h and then 
the solvent was evaporated in vacuo. Purification by flash chromatography (PE : 
EtOAc, gradient elution from 70 : 30 to 40 : 60) afforded the title compound 146 as a 
transparent oil (39.6 mg, 0.12. mmol) in 46% yield. 
 
δH (600 MHz, CDCl3) 7.46-7.43 (2H, m, 2 x CH-Ar), 7.32-7.30 (1H, t, J = 6.0 Hz, CH-
14), 7.20-7.18 (2H, d, J = 12 Hz, 2 x CH-Ar), 5.27 (1H, s, CH-9), 3.76-3.74 (2H, t, J 
= 6 Hz, CH2), 3.68-3.63 (8H, m, 4 x CH2), 3.55-3.54 (2H, m, CH2), 3.37 (3H, s, CH3-
1); δC (150 MHz, CDCl3) 169.9 (C=O), 165.6 (C=O), 159.5 (C), 153.9 (C), 130.4 (2 x 
CH), 126.9 (CH), 119.9 (2 x CH), 99.4 (CH), 72.0 (CH2), 70.72 (CH2), 70.70 (CH2), 
70.1 (CH2), 68.1 (CH2), 59.2 (CH3), 37.1 (CH2); IR 2917 (br), 1715 (s), 1633 (s), 
1312 (m); MS (CI+) m/z, (relative intensity): 336 ([M+H]+, 98), 216 (100). Exact mass 
calcd. for [C17H21NO6]++H: 336.1447. Measured: 336.1445 (CI+). 
 
138. 3-Bromo-1-phenyl-pyrrole-2,5-dione227 
 
 
To a solution of N-phenyl maleimide 137 (400 mg, 2.31 mmol) in (3 mL) was added 
dropwise a solution of bromine (237 µL, 4.62 mmol) in chloroform (1 mL) at room 
temperature. The reaction mixture was refluxed for 2 h and then allowed to cool to 
room temperature. The reaction mixture was diluted with chloroform (10 mL), 
washed with sat. aq. Na2S2O3 (5 mL), water (5 mL) and brine (5 mL). The crude 
product was dried (MgSO4), filtered and the solvent evaporated in vacuo to afford 
636 mg of crude dibromosuccinimide as a yellow solid. Then, a part of the 
dibromosuccinimide (400 mg, 1.32 mmol) was dissolved in acetic acid (8 mL) and 
sodium acetate (325 mg, 3.96 mmol) was added. The reaction mixture was refluxed 
for 2 h and then the solvent was evaporated in vacuo. The crude residue was diluted 
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with ethyl acetate (30 mL) and washed with water (20 mL), brine (20 mL), dried 
(MgSO4), filtered and concentrated in vacuo. Purification by flash chromatography 
(petroleum ether : ethyl acetate, gradient elution from 90 : 10 to 80 : 20) afforded the 
title compound 138 as a white solid (179.5 mg, 0.71mmol) in 54% yield. 
 
δH (600 MHz, CDCl3) 7.48 (2H, t, J = 7.8 Hz, 2 x CH-7), 7.41-7.38 (1H, m, CH-8), 
7.34 (2H, d, J = 7.5 Hz, 2 x CH-6), 7.03 (1H, s, CH-2); δC (150 MHz, CDCl3) 167.5 
(C=O), 164.3 (C=O), 132.0 (CH), 131.9 (C), 131.1 (C), 129.4 (2 x CH), 128.5 (CH), 
126.2 (2 x CH); IR 1711 (s), 1592 (m), 1504 (m), 1396 (s), 1148 (m); MS (EI+) m/z, 
(relative intensity): 253 ([81M]+, 100), 251 ([79M]+, 96), 86 (55), 84 (90). Exact mass 
calcd. for [C10H6Br79NO2]+: 250.9582. Measured: 250.9582 (EI+); m.p.: 153 °C (lit. 
m.p.229: 152 °C). 
 
139. 3-Phenoxy-1-phenyl-pyrrole-2,5-dione 
 
 
To a solution of phenol (22.3 mg, 0.24 mmol) in dry dioxane (0.5 mL) potassium tert-
butoxide (26.9 mg, 0.24 mmol) in dry dioxane (2.5 mL) was added dropwise. The 
solution was left stirring for 15 min and then added dropwise to a solution of N-
phenyl bromomaleimide 138 (50.0 mg, 0.20 mmol) in dry dioxane (1 mL). The 
resulting mixture was stirred at room temperature for 2.5 h and then the solvent was 
evaporated in vacuo. Purification by flash chromatography (PE : Et2O, gradient 
elution from 90 : 10 to 80 : 20) afforded the title compound 139 as a yellow solid 
(18.8 mg, 0.07 mmol) in 46% yield. 
 
δH (600 MHz, CDCl3) 7.61-7.51 (4H, m, 4 x CH-Ar), 7.42-7.35 (4H, m, 4 x CH-Ar), 
7.28-7.26 (2H, m, 2 x CH-Ar), 5.46 (1H, s, CH-2); δC (150 MHz, CDCl3) 168.9 (C=O), 
164.5 (C=O), 159.4 (C), 153.9 (C), 131.1 (C), 130.5 (2 x CH), 129.3 (2 x CH), 128.1 
(CH), 127.1 (CH), 126.2 (2 x CH), 120.0 (2 x CH), 99.5 (CH); IR 1715 (s), 1634 (m), 
1401 (m), 1201 (m); MS (ES+) m/z, (relative intensity): 266 ([M+H]+, 42), 180 (100). 
Exact mass calcd. for [C16H11NO3]++H: 266.0817. Measured: 266.0827 (ES+); m.p.: 
198 - 201 °C. 
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142. 2-(2-(2-Methoxyethoxy)ethoxy)ethyl 4-methylbenzenesulfonate196 
 
 
Triethylene glycol monomethyl ether 141 (2.92 mL, 18.3 mmol) and triethylamine 
(3.80 mL, 27.4 mmol) were dissolved in dry CH2Cl2 (15 mL) and the solution was 
cooled to 0 °C. A solution of tosyl chloride (3.48 g, 18.3 mmol) in dry CH2Cl2 (5 mL) 
was then added dropwise. The mixture was stirred for 3 h at 0 °C and then allowed 
to warm to room temperature over for 14 h. After that, Et2O (20 mL) was added and 
the resulting precipitate was filtered. The filtrate was concentrated in vacuo. 
Purification by flash column chromatography (Et2O) afforded the title compound 142 
as a colourless oil (4.57 g, 14.3 mmol) in 79% yield. 
 
δH (600 MHz, CDCl3) 7.80 (2H, d, J = 12.0 Hz, 2 x CH-Ar), 7.34 (2H, d, J = 12.0 Hz, 
2 x CH-Ar), 4.16 (2H, t, J = 6.0 Hz, CH2-7), 3.69 (2H, t, J = 6.0 Hz, CH2-6), 3.61-3.59 
(6H, m, 3 x CH2), 3.54-3.52 (2H, m, CH2), 3.37 (3H, s, CH3-1), 2.45 (3H, s, CH3-12); 
δC (150 MHz, CDCl3) 144.9 (C), 133.1 (C), 129.9 (2 x CH), 128.1 (2 x CH), 72.0 
(CH2), 70.9 (CH2), 70.7 (CH2), 70.6 (CH2), 69.3 (CH2), 68.8 (CH2), 59.2 (CH3), 21.8 
(CH3); IR 2881 (br), 1355 (m), 1189 (m), 1170 (s), 1099 (m); MS (CI+) m/z, (relative 
intensity): 319 ([M+H]+, 80), 199 (65), 147 (65), 103 (100). Exact mass calcd. for 
[C14H22O6S]++H: 319.1209. Measured: 319.1209 (CI+). 
 
 
143. 1-Azido-2-(2-(2-methoxyethoxy)ethoxy)ethane196 
 
 
To a solution of tosylated PEG 142 (1.90 g, 5.98 mol) in DMF (40 mL) was added 
sodium azide (0.96 g, 14.9 mmol). The reaction mixture was stirred for 20 h at 60 °C 
and then for 3 h at 120 °C. After this time, the mixture was allowed to cool to room 
temperature and then Et2O (50 mL) was added. The organic phase was washed 
with sat. aq. LiCl (5 x 20 mL), brine (20 mL), dried (Na2SO4), filtered and the solvent 
was evaporated in vacuo to afford the title compound 143 as a brown oil (887 mg, 
4.69 mmol) in 78% yield.  
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δH (600 MHz, CDCl3) 3.68-3.65 (8H, m, 4 x CH2), 3.55 (2H, t, J = 4.8 Hz, CH2), 3.40-
3.38 (5H, m, CH3-1 and CH-2); δC (150 MHz, CDCl3) 72.0 (CH2), 70.81 (CH2), 70.78 
(CH2), 70.74 (CH2), 70.2 (CH2), 59.2 (CH3), 50.8 (CH2); IR 2874 (br), 2098 (s), 1288 
(br), 1104 (s); MS (CI+) m/z, (relative intensity): 190 ([M+H]+, 20), 162 (65), 103 
(100). 
 
140. 2-(2-(2-Methoxyethoxy)ethoxy)ethanamine196 
 
 
The azide PEG 143 (880 mg, 4.65 mmol) was dissolved in Et2O (50 mL) and the 
solution cooled at 0 °C. Triphenyl phosphine (1.46 g, 5.58 mmol) was added and the 
mixture was stirred for 1 h at 0 °C and for another 1 h at room temperature. The 
reaction was quenched with water (20 mL) and the resulting mixture stirred 
vigorously for 4 h. Then, toluene (15 mL) was added and the mixture was stirred for 
12 h. The layers were separated and the aq. layer was washed with toluene (10 mL) 
and evaporated in vacuo to afford the title compound 140 as a brown oil (506 mg, 
3.10 mmol) in 67% yield.  
 
δH (600 MHz, CDCl3) 3.63-3.60 (6H, m, 3 x CH2), 3.53-3.52 (2H, m, CH2), 3.49 (2H, 
t, J = 4.8 Hz, CH2-7), 3.35 (3H, s, CH3-1), 2.85 (2H, t, J = 6.0 Hz, CH2-8); δC (150 
MHz, CDCl3) 73.0 (CH2), 71.9 (CH2), 70.7 (CH2), 70.6 (CH2), 70.3 (CH2), 59.1 (CH3), 
41.7 (CH2); IR 3379 (br), 2876 (br), 1570 (br), 1462 (br), 1304 (s), 1097 (s); MS 
(CI+) m/z, (relative intensity): 164 ([M+H]+, 100), 88 (25). Exact mass calcd. for 
[C7H17NO3]++H: 164.1287. Measured: 164.1289 (CI+). 
 
144. Methyl 3-bromo-pyrrole-2,5-dione carboxylate 
 
 
To a solution of bromomaleimide 22 (200 mg, 1.14 mmol) in THF (6 mL) were added 
a solution of methyl chloroformate (88.3 μL, 1.14 mmol) in THF (2 mL) and a 
solution of N-methylmorpholine (125 μL, 1.14 mmol) in THF (2 mL). The reaction 
mixture was stirred at room temperature for 30 min. After this time, CH2Cl2 (5 mL) 
192 
 
was added and the solution was washed with water (3 x 10 mL), dried (MgSO4), 
filtered and the solvent evaporated in vacuo to afford the title compound 144 as a 
pale pink solid (266 mg, 1.14 mmol) in 100% yield.  
 
δH (600 MHz, CDCl3) 7.04 (1H, s, CH-4), 4.01 (3H, s, CH3-1); δC (150 MHz, CDCl3) 
163.5 (C=O), 160.9 (C=O), 147.6 (C=O), 133.3 (C), 133.1 (CH), 54.7 (CH3); IR 1808 
(m), 1763 (s), 1724 (S), 1603 (m), 1438 (m), 1320 (s), 1263 (s), 1070 (s); MS (EI+) 
m/z, (relative intensity): 235 ([81M]+, 13), 233 ([79M]+, 13). Exact mass calcd. for 
[C6H479BrNO4]+: 232.9318. Measured: 232.9323 (EI+); m.p.: 121 °C. 
 
145. 3-Bromo-1-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)-pyrrole-2,5-dione 
 
 
A solution of PEG amine 140 (157 mg, 0.96 mmol) in CH2Cl2 (2 mL) was added to a 
solution of N-methoxycarbonyl bromomaleimide 144 (224 mg, 0.96 mmol) in CH2Cl2 
(8 mL) and stirred at room temperature for 1 h. After this time, the solvent was 
evaporated in vacuo. Purification by flash chromatography (CH2Cl2 : MeOH, gradient 
elution from 97 : 3 to 95 : 5) afforded the title compound 145 as a yellow oil (136.2 
mg, 0.42 mmol) in 44%. 
 
δH (600 MHz, CDCl3) 6.86 (1H, s, CH-9), 3.77 (2H, t, J = 6.0 Hz, CH2), 3.65 (2H, t, J 
= 6 Hz, CH2), 3.63-3.59 (6H, m, 3 x CH2), 3.53-3.52 (2H, m, CH2), 3.37 (3H, s, CH3-
1); δC (150 MHz, CDCl3)* 168.6 (C=O), 165.4 (C=O), 132.0 (CH), 131.5 (C), 72.0 
(CH2), 70.7 (CH2), 70.2 (CH2), 67.8 (CH2), 59.2 (CH3), 38.2 (CH2); IR 2878 (m), 1715 
(s), 1396 (s), 1105 (m); MS (CI+) m/z, (relative intensity): 324 ([81M+H]+, 70), 322 
([79M+H]+, 68). Exact mass calcd. for [C11H16Br79NO5]++H: 322.0290. Measured: 
322.0298 (CI+). 
* one CH2 missing due to overlap. 
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148. N-(9-(2-(4-(tert-Butoxycarbonylamino)piperidine-1-carbonyl)phenyl)-6-
(diethylamino)-3H-xanthen-3-ylidene)-N-ethylethanaminium chloride149 
 
 
Rhodamine B (90.0 mg, 0.19 mmol) was dissolved in oxalyl chloride (18 mL) and the 
reaction mixture was stirred at room temperature for 24 h. After this time, the solvent 
was evaporated in vacuo and the residue was dissolved in CH2Cl2 (9 mL). This 
solution was then added dropwise to a stirred solution of piperidin-4-yl-carbamic 
acid tert-butyl ester (376 mg, 0.20 mmol) and Cs2CO3 (612 mg, 20.0 mmol) in 
CH2Cl2 (9 mL) and the resulting reaction mixture was stirred at room temperature for 
24 h. After this time, the solvent was evaporated in vacuo. Purification by flash 
chromatography (CH2Cl2 : MeOH, gradient elution from 98 : 2 to 90 : 10) afforded 
the title compound 148 as a purple solid (81.0 mg, 0.12 mmol) in 64% yield. 
 
δH (600 MHz, MeOD)* 7.78-7.74 (2H, m, CH-11 and CH-14), 7.66-7.65 (1H, m, CH-
12 or CH-13), 7.51-7.49 (1H, m, CH-12 or CH-13), 7.27 (2H, dd, J = 9.4, 3.1 Hz, 
CH-8), 7.08-7.06 (2H, m, 2 x CH-9), 6.97 (2H, d, J = 2.5 Hz, 2 x CH-4), 4.08 (1H, d, 
J = 13.5 Hz, CHH), 3.70 (8H, q, J = 7.2 Hz, 4 x CH2-2), 3.48-3.42 (1H, m, CHH), 
3.05 (1H,br s,CHH), 2.68 (1H, br s, CHH), 1.75 (2H, t, J = 11.5 Hz,CH2), 1.41 (9H, s, 
3 x CH3-24), 1.32 (12H, t, J = 7.4 Hz, 4 x CH3-1), 1.19-1.10 (2H, m, CH2); δC (150 
MHz, MeOD) 169.3 (2 x C), 159.3 (2 x C), 157.2 (C), 157.0 (C), 137.0 (C), 133.2 
(CH), 132.0 (CH), 131.7 (CH), 131.3 (CH), 131.1 (2 x CH), 128.6 (CH), 115.4 (CH), 
115.2 (CH), 113.4 (C), 97.3 (2 x CH), 80.1 (C), 47.7 (2 x CH2), 46.9 (4 x CH2), 41.8 
(2 x CH2), 28.7 (3 x CH3), 12.8 (4 x CH3); IR 3370 (br), 2973 (br), 1623 (m), 1584 (s), 
1409 (m), 1262 (s); MS (FAB+) m/z, (relative intensity): 625 ([M]+, 15); Exact mass 
calcd. for [C38H49N4O4]+: 625.3748. Measured: 625.3747 (EI+). 
* one H missing due to overlap 
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149. 1-(2-(6-(diethylamino)-3-(diethyliminio)-3H-Xanthen-9-yl)benzoyl)piperidin-
4-aminium 2,2,2-trifluoroacetate chloride149 
 
 
To a stirred solution of carbamate 148 (230 mg, 0.37 mmol) in CH2Cl2 (26 mL) was 
added TFA (26 mL) and the resulting reaction mixture was stirred at room 
temperature for 15 h. Toluene (2 x 2 mL) was added to aid evaporation of the 
solvent to give 240 mg (0.37 mmol, quantitative) of the title compound 149 as a 
purple solid.  
 
δH (600 MHz, MeOD) 7.79-7.75 (2H, m, CH-11 and CH-14), 7.67-7.65 (1H, dd, J = 
5.6, 2.2 Hz, CH-12 or 13), 7.50 (1H, dd, J = 5.8, 2.2 Hz, CH-13 or 12), 7.26 (2H, d, J 
= 9.4 Hz, 2 x CH-8), 7.08 (2H, t, J = 11.2 Hz, 2 x CH-9), 6.97 (2H, d, J = 1.6 Hz, 2 x 
CH-4), 4.30 (1H, d, J = 12.8 Hz, CHH), 3.84 (1H, d, J = 13.4 Hz, CHH), 3.72-3.65 
(8H, m, 4 x CH2-2), 3.31-3.27 (1H, m, CH-19), 3.02-2.92 (1H, br s,CHH), 2.62-2.52 
(1H, br s, CHH), 2.00-1.92 (2H, m, CH2), 1.41-1.29 (14H, m, 4 x CH3-1 and CH2) δC 
(150 MHz, CDCl3) 169.6 (2 x C), 159.3 (C), 157.3 (C), 157.2 (C), 156.7 (C), 136.6 (2 
x C), 133.4 (CH), 132.9 (CH), 131.9 (CH), 131.8 (CH), 131.4 (CH), 129.3 (CH), 
128.5 (CH), 126.3 (CH), 115.4 (CH), 115.3 (CH), 114.9 (C), 114.5 (C), 97.4 (CH), 
97.3 (CH), 47.1 (CH2), 46.9 (4 x CH2), 41.1 (CH2), 31.3 (CH2), 30.5 (CH2), 12.8 (4 x 
CH3); IR 2983 (br), 1677 (s), 1590 (s), 1340 (m), 1199 (s); MS (FAB+) m/z, (relative 
intensity): 525 ([M]+, 100), 497.29 (10). Exact mass calcd. for [C33H41N4O2]+: 
525.3224. Measured: 525.3211 (NSI+). 
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150. N-(9-(2-(4-(3-Bromo-pyrrole-2,5-dione-1-yl)piperidine-1-carbonyl)phenyl)-
6-(diethylamino)-3H-xanthen-3-ylidene)-N-ethylethanaminium chloride149 
 
 
Bromomaleic anhydride (19 µL, 0.20 mmol) was added to rhodamine trifluoroacetate 
salt 149 (77 mg, 0.15 mmol) in AcOH (4.5 mL). The resulting reaction mixture was 
heated to 120 °C for 5 h. After this time, toluene (2 x 2 mL) was added to aid the 
evaporation of the solvent. Purification by flash chromatography (CH2Cl2 : MeOH, 
gradient elution from 98 : 2 to 80 : 20) afforded the title compound 150 as a purple 
solid (36.6 mg, 0.05 mmol) in 35% yield. 
 
δH (600 MHz, MeOD) 7.77-7.74 (2H, m, CH-1 and CH-4), 7.65-7.64 (1H, m), 7.52-
7.50 (1H, m, CH-12 or CH-13), 7.28-7.26 (2H, m, 2 x CH-8), 7.07-7.05 (3H, m, CH-
24 and 2 x CH-9), 7.00-6.98 (2H, m, 2 x CH-4), 4.36 (1H, d, J = 13.2 Hz, CHH), 
4.11-4.07 (1H, m, CH), 3.86 (1H, d, J = 13.3 Hz, CHH), 3.75-3.65 (8H, m, 4 x CH2-
2), 3.19-3.10 (1H, m, CHH), 2.63-2.58 (1H, m, CHH), 1.80-1.64 (2H, m, CH2), 1.59-
1.51 (2H, m, CH2), 1.33-1.31 (12H, m, 4 x CH3-1); δC (150 MHz, MeOD)* 169.5 (C), 
169.3 (C), 166.3 (C), 159.3 (C), 157.3 (C), 157.2 (C), 156.9 (C), 136.9 (C), 133.4 
(CH), 132.2 (C), 132.1 (C), 131.6 (CH), 131.2 (CH), 131.0 (CH), 128.8 (CH), 128.3 
(CH), 114.8 (C), 97.7 (CH), 97.2 (CH), 47.0 (CH2), 46.9 (4 x CH2), 42.5 (CH2), 29.5 
(CH2), 12.8 (4 x CH3); IR 3409 (br), 1713 (m), 1588 (s), 1413 (m), 1338 (m); MS 
(ES+) m/z, (relative intensity): 685 ([81M]+, 87), 683 ([79M]+, 85). Exact mass calcd. 
for [C37H4081BrN4O4]+: 685.2202. Measured: 685.2207 (NSI+). 
* one CH2 missing due to overlap. 
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152. 3-Phenoxy-pyrrole-2,5-dione 
 
 
To melted phenol (3.23 g, 34.3 mmol) a solution of potassium tert-butoxide (307 mg, 
2.74 mmol) in dry dioxane (2 mL) was added dropwise and the resulting mixture was 
stirred for 10 min at 40 °C. Then a solution of bromomaleimide 22 (400 mg, 2.28 
mmol) in dry dioxane (2 mL) was added dropwise and the resulting mixture was 
stirred at 40 °C for 30 min. After this time, the solvent was evaporated in vacuo. 
Purification by flash chromatography (PE : EtOAc, gradient elution from 90 : 10 to 70 
: 30) afforded the title compound 152 as a white solid (328 mg, 1.73 mmol) in a 76% 
yield. 
 
δH (600 MHz, CDCl3) 8.44 (1H, br s, NH), 7.43-7.40 (2H, m, 2 x CH-Ar), 7.29-7.26 
(1H, m, CH-8), 7.17-7.15 (2H, m, 2 x CH-Ar), 5.28 (1H, s, CH-2); δC (150 MHz, 
CDCl3) 170.4 (C=O), 166.1 (C=O), 159.6 (C), 153.9 (C), 130.5 (2 x CH), 127.0 (CH), 
119.9 (2 x CH), 100.5 (CH); IR 3264 (br), 1732 (s), 1708 (s), 1627 (s), 1584 (s), 
1488 (s), 1288 (s), 1215 (s); MS (EI+) m/z, (relative intensity): 189 ([M]+, 85), 94 
(100), 84 (95). Exact mass calcd. for [C10H7NO3]+: 189.0426. Measured: 189.0420 
(EI+); m.p.: 85 °C. 
 
151. Methyl 3-phenoxy-pyrrole-2,5-dione carboxylate 
 
 
To a solution of phenoxymaleimide 152 (360 mg, 1.41 mmol) in CH2Cl2 (6 mL) were 
added a solution of methyl chloroformate (1.09 mL, 14.1 mmol) in CH2Cl2 (1 mL) 
and a solution of N-methylmorpholine (186 μL, 1.69 mmol) in CH2Cl2 (1 mL). The 
reaction mixture was stirred at room temperature for 30 min. After this time, the 
solution was washed with water (3 x 5 mL), dried (MgSO4), filtered and the solvent 
was evaporated in vacuo to afford the title compound 151 as a pale pink solid (329 
mg, 1.33 mmol) in 95% yield.  
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δH (600 MHz, CDCl3) 7.46-7.43 (2H, m, 2 x CH-Ar), 7.33-7.30 (1H, m, CH-10), 7.17-
7.15 (2H, m, 2 x CH-Ar), 5.42 (1H, s, CH-2), 3.98 (3H, s, CH3-6); δC (150 MHz, 
CDCl3) 164.6 (C=O), 161.0 (C=O), 159.3 (C=O), 153.6 (C), 148.0 (C), 130.6 (2 x 
CH), 127.4 (CH), 119.8 (2 x CH), 101.6 (CH), 54.4 (CH3); IR 1769 (s), 1720 (s), 
1641 (m), 1304 (s), 1259 (s), 1104 (m), 1075 (m); MS (CI+) m/z, (relative intensity): 
248 ([M+H]+, 100), 216 (75). Exact mass calcd. for [C12H9NO5]++H: 248.0559. 
Measured: 248.0554. (CI+); m.p.: 70 - 72 °C. 
 
153. 3-Phenoxy-1-(prop-2-ynyl)-pyrrole-2,5-dione 
 
 
A solution of propargylamine (32.4 µL, 0.50 mmol) in CH2Cl2 (0.5 mL) was added to 
a solution of N-methoxycarbonyl phenoxymaleimide 151 (125 mg, 0.50 mmol) in 
CH2Cl2 (5 mL) and left to stir at room temperature for 1.5 h. After this time, the 
solvent was evaporated in vacuo. Purification by flash chromatography (PE : EtOAc, 
gradient elution from 50 : 50 to 30 : 70) afforded  the title compound 153 as a white 
solid (79.2 mg, 0.35 mmol) in 70% yield. 
 
δH (600 MHz, CDCl3) 7.47-7.44 (2H, m, 2 x CH-Ar), 7.34-7.31 (1H, m, CH-11), 7.20-
7.18 (2H, m, 2 x CH-Ar), 5.33 (1H, s, CH-2), 4.32 (2H, s, CH2-5), 2.24 (1H, s, CH-7); 
δC (150 MHz, CDCl3) 168.5 (C=O), 164.4 (C=O), 159.8 (C), 153.8 (C), 130.5 (2 x 
CH), 127.1 (CH), 119.9 (2 x CH), 99.8 (CH), 71.8 (CH), 26.9 (CH2); IR 1715 (s), 
1631 (s), 1585 (m), 1310 (s), 1220 (m); MS (CI+) m/z, (relative intensity): 228 
([M+H]+, 100). Exact mass calcd. for [C13H9NO3]++H: 228.0661. Measured: 228.0657 
(CI+); m.p.: 55 °C. 
 
155. 2-Azidoethanol200 
 
 
To a round-bottom flask containing sodium azide (2.42 g, 37.2 mmol) and 
tetrabutylammonium bromide (399 mg, 0.1 mmol) was added 2-chloroethanol (1.00 
g, 124 mmol) and the resulting mixture was stirred at 110 °C for 18 h. Purification by 
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flash chromatography (PE : EtOAc, gradient elution from 70 : 30 to 50 : 50) afforded 
the title compound as a transparent oil (482 mg, 5.53 mmol) in 45% yield. 
 
δH (600 MHz, CDCl3) 3.78 (2H, t, J = 6.0 Hz, CH2-2), 3.45 (2H, t, J = 6.0 Hz, CH2-1), 
1.80 (1H, br s, OH); δC (150 MHz, CDCl3) 61.6 (CH2), 53.6 (CH2); IR 3350 (br), 2937 
(br), 2094 (s), 1288 (m); MS (CI+) m/z, (relative intensity): 116 ([M+K]+, 53), 88 
([M+H]+, 100). Exact mass calcd. for [C2H5N3O]++H: 88.0511. Measured: 88.0513 
(CI+). 
 
154. N-(9-(2-((2-Azidoethoxy)carbonyl)phenyl)-6-(diethylamino)-3H-xanthen-3-
ylidene)-N-ethylethanaminium chloride199 
 
 
A round bottom flask containing CH2Cl2 (1.5 mL) was wrapped in aluminium foil and 
rhodamine B (100 mg, 0.21 mmol), EDC·HCl (44.1 mg, 0.23 mmol), azide 155 (20 
mg, 0.23 mmol) and DMAP (5.30 mg, 0.04 mmol) were added. The resulting 
reaction mixture was stirred at room temperature for 4 h. After this time, CH2Cl2 (5 
mL) was added and the reaction mixture was washed with water (10 mL). The 
aqueous layer was extracted with CH2Cl2 (4 x 5 mL) and the organic layers were 
combined, washed with 0.1 M aq. HCl (5 mL), brine (5 mL), dried (Na2SO4), filtered 
and the solvent was evaporated in vacuo. Purification by flash chromatography 
(CHCl3 : MeOH, 98 : 2) afforded the title compound 154 as a purple solid (115 mg, 
0.21 mmol) in 100% yield.  
 
δH (600 MHz, CDCl3) 8.24 (1H, d, J = 7.8 Hz, CH-8 or CH-5), 7.77 (1H, m, CH-6 or 
7), 7.69 (1H, t, J = 7.8 Hz, CH-6 or CH-7), 7.25 (1H, d, J = 10.2 Hz, CH-8 or CH-5), 
7.01 (2H, d, J = 9.6 Hz, 2 x CH-11), 6.85 (2H, dd, J = 9.6,2.4 Hz, 2 x CH-12), 6.73 
(2H, d, J = 1.8 Hz, 2 x CH-14), 4.11 (2H, t, J = 4.8 Hz, CH2-2), 3.59-3.56 (8H, m, 4 x 
CH2-17), 3.32 (2H, t, J = 4.8 Hz, CH2-1), 1.25 (12H, m, 4 x CH3-18); δC (150 MHz, 
CDCl3) 164.8 (C), 158.4 (C), 157.8 (2 x C), 155.6 (2 x C), 133.7 (C), 133.5 (CH), 
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131.6 (CH), 131.3 (2 x CH), 130.6 (CH), 130.4 (CH), 129.4 (C), 114.4 (2 x CH), 
113.5 (2 x C), 96.3 (2 x CH), 63.9 (CH2), 49.6 (CH2), 46.2 (4 x CH2), 12.7 (4 x CH3); 
IR 3384 (bs), 2971 (w), 2928 (w), 2102 (w), 1721 (m), 1586 (s), 1482 (m), 1413 (m), 
1413 (s), 1338 (s), 1180 (s). Exact mass calcd. for [C30H34N5O3]+: 512.2656. 
Measured: 512.2656 (NSI+). 
 
156. N-(6-(Diethylamino)-9-(2-((2-(4-((2,5-dioxo-3-phenoxy-2,5-dihydro-1H-
pyrrole-1-yl)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)carbonyl)phenyl)-3H-xanthen-
3-ylidene)-N-ethylethanaminiumchloride  
 
 
To a mixture of copper iodide (0.19 mg, 1.00 µmol), DIPEA (9.58 µL, 1.00 µmol) and 
AcOH (9.00 µL, 1.00 µmol) in CH2Cl2 (1 mL) was added a mixture of azide 154 (15.5 
mg, 0.03 mmol) and alkyne 153 (7.06 mg, 0.03 mmol) in CH2Cl2 (0.5 mL). The 
resulting reaction mixture was stirred at room temperature for 4 h and then the 
solvent was removed in vacuo. Purification by flash chromatography (CHCl3 : 
MeOH, gradient elution 98 : 2 to 90 : 10) afforded the title compound 156 as a 
purple solid (13.3 mg, 0.02 mmol) in 62% yield. 
 
δH (600 MHz, CDCl3) 8.21-8.20 (1H, m, CH-11 or CH-14), 7.89 (1H, s, CH-19), 7.77 
(2H, m, CH-12 and CH-13), 7.46-7.43 (2H, m, 2 x CH-Ar), 7.32-7.30 (1H, m, CH-Ar), 
7.28-7.27 (1H, m, CH-11 or CH-14) 7.18 (2H, d, J = 7.9 Hz, 2 x CH-Ar), 7.07 (2H, d, 
J = 9.4 Hz, 2 x CH-7), 6.93 (2H, dd, J = 9.4, 2.2 Hz, 2 x CH-9), 6.79 (2H, d, J = 2.3 
Hz, 2 x CH-4), 5.29 (1H, s, CH-24), 4.83 (2H, s, CH2-21), 4.65 (2H, t, J = 5.2 Hz, 
CH2-17), 4.49 (2H, t, J = 5.2 Hz, CH2-18), 3.67-3.59 (8H, m, 4 x CH2-2), 1.32 (12H, t, 
J = 7.1 Hz, 4 x CH3-1); δH (150 MHz,CDCl3) 169.2 (C), 165.1 (C), 164.5 (C), 159.6 
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(C), 158.7 (C), 157.8 (2 x C), 155.7 (2 x C), 153.9 (C), 142.7 (C), 133.8 (C), 133.4 
(CH), 131.8 (CH), 131.5 (2 x CH), 130.9 (CH), 130.5 (2 x CH), 130.3 (CH), 129.3 
(C), 127.0 (CH), 123.9 (CH), 119.9 (2 x CH), 114.6 (2 x CH), 113.6 (2 x C), 99.7 
(CH), 96.4 (2 x CH), 63.6 (CH2), 49.0 (CH2), 46.3 (4 x CH2), 32.9 (CH2), 12.8 (4 x 
CH3); IR 2970 (w), 1721 (s), 1588 (s), 1411 (m), 1342 (m), 1268 (s), 1247 (s); MS 
(ES+) m/z, (relative intensity): 739 ([M]+, 100), 711 (50). Exact mass calcd. for 
[C43H43N6O6]+:739.3239. Measured: 739.3221 (NSI+). 
 
159. tert-Butyl 4-hydroxybenzoate203 
 
 
To a solution of 4-hydroxybenzoic acid (2.50 g, 18.1 mmol), DMAP (0.08 g, 0.07 
mmol) and tert-butanol (50 ml) in dry THF (75 ml), a solution of DCC (3.82 g, 18.5 
mmol) in dry THF (25 ml) was added dropwise at room temperature over 30 min. 
The reaction mixture was stirred at room temperature for a further 22 h. The white 
solid was filtered and the filtrate was concentrated in vacuo. The crude product was 
dissolved in Et2O (40 mL), washed with 0.3 M aq. Na2CO3 (3 x 20 mL), dried 
(MgSO4), filtered and then the solvent was evaporated in vacuo. Purification by flash 
chromatography on silica gel (PE : EtOAc, 90 : 10) afforded 1.1 g (5.67 mmol, 31%) 
of the title compound 159 as a white solid. 
 
δH (600 MHz, CDCl3) 7.90 (2H, d, J = 8.4 Hz, 2 x CH-Ar), 6.83 (2H, d, J = 8.4 Hz, 2 x 
CH-Ar), 5.40 (1H, s, OH), 1.58 (9H, s, 3 x CH3-1); δC (150 MHz, CDCl3) 165.7 
(C=O), 159.4 (C), 131.8 (2 x CH), 124.8 (C), 115.1 (2 x CH), 81.8 (C), 28.4 (3 x 
CH3); IR 3338 (br), 1674 (s), 1607 (s), 1368 (s), 1154 (s); IR 3338 (br), 1673 (s), 
1607 (s), 1368 (s), 1154 (s); MS (CI+) m/z, (relative intensity): 195 ([M+H]+, 100). 
Exact mass calcd. for [C11H14O3]++H: 195.1016. Measured: 195.1013 (CI+); m.p.: 
119 °C (lit. m.p.203: 118 - 120 °C). 
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158. tert-Butyl 4-(1-methyl-pyrrole-2,5-dione-3-yloxy)benzoate 
 
 
A solution of tert-butyl 4-hydroxybenzoate (300 mg, 1.55 mmol) in dry dioxane (1.5 
mL) was added dropwise to a solution of potassium tert-butoxide (173 mg, 1.55 mol) 
in dry dioxane (4.5 mL) and stirred at room temperature for 15 min. The mixture was 
added dropwise to a solution of bromomaleimide 57 (255 mg, 1.29 mmol) in dry 
dioxane (1 mL) and the resulting solution was stirred at room temperature for 24 h. 
After this time, the solvent was concentrated in vacuo and the resulting crude 
redissolved in EtOAc (20 mL), washed with 1 M aq. NaOH (20 mL), water (20 mL) 
and brine (20 mL). The organic layer was dried (MgSO4), filtered and the solvent 
was evaporated in vacuo. Purification by flash chromatography (CH2Cl2 : Et2O, 95 : 
5) afforded the title compound 158 as a white solid (260 mg, 0.86 mmol) in 55% 
yield. 
 
δH (600 MHz, CDCl3) 8.05-8.04 (2H, m, 2 x CH-Ar), 7.21-7.19 (2H, d, 2 x CH-Ar), 
5.32 (1H, s, CH-3), 3.01 (3H, s, CH3-1) 1.56 (9H, s, 3 x CH3-12); δC (150 MHz, 
CDCl3) 169.7 (C=O), 169.7 (C=O), 164.5 (C=O), 158.6 (C), 156.8 (C), 131.9 (2 x 
CH), 130.7 (C), 119.7 (2 x CH), 100.1 (CH), 81.8 (C), 28.2 (3 x CH3), 23.8 (CH3); IR 
1712 (s), 1638 (m), 1291 (m); MS (CI+) m/z, (relative intensity): 304 ([M+H]+, 30), 
248 (100). Exact mass calcd. for [C16H17NO5]++H: 304.1179. Measured: 304.1174 
(CI+); m.p.: 139 °C. 
 
102. 4-(1-Methyl-pyrrole-2,5-dione-3-yloxy)benzoic acid 
 
 
A solution of phenoxymaleimide 158 (250 mg, 0.82 mmol) and thioanisole (1.76 mL, 
15 mmol) in CH2Cl2 (2 mL) was cooled to 0 °C and added dropwise over 10 min to 
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TFA (2 mL, 26.3 mmol). The reaction mixture was stirred at room temperature for 4 
h and then toluene (2 x 2 mL) was added to aid evaporation of TFA. Purification by 
flash chromatography (CH2Cl2 : MeOH, gradient elution from 95 : 5 to 80 : 20) 
afforded the title compound 102 as a white solid (123 mg, 0.50 mmol) in 61% yield. 
 
δH (600 MHz, MeOD) 8.15 (2H, d, J = 9.0 Hz, 2 x CH-Ar), 7.38 (2H, d, J = 9.0 Hz, 2 
x CH-Ar), 5.32 (1H, s, CH-3), 2.99 (3H, s, CH3-1); δC (150 MHz, MeOD) 171.4 
(C=O), 168.7 (C=O), 166.9 (C=O), 159.9 (C), 158.8 (C), 133.2 (2 x CH), 130.6 (C), 
120.7 (2 x CH), 101.5 (CH), 23.6 (CH3); IR 1726 (s), 1678 (m), 1643 (m), 1603 (m), 
1294 (m); MS (CI+) m/z, (relative intensity): 248 ([M+H]+, 100). Exact mass calcd. 
for [C12H9NO5]++H: 248.0553. Measured: 248.0550 (CI+); m.p.: 237 °C. 
 
157. N-(2-(2-(2-Methoxyethoxy)ethoxy)ethyl)-4-(1-methyl-pyrrole-2,5-dione-3-
yloxy)benzamide 
 
 
To a solution of phenoxymaleimide 102 (50.0 mg, 0.20 mmol), HOBt (2.93 mg, 0.02 
mmol) and HBTU (75.8 mg, 0.20 mmol) in dry DMF (14 mL), DIPEA (34 µL, 0.20 
mmol) was added dropwise and the resulting reaction mixture was stirred at room 
temperature for 20 min. Then a solution of PEG amine 140 (32.2 mg, 0.20 mmol) in 
dry DMF (2 mL) was added dropwise and the stirring was continued for a further 4 h. 
After this time, the solvent was evaporated in vacuo and the resulting crude was 
dissolved in CH2Cl2 (25 mL), washed with sat. aq. LiCl (2 x 20 mL), 15 % aq. citric 
acid (10 mL), water (10 mL) and brine (10 mL). The combined organic layers were 
dried (MgSO4), filtered and then the solvent evaporated in vacuo. Purification by 
flash chromatography (EtOAc : MeOH, gradient elution from 100 : 0 to 80 : 20) 
afforded the title compound 157 as a yellow oil (52.6 mg, 0.13 mmol) in 67% yield.  
 
δH (600 MHz,CDCl3) 7.94-7.92 (2H, m, 2 x CH-Ar), 7.25-7.22 (2H, m, 2 x CH-Ar), 
5.33 (1H, s, CH-3), 3.66-3.62 (10H, m, 5 x CH2), 3.53-3.51 (2H, m, CH2), 3.31 (3H, 
s, CH3-17), 3.05-3.03 (3H, s, CH3-1); δC (150 MHz, CDCl3) 169.7 (C=O), 166.4 
(C=O), 165.5 (C=O), 158.8 (C), 155.9 (C), 133.2 (C), 129.8 (2 x CH), 119.9 (2 x 
CH), 100.1 (CH), 71.8 (CH2), 70.5 (CH2), 70.4 (CH2), 70.2 (CH2), 70.0 (CH2), 59.1 
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(CH3), 40.0 (CH2), 23.8 (CH3); IR 1716 (s), 1639 (m), 1311 (w); MS (CI+) m/z, 
(relative intensity): 393 ([M+H]+, 82), 273 (100). Exact mass calcd. for 
[C19H24N2O7]++H: 393.1656. Measured: 393.1661 (CI+). 
 
176. 3,4-Dibromo-1-phenyl-pyrrole-2,5-dione189 
 
 
To a solution of dibromomaleic anhydride (300 mg, 1.17 mmol) in AcOH (3.5 mL) 
was added aniline (118 µL, 1.29 mmol). The reaction mixture was refluxed for 3 h, 
allowed to cool to room temperature over 15 h and then the solvent was evaporated 
in vacuo. Purification by flash chromatography (PE : EtOAc, gradient elution from 90 
: 10 to 80 : 20) afforded the title compound 176 as a yellow solid (91.5 mg, 0.28 
mmol) in 24% yield. 
 
δH (600 MHz, CDCl3) 7.50-7.47 (2H, m, 2 x CH-Ar), 7.43-7.40 (1H, m, CH-8), 7.34-
7.33 (2H, m, 2 x CH-Ar); δC (150 MHz, CDCl3) 163.0 (2 x C=O), 131.0 (C), 130.0 (2 x 
C), 129.5 (2 x CH), 128.8 (CH), 126.2 (2 x CH); IR 1727 (s), 1717 (s), 1369 (w), 
1229 (w); MS (CI+) m/z, (relative intensity): 334 ([81,81M+H]+, 45), 332 ([79,81M+H]+, 
100), 330 ([79,79M+H]+, 45). Exact mass calcd. for [C10H579,79Br2NO2]++H: 329.9765. 
Measured: 329.8749 (CI+); m.p.: 169 °C. 
 
179. 3-Bromo-1-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-
5-yl)-pyrrole-2,5-dione228  
 
 
To a solution of fluorescein amine isomer 1 (104 mg, 0.3 mmol) in AcOH (10 mL) 
was added bromomaleic anhydride (28.7 µL, 0.3 mmol) and the resulting reaction 
mixture was stirred for 6 h at room temperature, then refluxed for 3 h. After this time 
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the reaction mixture was allowed to cool to room temperature and the orange 
precipitate was filtered and dried in vacuo to afford the title compound 179 as an 
orange solid (96.8 mg, 0.19 mmol) in 64% yield. 
 
δH (600 MHz, DMSO-d6) 7.99 (1H, d, J = 1.3 Hz, CH-6), 7.77 (1H, dd, J = 8.3 and 
1.9 Hz, CH-24), 7.73 (1H, s, CH-2), 7.43 (1H, dd, J = 8.1 Hz, CH-23), 6.69 (2H, d, J 
= 2.3 Hz, CH-14 and CH-17), 6.62-6.57 (4H, m, CH-19, CH-23, CH-11 and CH-12); 
δC (150 MHz, DMSO-d6) 167.9 (C=O), 167.6 (C=O), 164.5 (C=O), 159.6 (2 x C), 
151.8 (2 x C), 151.5 (C), 133.7 (CH), 133.0 (C), 132.9 (CH), 131.2 (C), 129.1 (2 x 
CH), 126.7 (C), 124.8 (CH), 122.3 (CH), 112.8 (2 x CH), 109.1 (2 x C), 102.3 (2 x 
CH), 83.4 (C); IR 3063 (br), 1724 (s), 1579 (s), 1536 (s), 1369 (s), 1208 (s); MS (ES-
) m/z (relative intensity): 506 ([81M-H+]-, 100), 504 ([79M-H+]-, 100). Exact mass calcd. 
for [C24H1279BrNO7]++H: 505.9875. Measured: 505.9897 (ES+). 
 
197. 1,2-Diethyl-4-phenoxy-1,2-dihydropyridazine-3,6-dione 
 
 
To a solution of phenol (22.6 mg, 0.24 mmol) in dry dioxane (0.5 mL) a solution of 
potassium tert-butoxide (27.2 mg, 0.24 mmol) in dry dioxane (2 mL) was added 
dropwise and the solution was stirred for 15 min at room temperature. The resulting 
mixture was added dropwise to a solution of bromopyridazinedione 187 (50 mg, 
0.20 mmol) in dry dioxane (0.5 mL) and the stirring was continued at room 
temperature for another 18 h. After this time, the solvent was evaporated in vacuo. 
Water (5 mL) was added and the crude product was extracted with EtOAc (3 x 20 
mL), washed with brine (5 mL), dried (MgSO4), filtered and the organic solvent was 
evaporated in vacuo. Purification by flash chromatography (PE : EtOAc, 50 : 50) 
afforded the title compound 197 as a white solid (30.0 mg, 0.11 mmol) in 58% yield. 
 
δH (600 MHz, CDCl3) 7.43-7.41 (2H, m, 2 x CH-Ar), 7.29-7.26 (1H, m, CH-9), 7.11-
7.09 (2H, m, 2 x CH-Ar), 5.80 (1H, s, CH-4), 4.20 (2H, q., J = 7.1 Hz, CH2-2 or 11), 
4.08 (2H, q., J = 7.0 Hz, CH2-2 or 11), 1.30 (3H, t, J = 7.2 Hz, CH3-1 or 12), 1.22 
(3H, t, J = 7.0 Hz, CH3-1 or 12); δC (150 MHz, CDCl3) 159.5 (C=O), 157.3 (C=O), 
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154.4 (C), 152.7 (C), 130.7 (2 x CH), 126.7 (CH), 121.4 (2 x CH), 108.3 (CH), 40.7 
(CH2), 40.3 (CH2), 13.2 (2 x CH3); IR 1638 (s), 1210 (m); MS (CI+) m/z (relative 
intensity): 261 ([M+H]+, 100); Exact mass calcd. for [C14H16N2O3]++H: 261.1234. 
Measured: 261.1232 (CI+); m.p.: 130 °C. 
V.4 Modification of Grb2 SH2 (L111C)139 (PDB id: 3MXC) 
Sequence of Grb2 SH2 (L111C): 
MGIEMKPHPWFFGKIPRAKAEEMLSKQRHDGAFLIRESESAPGDFSLSVKFGDVQ 
HFKVCRDGAGKYFLWVVKFNSLNELVDYHRSTSVSRNQQIFLRDIEQUIVVPQQPT
YVQAGSRSHHHHHH. Calculated mass = 14185.  
General procedure for the labelling of Grb2 SH2 (L111C) with monosubstituted 
maleimides  
To a solution of Grb2 SH2 (L111C) 26 (100 μL, 70 μM, 100 mM sodium phosphate 
buffer, 150 mM NaCl, pH 8.0) at 0 °C were added various amounts (1, 10 or 100 
eq.) of the relevant maleimide. In cases when 100 eq. of the labelling reagent were 
used the stock solution was 400x more concentrated (28.2 mM in DMF) than the 
peptide solution, while in the rest of the cases the stock solution used was 20x more 
concentrated (1.41 mM in DMF). The mixture was maintained on ice. Aliquots were 
taken at various times and immediately analysed by LC-MS. The reaction progress 
was estimated based on the ratio of the MS peak heights corresponding to the 
native protein 26 and the resulting protein conjugates(s).  
 
Competition experiments between bromomaleimide 22 and the N-Methyl-
sulfoxymaleimide 66 
Experiment 1: To a mixture of bromomaleimide 22 (1 μL, 2 eq., from a 1.41 mM 
stock solution in DMF) and sulfoxymaleimide 66 (1 μL, 2 eq., from a 1.41 mM stock 
solution in DMF) was added Grb2 SH2 (L111C) 26 (10 μL, 70 μM, 100 mM sodium 
phosphate buffer, 150 mM NaCl, pH 8.0) at 0 °C. The mixture was maintained at 0 
°C. After 1 min, an aliquot was taken from the reaction mixture and immediately 
analysed by LC-MS. The ratio between the products was estimated based on the 
MS peak heights of the two resulting protein conjugates 113 and 114.  
Experiment 2: To a mixture of bromomaleimide 22 (2 μL, 4 eq., from a 1.41 mM 
stock solution in DMF) and sulfoxymaleimide 66 (2 μL, 4 eq., from a 1.41 mM stock 
solution of in DMF) was added a solution of Grb2 SH2 (L111C) (10 μL, 70 μM, 100 
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mM sodium phosphate buffer, 150 mM NaCl, pH 8.0) at 0 °C. The mixture was 
maintained at 0 °C. After 1 min, an aliquot was taken from the reaction mixture and 
immediately analysed by LC-MS. The ratio between the products was estimated 
based on the MS peak heights of the two resulting protein cojugates 113 and 114. 
 
General procedure for the labelling of Grb2-SH2 (L111C) with disubstituted 
maleimides  
To a solution of Grb2 SH2 (L111C) 26 (70 μM, 100 mM sodium phosphate buffer, 
150 mM NaCl, pH 8.0) at 0 °C was added the relevant disubstituted maleimide (1 
eq., from a 1.41 mM stock solution in DMF). The mixture was maintained at 0 °C. 
Aliquots were taken at various times and immediately analysed by LC-MS. The 
reaction progress was estimated based on the ratio of the MS peak heights 
corresponding to the native protein 26 and the resulting protein conjugate(s).  
V.5 Modification of somatostatin  
Sequence of somatostatin:  
AGCKNFFWKTFTSC (cyclic, Cys3-Cys14). Calculated mass = 1636. 
 
Reduction of somatostatin 
A solution of somatostatin 29* (200 μM, 50 mM sodium phosphate buffer, pH 6.4, 
40% CH3CN, 2.5% DMF) was reduced with TCEP (1.5 eq., 20 mM stock solution in 
the same buffer) for 1 h at room temperature. Completion of the reduction was 
checked as described below. 
* Reactions were performed starting from 50 - 700 μL somatostatin solution. 
 
General procedure for checking the completion of the reduction of 
somatostatin 
To an aliquot from the reduced somatostatin solution 118 (30 μL, 200 μM, 50 mM 
sodium phosphate buffer, pH 6.4, 40% CH3CN, 2.5 % DMF) was added 2,3-
dibromomaleimide (3 μL, 10 eq., from a 20 mM stock solution in DMF). The reaction 
mixture was left to stand at room temperature for 1 min. Completion of the reaction 
was then checked by LC-MS, based on the disappearance of the MS peak 
corresponding to the native peptide and appearance of the peak corresponding to 
the resulting peptide bridged conjugate 119. 
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General procedure for the stepwise bridging of somatostatin with 
dibromomaleimides 
A solution of somatostatin 29 (200μL, 200 μM, 50 mM sodium phosphate buffer, pH 
6.4, 40% CH3CN, 2.5% DMF) was reduced with TCEP (3 μL, 1.5 eq., 20 mM stock 
solution in the same buffer) for 1 h at room temperature. Completion of the reduction 
was determined, as described above, by LC-MS. The reduced somatostatin solution 
was then treated with the relevant 2,3-dibromomaleimides (4 μL, 2 eq., from a 20 
mM stock solution in DMF) and the reaction was left to stand at room temperature 
for 1 h. Completion of the reaction was checked by LC-MS, based on the 
disappearance of the MS peak corresponding to native peptide 29 and appearance 
of the peak corresponding to the resulting peptide conjugat(s).  
 
General procedure for the stepwise bridging of somatostatin with 
disubstituted maleimides  
A solution of somatostatin 29 (100 μL, 153 μM, 50 mM sodium phosphate buffer, pH 
6.4, 40% CH3CN, 2.5% DMF) was reduced with TCEP (1.2 μL, 1.2 eq., from a 15.3 
mM stock solution in the same buffer) for 1 h at room temperature. Completion of 
the reduction was determined, as described above, by LC-MS. To the solution of 
reduced somatostatin were added various amounts (1 - 100 eq.) of the relevant 
disubstituted maleimide and the reaction mixture was left to stand at room 
temperature. In cases when 100 eq. of the labelling reagent were used, the stock 
solution was 1000x more concentrated (153 mM in DMF) than the peptide solution, 
while in the rest of the cases the stock solution used was 100x more concentrated 
(15.3 mM stock solution in DMF). Aliquots were taken at various times and 
immediately analysed by LC-MS. The reaction progress was estimated based on the 
ratio of the MS peak heights corresponding to the native peptide 29 and the 
resulting peptide conjugatet(s).  
 
Competition experiment between iodophenoxymaleimide 108 and 
dibromomaleimide 25 
To a mixture of dibromomaleimide 25 (0.5 μL, 1 eq., from a 15.3 mM stock solution 
in DMF) and iodophenoxymaleimide 108 (0.5 μL, 1 eq., from stock solution 15.3 mM 
In DMF) was added a solution of reduced somatostatin 118 (50 μL, 153 μM, 50 mM 
sodium phosphate buffer, pH 6.4, 40% CH3CN, 2.5% DMF) at room temperature. 
The mixture was maintained at room temperature for 1 min and then an aliquot was 
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taken and immediately analysed by LC-MS. Completion of the reaction was checked 
by LC-MS, based on the disappearance of the MS peak corresponding to the 
reduced peptide 118 and appearance of the peak corresponding to the resulting 
peptide conjugats 119 and 120. 
  
General procedure for the in situ bridging of somatostatin with disubstituted 
maleimides  
A solution of somatostatin 29* (153 μM, 50 mM sodium phosphate buffer, pH 6.4, 
40% CH3CN, 2.5% DMF) was mixed with various amounts (1 or 100 eq.) of the 
relevant disubstituted maleimides. To the resulting mixture was added TCEP (1.5 
equiv, from a 20 mM stock solution in the same buffer) and the mixture was left to 
stand at room temperature. In cases when 100 eq. of the labelling reagent were 
used the stock solution was 1000x more concentrated (153 mM in DMF) than the 
peptide solution, while when 1 eq. of the labelling reagent was used the stock 
solution used was 100x more concentrated (15.3 mM in DMF). Aliquots were taken 
at various times and immediately analysed by LC-MS. The reaction progress was 
estimated based on the ratio of the MS peak heights corresponding to the native 
peptide 29 and the resulting peptide conjugate.  
* Reactions were performed starting from 100 - 700 μL somatostatin solution. 
 
Stepwise bridging of somatostatin with phenoxymaleimides 101, 139 and 146 
A solution of somatostatin 29* (200 μM, 50 mM sodium phosphate, pH 6.4, 40% 
CH3CN, 2.5% DMF) was reduced with TCEP (1.5 eq., from a 20 mM stock solution 
in the same buffer) for 1 h at room temperature. Completion of the reduction was 
assumed, as described above, by LC-MS. The reduced somatostatin solution was 
then treated with the relevant phenoxymaleimide (1.5 eq., from a stock solution of 
20 mM in DMF) and the reaction left to stand at room temperature for 1 h. 
Completion of the reaction was checked by LC-MS, based on the disappearance of 
the MS peak corresponding to the reduced peptide 118 and appearance of the peak 
corresponding to the resulting peptie conjugate.  
* Reactions were performed starting from 100 - 700 μL somatostatin solution. 
 
Stepwise bridging of somatostatin with N-Rhodamine phenoxymaleimide 156  
A solution of somatostatin 29 (100 μL, 200 μM, 50 mM sodium phosphate, pH 6.4, 
40% CH3CN, 2.5% DMF) was reduced with TCEP (1.2 μL, 1.2 eq., from a 20 mM 
209 
 
stock solution in DMF) and then N-Rhodamine phenoxymaleimide 156 (1.2 μL, 1.2 
eq., from a 20 mM stock solution in DMF) was added. The reaction mixture was left 
at room temperature for 30 min and after that TCEP (1.2 μL, 0.6 eq., from a 20 mM 
stock solution in the same buffer) was added. Completion of the reaction after 
another 30 min of incubation at room temperature was assumed by LC-MS, based 
on the disappearance of the MS peak corresponding to the native peptide and 
appearance of the resulting protein conjugate 162. 
 
Competition experiment between phenoxymaleimide 101 and bromomaleimide 
22 
A solution of somatostatin 29 (200 μL, 200 μM, 50 mM sodium phosphate buffer, pH 
6.4, 40% CH3CN, 2.5% DMF) was reduced with TCEP (3 μL, 1.5 eq., from a 20 mM 
stock solution in the same buffer) for 1 h at room temperature. Completion of the 
reduction was determined, as described above, by LC-MS. The reduced 
somatostatin solution was divided into two equal volumes and added to a mixture of 
N-methyl phenoxymaleimide 101 and bromomaleimide 22 (1 : 1 molar ratio, 1.5 eq., 
from a 20 mM stock solution in DMF) and to a mixture of 101 and 22 (5 : 1 molar 
ratio, 7.5 eq. 101 and 1.5 eq. 22, from a 20 mM stock solution in DMF) respectively. 
The two reaction mixtures were left to stand at room temperature for 5 min and then 
checked by LC-MS. The reaction progress was monitored by LC-MS over 1 h, 
based on the heights of the MS peaks corresponding to the resulting peptide 
conjugates 127 and 130. 
 
Procedure for the in situ bridging of somatostatin with phenoxymaleimides 
101 and 146  
A solution of somatostatin 29 (200 μM, 50 mM sodium phosphate buffer, pH 6.4, 
40% CH3CN, 2.5% DMF) was mixed with the relevant phenoxymaleimide (1.5 eq., 
from a 20 mM stock solution in DMF). To the resulting mixture was added TCEP 
(1.5 equiv, from a 20 mM stock solution in the same buffer) and the reaction mixture 
was left to stand at room temperature for 2 h. Completion of the reaction was 
determined by LC-MS, based on the disappearance of the peak corresponding to 
the native peptide 29 and appearance of the peak corresponding to the resulting 
peptide conjugate. 
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Organic solvent free in situ bridging of somatostatin with phenoxymaleimide 
157 
A solution of somatostatin (200 μL, 200 μM, 50 mM sodium phosphate buffer, pH 
6.4) was mixed with phenoxymaleimide 157 (6 μL, 1.5 eq., from a 10 mM stock 
solution in the same buffer). To the resulting mixture was added TCEP (3 μL, 1.5 
equiv, from a 20 mM stock solution in the same buffer) and the reaction mixture was 
left to stand at room temperature for 4 h. Completion of the reaction was determined 
by LC-MS, based on the disappearance of the MS peak corresponding to the native 
peptide 29 and appearance of the peak corresponding to the resulting peptide 
conjugate 128. 
 
Reaction of succinimide bridged somatostatin conjugate 128 with maleimide 
Succinimide bridged somatostatin conjugate 128 (100 μL, 200 μM, 50 mM sodium 
phosphate, pH 6.4, 40% CH3CN, 2.5% DMF) was treated with maleimide (1 μL, 1 
eq., from a 20 mM stock solution in DMF) and the reaction mixture was left to stand 
at room temperature for 5 min. Then, an aliquot was taken and immediately 
analysed by LC-MS to indicate that no reaction had occured. 
 
Thiol stability of maleimide and succinimide bridges 
Unpurified somatostatin conjugates 120 and 128 (100 μL, 200 μM, 50 mM sodium 
phosphate buffer, pH 6.4, 40% CH3CN, 2.5% DMF) were treated with 2-
mercaptoethanol (10 μL, 100 eq., from a 200 mM stock solution in DMF) or reduced 
glutathione (10 μL, 100 eq., from a 200 mM stock solution in 50 mM phosphate 
buffer, pH 6.4). The reaction mixtures were left to stand on ice. Aliquots were taken 
from the reaction mixture after 1 h and 13 h and the reaction progress was 
monitored by LC-MS, based on the ratio between the MS peak height corresponding 
to the peptide conjugates under investigation and the MS peak height corresponding 
to the reduced peptide 118.  
 
Thiol stability of succinimide and maleimide bridges under cytoplasm 
mimicking conditions  
Succinimide bridged somatostatin conjugates 120 and 128 were dialysed (Slide-A-
Lyzer MINI Dialysis Devices, 2K MWCO), 5000x dilution into 20 mM HEPES buffer 
(100 mM KCl, 1 mM MgCl2, 1 mM EDTA, pH 7.4). The concentration of the peptide 
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conjugates was adjusted to 100 μM and the resulting reaction mixtures* were 
incubated at 37 °C for 21 h in the presence of 1 mM reduced glutathione (from a 20 
mM stock solution in the same buffer). Aliquots from the reaction mixtures were 
taken at various times and were immediately analysed by LC-MS. The progress of 
the reactions was estimated, based on the ratio of the peak heights corresponding 
to the MS peptide conjugates under investigation and the MS peak height 
corresponding to the reduced peptide 118.  
* Reactions were done starting from 100 and 300 μL of peptide conjugates. 
 
Hydrolytic stability of maleimide and succinimide bridges 
Unpurified somatostatin conjugates 128, 174, 175 (200 μM, 50 mM sodium 
phosphate buffer, pH 6.4, 40% CH3CN, 2.5% DMF) were dialysed (Slide-A-Lyzer 
MINI Dialysis Devices, 2K MWCO), 5000x dilution into pH 8 buffer (50 mM sodium 
phosphate) for 12 h at 0 °C. The concentration of the peptide conjugates was 
adjusted to 100 μM and the resulting reaction mixtures (100 μL) were incubated at 
37 °C. The progress of the reaction was monitored by LC-MS, based on the ratio of 
the MS peak heights corresponding to the peptide conjugates under investigation 
and the MS peak height corresponding to the hydrolysed peptide conjugates.  
 
Thiol stability of hydrolysed succinimide and maleimide bridges 
Hydrolysed somatostatin conjugates 174 and 175 (100 μL, 200 μM, 50 mM sodium 
phosphate, pH 8), were treated with 2-mercaptoethanol (10 μL, 100 eq., from a 200 
mM stock solution in DMF). The reaction mixture was incubated at 37 °C for 21 h. 
The progress of the reaction was monitored by LC-MS to indicate that no reaction 
had occurred. 
 
General procedure for the dual labelling of somatostatin 
Succinimide bridged somatostatin conjugate 128, 161 and 162 (200 μM, 50 mM 
sodium phosphate, pH 6.4, 40% CH3CN, 2.5% DMF) was treated with various 
amounts of the relevant bromomaleimide (from a 20 mM stock solution in DMF), 
(Table 6) and heated at 37 °C for 2 h. Completion of the reaction was confirmed by 
LC-MS, based on the disappearance of the peak corresponding to the starting 
succinimide bridged conjugate and the appearance of the peak of the resulting dual 
conjugate. 
* Reactions were performed starting from 100 or 200 μL of peptide conjugate. 
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Dual labelled conjugate Reagent code (eq.) 
177 Bromomaleimide 22 (1.5 eq.) 
180 N-Fluorescein bromomaleimide 179 (4 eq.) 
181 Bromomaleimide 57 (1.5 eq.) 
182 N-Fluorescein bromomaleimide 179 (4 eq.) 
Table 6. Amounts of bridging reagents used for the dual labelling of somatostatin 
 
Preparation of the dual labelled somatostatin conjugate with a maleimide and 
succinimide tag 178 
Succinimide bridged somatostatin conjugate 128 (100 μL, 200 μM, 50 mM sodium 
phosphate, pH 6.4, 40 % CH3CN, 2.5% DMF) was treated with maleimide (5 μL, 5 
eq., from a 20 mM stock solution in DMF) and the resulting reaction mixture was left 
to stand at room temperature for 12 h. Completion of the reaction was determined 
by LC-MS, based on the disappearance of the MS peak corresponding to the 
succinimide bridged somatostatin conjugate 128 and appearance of the peak 
corresponding to the resulting dual labelled peptide conjugate 178. 
 
Thiol cleavage of dual labelled somatostatin conjugate 177  
Dual labeled somatostatin conjugate 177 (100 μL, 200 μM, 50 mM sodium 
phosphate, pH 6.4, 40 % CH3CN, 2.5% DMF), prepared as described above, was 
treated with 2-mercaptoethanol (10 μL, 100 eq., from a 200 mM stock solution in 
DMF) and the reaction mixture incubated at 37 °C for 3 h. Complete cleavage of the 
2 labels to afford reduced somatostatin was determined by LC-MS, based on the 
disappearance of the MS peak corresponding to the dual labelled somatostatin 177 
and appearance of the peak corresponding to the reduced somatostatin 118. 
 
Trypsin digest of the dual labelled somatostatin conjugate 181 
A solution of dual labelled somatostatin conjugate 181 (200 μM, 50 mM sodium 
phosphate, pH 6.4, 40 % CH3CN, 2.5% DMF) was dialysed (Slide-A-Lyzer MINI 
Dialysis Devices, 2K MWCO), 5000x dilution into pH 8.1 buffer (100 mM ammonium 
acetate, 1 mM calcium chloride). The concentration of the peptide conjugate was 
adjusted to 100 μM and to the resulting reaction mixture (100 μL) was added trypsin 
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(1 μL, 0.1 eq., from a 1 mM stock solution in the same buffer). The reaction mixture 
was incubated at 37 °C for 15 h and then the reaction mixture was analysed by LC-
MS. 
 
Screening of reducing reagents for trapping the intermediate of the retro-
Michael addition reaction 
DTT 
A solution of succinimide bridged somatostatin conjugate* 128 (200 μM, 50 mM 
sodium phosphate, pH 6.4, 40 % CH3CN, 2.5% DMF), was mixed with added 
various amounts (10 - 250 eq.) of DTT (from a 100 mM stock solution in the same 
buffer). The reaction was incubated at 37 °C for 1.5 or 2 h. After this time, various 
amounts (100 - 300 eq.) of maleimide (from a 400 mM stock solution in the same 
buffer) were added to quench the reaction. When 250 eq. of DTT was added, the 
reaction mixture was dialysed (Slide-A-Lyzer MINI Dialysis Devices, 2K MWCO), 
5000x dilution into pH 8 buffer (50 mM sodium phosphate) for 4 h at 0 °C prior to 
quenching and the concentration was readjusted to 200 μM. The progress of the 
reactions was monitored by LC-MS, based on the ratio between the MS peak 
heights of the peptide conjugates 201 and 202.  
* Reactions were done starting from 100 and 300 μL of somatostatin conjugate 128. 
TCEP 
A solution of succinimide bridged somatostatin conjugate 128 (200 μL, 200 μM, 50 
mM sodium phosphate buffer, pH 6.4, 40% CH3CN, 2.5% DMF), prepared as 
described above, was mixed with TCEP (26 μL, 65 eq., from a 100 m stock solution 
in the same buffer) and the reaction mixture was incubated at room temperature for 
6 h. After this time, maleimide (40 μL, 100 eq., from a 100 mM stock solution in the 
same buffer) was added to quench the reaction. The progress of the reactions was 
monitored by LC-MS to show that no reaction had occured.  
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V.6 Modification of octreotide 
Sequence of octreotide: 
FCFWKWCW (cyclical, C2-C7), acetate salt. Calculated mass: 1019. 
 
Reduction of octreotide 
A solution of octreotide 163* (200 μM, 50 mM sodium phosphate buffer, pH 6.4, 40% 
CH3CN, 2.5% DMF) was reduced with TCEP (1.5 eq., 20 mM stock solution in the 
same buffer) for 1 h at room temperature. Completion of the reduction was checked 
as described below. 
* Reactions were performed starting from 50 - 500 μL octreotide solution. 
 
General procedure for checking the completion of the reduction of octreotide 
To an aliquot from the reduced octreotide solution (30 μL, 200 μM, 50 mM sodium 
phosphate buffer, pH 6.4) was added 2,3-dibromomaleimide (3 μL, 10 eq., from a 20 
mM stock solution in DMF). The reaction mixture was left to stand at room 
temperature for 1 min. Completion of the reaction was then checked by LC-MS, 
based on the disappearance of the MS peak corresponding to the native peptide 
and appearance of the peak corresponding to peptide conjugate. 
 
Stepwise bridging of octreotide with phenoxymaleimide 103 
A solution of octreotide 163 (100 μL, 200 μM, 50 mM sodium phosphate buffer, pH 
6.4, 40% CH3CN, 2.5% DMF) was reduced with TCEP (2 μL, 2 eq., from a 20 mM 
stock solution in the same buffer) for 1 h at room temperature. Completion of the 
reduction was confirmed, as described above, by LC-MS. The reduced octreotide 
solution was then treated with phenoxymaleimide 103 (1.2 μL, 1.2 eq., from a stock 
solution of 20 mM in DMF) and the reaction left to stand at room temperature for 1 h. 
Completion of the reaction was determined by LC-MS, based on the disappearance 
of the MS peak corresponding to the reduced peptide and appearance of the peak 
corresponding to peptide conjugate 164.  
 
Stepwise bridging of octreotide with bromopyridazinedione 187 
A solution of octreotide 163 (100 μL, 200 μM, 50 mM sodium phosphate buffer, pH 
6.4, 40% CH3CN, 2.5% DMF) was reduced with TCEP (2 μL, 2 eq., from a 20 mM 
stock solution in the same buffer) for 1 h at room temperature. Completion of the 
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reduction was determined, as described above, by LC-MS. The reduced octreotide 
solution was treated various amounts (5 or 10 eq.) of bromopyridazinedione 187 
(from a 20 mM stock solution in DMF) and the reaction was left to stand at room 
temperature for 1 h. The progress of the reaction was checked by LC-MS, based on 
the MS peak heights corresponding to the native peptide and the resulting peptide 
conjugates 189 and 190. 
 
Stepwise bridging of octreotide with phenoxypiridazinedione 197 
A solution of octreotide 163 (200 μL, 200 μM, 50 mM sodium phosphate, pH 6.4, 
40% CH3CN, 2.5% DMF) was reduced with TCEP (4 μL, 2 eq., from a 20 mM stock 
solution in the same buffer) for 1 h at room temperature. Completion of the reduction 
was determined, as described above, by LC-MS. The reduced octreotide solution 
(50 μL, 200 μM, 50 mM sodium phosphate, pH 6.4, 40% CH3CN, 2.5% DMF) was 
then treated with various amounts (5 - 500 eq.) of phenoxypyridazinedione 197 and 
the reaction was left to stand at 37 °C. In cases when more than 100 eq. of the 
labelling reagent were used the stock solution was 5000x more concentrated (1 M in 
DMF) than the peptide solution, while in the rest of the cases the stock solution used 
was 100x more concentrated (20 mM in DMF). The progress of the reaction was 
checked by LC-MS, based on the heights of the MS peak corresponding to the 
reduced peptide and peptide conjugates 189 and 190. 
 
In situ bridging of octreotide with phenoxymaleimides 101 and 146  
A solution of octreotide 163 (100 μL, 200 μM, 50 mM sodium phosphate, pH 6.4, 
40% CH3CN, 2.5% DMF) was mixed with the relevant phenoxymaleimide (1.5 μL, 
1.5 eq., from a 20 mM stock solution in DMF). To the resulting solution was added 
TCEP (1.5 equiv, from a 20 mM stock solution in the same buffer) and the mixture 
was left to stand at room temperature for 3 h. The completion of the reaction was 
determined by LC-MS, based on the disappearance of the MS peak corresponding 
to the native peptide 163 and appearance of the peak corresponding to the resulting 
peptide conjugate. 
 
pH screen for the dual labelling of octreotide with bromomaleimide 22 
Succinimide bridged octreotide conjugate 164 (600 μL, 200 μM, 50 mM sodium 
phosphate, pH 6.4, 40% CH3CN, 2.5% DMF) was divided in 4 equal volumes and 
dialysed (Slide-A-Lyzer MINI Dialysis Devices, 2K MWCO), 5000x dilution into 4 
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different buffers: 1) pH 8 buffer (50 mM sodium phosphate); 2) pH 7 (50 mM sodium 
phosphate); 3) pH 6 (50 mM sodium phosphate); 4) pH 5 (50 mM sodium citrate). 
The concentration of the dialysed solutions was adjusted to 174.5 μM and then 
bromomaleimide 22 (5 eq., 20 mM stock solution in DMF) was added. The resulting 
reaction mixtures were incubated at 37 °C for 18 h. The progress of the reaction was 
monitored by LC-MS, based on the heights of the MS peaks corresponding to the 
peptide conjugates 183 and 184. 
 
Dual labelling of octreotide with maleimide 
Succinimide bridged octreotide conjugate 164 (100 μL, 200 μM, 50 mM sodium 
phosphate, pH 6.4, 40 % CH3CN, 2.5% DMF) was treated with maleimide (5 μL, 5 
eq., from a 20 mM stock solution in DMF) and the reaction mixture was incubated at 
37 °C for 2 h. The progress of the reaction was monitored by LC-MS, based on the 
heights of the MS peaks corresponding to the resulting peptide conjugates. 
 
Dual labelling of octreotide with phenoxymaleimide 101 
Succinimide bridged octreotide conjugate 191 (100 μL, 200 μM, 50 mM sodium 
phosphate, pH 6.4, 40 % CH3CN, 2.5% DMF) was treated with N-methyl 
phenoxymaleimide 101 (15 μL, 15 eq., from a 20 mM stock solution in DMF) and the 
reaction mixture was incubated at 37 °C for 30 h. The progress of the reaction was 
monitored by LC-MS, based on the heights of the MS peaks corresponding to 
conjugates 192 and 193. 
 
Dual labelling of octreotide with pyridazinediones 186, 187 and propiolamide 
188 
Succinimide bridged octreotide conjugate 164 (200 μM, 50 mM sodium phosphate, 
pH 6.4, 40% CH3CN, 2.5% DMF) was treated with various amounts (1.5 - 300 eq.) 
of the relevant labelling reagent and the reaction mixture incubated at 37 oC for 
various periods of time (2 h - 5 days). In cases when more than 100 eq. of the 
labelling reagent were used the stock solution was 5000x more concentrated (1 M in 
DMF) than the peptide solution, while in the rest of the cases the stock solution used 
was 100x more concentrated (20 mM in DMF). The progress of the reactions was 
monitored by LC-MS, based on the heights of the MS peaks corresponding to the 
resulting peptide conjugates. 
217 
 
V.7 Modification of an anti-CEA ds-scFv (representation of 
the protein was taken from Baker et al.)146 
Sequence of anti-CEA ds-scFv: 
AGIHVAQPAMAQVKLEQUIVSGAEVVKPGASVKLSCKASGFNIKDSYMHWLRQGP
QCLEWIGWIDPENGDTEYAPKFQGKATFTTDTSANTAYLGLSSLRPEDTAVYYCN
EGTPTGPYYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSENVLTQSPS
SMSASVGDRVTIACSASSSVPYMHWFQQKPGKSPKLLIYSTSNLASGVPSRFSGS
GSGTDYSLTISSVQPEDAATYYCQQRSSYPLTFGCGTKLEIKHHHHHH. Calculated 
mass = 27531.  
 
In situ bridging of ds-scFv with N-methyl phenoxymaleimide 101 
To a solution of ds-scFv 33 (50 μL, 70 μM, pH 7.4 PBS) were added 
phenoxymaleimide 101 (0.25 μL, 5 eq., from a 70 mM stock solution in DMF) and 
benzeneselenol (2.5 μL, 25 eq., from a 35 mM stock solution in DMF). The reaction 
mixture was left to stand at room temperature for 30 min. Completion of the reaction 
was determined by LC-MS, based on the disappearance of the MS peak 
corresponding to the native protein 33 and appearance of the peak corresponding to 
the protein conjugate 169. 
 
In situ bridging of ds-scFv with N-PEG-phenoxymaleimide 146 
To a solution of ds-scFv 33 (50 μL, 70 μM, pH 7.4 PBS) were added 
phenoxymaleimide 146 (0.75 μL, 15 eq., from a 70 mM stock solution in DMF) and 
benzeneselenol (5 μL, 50 eq., from a 35 mM stock solution in DMF). The reaction 
mixture was left to stand at room temperature for 30 min. Completion of the reaction 
was confirmed by LC-MS, based on the disappearance of the MS peak 
corresponding to the native protein 33 and appearance of the peak corresponding to 
the protein conjugate 170. 
 
Thiol stability of succinimide bridged ds-scFv conjugate 169 
Unpurified ds-scFv conjugate 169 (100 μL, 70 μM, pH 7.4 PBS) was treated with 2-
mercaptoethanol (10 μL, 100 eq., 70 mM stock solution in DMF). The same 
experiment was repeated using reduced glutathione (10 μL, 100 equiv, 70 mM stock 
solution in pH 7.4 PBS). The reaction mixtures were left to stand at room 
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temperature for 48 h. The reaction progress was monitored by LC-MS to show that 
no reaction had occurred. 
 
General procedure for the dual labelling of ds-scFv  
Succinimide bridged ds-scFv conjugate 169 (200 μL, 70 μM, pH 7.4 PBS) was 
purified on a PD MiniTrap G-25 (GE Healthcare) desalting column and concentrated 
by centrifugation using 10 KDa MWCO filters. The protein concentration was 
adjusted to 70 μM (pH 7.4 PBS, 10% DMF) and then bromomaleimide 22 (50 eq., 
from a 70 mM stock solution in DMF) was added. To the resulting solution was 
added guanidinium chloride (from a 6M stock solution in PBS) to afford a final 
concentration of 2 M. The reaction mixture was incubated at 37 °C for 2 h. The 
completion of the reaction was confirmed by LC-MS, based on the disappearance of 
the MS peak corresponding to the succinimide bridged protein conjugate 169 and 
appearance of the peak corresponding to the dual labelled proetein conjugate 203. 
V.8 Modification of Rituximab-Fab (PDB id: 2OSL) 
Sequence of the light chain: 
QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPG
NGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYF
NVWGAGTTVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV. 
Calculated mass: 23167. 
Sequence of the heavy chain: 
QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPG
NGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYN
VWGAGTTVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS
GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKEK
SC. Calculated mass: 23712. 
 
Stepwise bridging of Rituximab Fab with N-PEG phenoxymaleimide 146 
A solution of Rituximab Fab 165 (50 μL, 22.9 μM, PBS buffer 7.4) was reduced with 
DTT (10 μL, 200 eq., from a 22.9 mM stock solution in the same buffer) for 5 h at 
room temperature. Alternatively, the reduction was achieved by using TCEP (3.4 μL, 
30 eq., from a 10 mM stock solution in the same buffer) and incubating the reaction 
mixture at room temperature for 2 h. After this time, the Fab solution was buffer 
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swapped in pH 7.4 PBS (1 mM EDTA) using 10 kDa MWCO filters. The 
concentration of the reduced Fab was adjusted to 20.1 μM. Completion of the 
reduction was determined by LC-MS, based on the disappearance of the MS peak 
corresponding to the native Fab. The reduced Fab solution (30 μL) was then treated 
with N-PEG phenoxymaleimide 146 (1.5 μL, 5 eq., from a 2.01 mM stock solution in 
DMF) and the reaction left to stand at room temperature for 1 h. The completion of 
the reaction was determined by LC-MS, based on the disappearance of the peaks 
corresponding to the light and heavy chains and appearance of the peak 
corresponding to conjugate 166.  
V.9 Modification of Herceptin Fab (PDB id: 1N8Z) 
Sequence of the light chain: 
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTN
GYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDY
WGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNAL
TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP. 
Calculated mass = 23404. 
Sequivuence of the heavy chain: 
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYS
GVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAA
PSVFIFPPSDEQUIVLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
QUIVDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC. 
Calculated mass = 23443. 
 
Preparation of Herceptin Fab fragment using pepsin and papain digest212 
Immobilised pepsin (0.15 mL) (Thermo Scientific) was buffer swapped 4x with 
digestion buffer (20 mM sodium acetate trihydrate, pH 3.1). After this, Herceptin (0.5 
mL, 6.41 mg/mL in digestion buffer) was added and the resulting mixture was 
incubated for 5 h at 37 °C while shaking at 1100 rpm. The digest was separated 
from the resin using a filter column (Pierce Centrifuge Column 0.8 mL, Thermo 
Scientific) and the digest was buffer swapped 3x with digest buffer (50 mM sodium 
phosphate, 1 mM EDTA, 150 mg NaCl, pH 6.8) using 10 kDa MWCO filters 
(Vivaspin 6 mL, Santorius). The digest was mixed with the washes and the volume 
adjusted to 0.5 mL. After this, the papain resin (1 mL, 0.25 mg/mL) (Thermo 
Scientific) was treated with DTT (from a 10 mM stock solution in digest buffer), to 
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activate it, for 1 h at 25 °C, under argon, in the dark while shaking (1100 rpm). The 
resin was washed with digest buffer and then the 0.5 mL of antibody solution was 
added. The mixture was incubated at 37 °C for 16 h, and in the dark, with shaking 
(1100 rpm). The resin was separated from the digest using a filter column (Pierce 
Centrifuge Column 0.8 mL, Thermo Scientific), and buffer swapped 3x with PBS (pH 
7.4). The digest was mixed with the washes and the buffer was exchanged for PBS 
(pH 7.4) using 10 kDa MWCO filters (Vivaspin 6 mL, Santorius) to give a final 
volume of 0.4 mL. The digest was analysed by SDS-PAGE and LCMS to reveal a 
single Herceptin Fab fragment 167, observed mass: 47652. The concentration of 
Herceptin Fab was determined by UV/VIS spectroscopy using a molecular extinction 
coefficient of ɛ280= 68590 M-1 cm-1. [Herceptin Fab fragment] 2 mg/L (0.4 mL), 38 %. 
 
Sequential bridging of Herceptin Fab with phenoxymaleimide 101 
A solution of Herceptin Fab 167 (50 μL, 22.9 μM, pH 8 borate buffer) was reduced 
with TCEP (1.5 μL, 3 eq., from a 2.29 mM stock solution in the same buffer) and 
then incubated at 37 °C for 2 h, with shaking (400 rpm). Completion of the reduction 
was determined by LC-MS, based on the disappearance of the MS peaks 
corresponding to the unreacted Fab. The reduced Fab solution (30 μL) was then 
treated with N-methyl phenoxymaleimide 101 (0.6 μL, 2 eq., 2.29 mM stock solution 
in DMF) and the reaction was left to stand at room temperature for 1 h. The 
completion of the reaction was checked by LC-MS, based on the disappearance of 
the peaks corresponding to the light and heavy chains.  
V.10 Kinetic study 
Reactions with 2-mercaptoethanol were carried out at room temperature, while 
reactions with GSH were carried out at 22 °C. 
 
Experiments with 2-mercaptoethanol 
To the cuvette containing the relevant substituted maleimide 57, 86, 88 or 101 (50 
μL, 500 μM stock solution in pH 6 buffer, 50 mM phosphate, 20% CH3CN) in the 
background solution (50 μL, same buffer) was added freshly prepared 2-
mercaptoethanol (50 μL, from a 500 μM stock solution in the same buffer) and the 
acquisition of the signal at 360 nm was started. In the case of halomaleimides 57, 
86, 88 the acquisition was stopped after 10 min while in the case of 
phenoxymaleimide 101 the acquisition was stopped after 60 min.  
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Experiments with glutathione  
To the cuvette containing reduced GSH (75 μL, 300 μM stock solution in pH 6 buffer 
(50 mM phosphate buffer)) was added the relevant monosubstituted maleimide 57, 
86, 88 or 101 (75 μL, 300 μM stock solution pH 6 buffer, 50 mM sodium phosphate, 
20% CH3CN) and the acquisition of the signal at 360 nm was started. The 
acquisition was stopped after 30 min. The reaction mixture was also analysed by 1H-
NMR. 
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V.11 LC-MS spectra  
Unreacted Grb2 SH2 (L111C) 26 (eluted at 2.13 min; observed mass: 14169) 
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Grb2 SH2 (L111C) thiomaleimide conjugate 113 (eluted at 1.41 min; expected 
mass: 14282; observed mass: 14276) 
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Grb2 + 100 eq. N-methyl methoxymaleimide 95 (eluted at 1.41 min) 
 
 
 
Grb2 + 1 eq. N-methyl selenomaleimide 79 (eluted at 1.28 min) 
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Grb2 + 1 eq. N-methyl benzoatemaleimide 82 (eluted at 1.28 min) 
 
 
 
Unreacted octreotide 163 (eluted at 1.73 min; expected mass: 1019; observed 
mass: 1019) 
 
 
226 
 
Maleimide bridged octreotide (eluted at 1.15 min; expected mass: 1114; observed 
mass: 1114) 
 
 
N-Methyl succinimide bridged octreotide 164 (eluted at 1.21 min; expected 
mass: 1130; observed mass: 1130) 
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N-PEG succinimide bridged octreotide 191 (eluted at 2.7 min; expected mass: 
1262; observed mass: 1262) 
 
Octreotide + 5 eq. N,N’-diethyl bromopyridazinedione 187 (195, eluted at 1.28 
min: expected mass: 1187; observed mass: 1187; 196, eluted at 1.36 min: expected 
mass: 1353; observed mass: 1354) 
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Octreotide + 10 eq. N,N’-diethyl bromopyridazinedione 187 (195, eluted at 1.28; 
expected mass: 1187; observed mass: 1187; 196, eluted at 1.36 min; expected 
mass: 1353; observed mass: 1354) 
 
 
Unreacted somatostatin 29 (eluted at 1.24 min; expected mass: 1637; observed 
mass: 1637) 
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Reduced somatostatin 118 (eluted at 1.26 min; expected mass: 1639; observed 
mass: 1641) 
 
 
 
Maleimide bridged somatostatin 119 (eluted ar 1.27 min; expected mass: 1732; 
observed mass: 1732) 
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N-methyl maleimide bridged somatostatin 120 (eluted at 1.30 min; expected 
mass: 1746; observed mass: 1747) 
 
 
 
N-Phenyl maleimide bridged somatostatin 175 (eluted at 1.81 min; expected 
mass: 1808; observed mass: 1810) 
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N-Methyl succinimide bridged somatostatin 128 (eluted at 1.50 min; expected 
mass: 1748; observed mass: 1749) 
 
 
N-Phenyl succinimide bridged somatostatin 174 (eluted at 1.50 min; expected 
mass: 1810; observed mass: 1812) 
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N-PEG succinimide bridged somatostatin 161 (eluted at 1.54 min; expected 
mass: 1880; observed mass: 1882) 
 
 
Rhodamine succinimide bridged somatostatin 162 (eluted at 1.88 min; expected 
mass: 2283; observed mass: 2284) 
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Hydrolysed N-phenyl succinimide bridged somatostatin (eluted at 1.68 min; 
expected mass: 1830; observed mass: 1830) 
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Hydrolysed N-phenyl maleimide bridged somatostatin (eluted at 1.73 min; 
expected mass: 1827; observed mass: 914 (M+2/2)) 
 
 
Hydrolysed N-methyl succinimide bridged somatostatin (eluted at 1.55 min; 
expected mass: 1766; observed mass: 1768) 
 
 
235 
 
Dual labelled somatostatin conjugate 177 (eluted at 1.49 min; expected mass: 
1845; observed mass: 1845) 
 
 
Dual labelled somatostatin conjugate with a maleimide and succinimide tag 
178 (eluted at 1.45 min; expected mass: 1845; observed mass: 1847) 
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Fluorescein-PEG dual labelled somatostatin conjugate 180 (eluted at 1.73 min; 
expected mass: 2305; observed mass: 2307)  
 
 
 
 
 
237 
 
Rhodamine-fluorescein dual labelled somatostatin conjugate 182 (eluted at 
2.33; expected mass: 2709; observed mass: 2710) 
 
 
 
 
 
238 
 
PEG-methyl dual labelled somatostatin conjugate 25 (expected mass: 1989; 
observed mass: 1991) 
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Unreacted anti-CEA ds-scFv 33 (eluted at 1.36-1.75 min; observed mass: 26748) 
 
 
 
240 
 
N-Methyl succinimide bridged anti-CEA ds-scFv 169 (eluted at 1.38 min; 
expected mass: 26859; observed mass: 26856) 
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N-PEG succinimide bridged anti-CEA ds-scFv 170 (eluted at 1.50 min; expected 
mass: 26991; observed mass: 26983)  
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Dual labelled ds-scFv conjugate 203 (eluted at 1.49 min; expected mass: 26953; 
observed mass: 26949) 
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Unreacted Rituximab Fab 165 (eluted at 3.74 min; observed mass: 47192) 
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Reduced Rituximab Fab (eluted at 3.71 min; observed mass: 23040 (light chain); 
24151 (heavy chain)) 
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N-PEG succinimide bridged Rituximab Fab 166 (eluted at 3.69 min; expected 
mass: 47439; observed mass: 47429) 
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Unreacted Trastuzumab Fab 167 (eluted at 4.19 min; observed mass: 47652) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
247 
 
Reduced Trastuzumab Fab (eluted at 3.98 min; observed mass: 23454 (light 
chain); 24218 (heavy chain) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
248 
 
N-Methyl succinimide bridged Trastuzumab Fab 168 (eluted at 4.49 min; 
expected mass: 47767; observed mass: 47775) 
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(66)  Tavaré, R.; Torres Martin De Rosales, R.; Blower, P. J.; Mullen, G. E. D. 
Bioconjug. Chem. 2009, 20, 2071. 
(67)  Pradier, L.; Yee, A. S.; McNamee, M. G. Biochemistry 1989, 28, 6562. 
(68)  Juszczak, L. J.; Manjula, B.; Bonaventura, C.; Acharya, S. A.; Friedman, J. M. 
Biochemistry 2001, 41, 376. 
253 
 
(69)  Egenberger, B.; Gorboulev, V.; Keller, T.; Gorbunov, D.; Gottlieb, N.; Geiger, 
D.; Mueller, T. D.; Koepsell, H. J. Biol. Chem. 2012, 287 , 31561. 
(70)  Thibaudeau, K.; Léger, R.; Huang, X.; Robitaille, M.; Quraishi, O.; Soucy, C.; 
Bousquet-Gagnon, N.; van Wyk, P.; Paradis, V.; Castaigne, J.-P.; Bridon, D. 
Bioconjug. Chem. 2005, 16, 1000. 
(71)  Ryppa, C.; Mann-Steinberg, H.; Fichtner, I.; Weber, H.; Satchi-Fainaro, R.; 
Biniossek, M. L.; Kratz, F. Bioconjug. Chem. 2008, 19, 1414. 
(72)  Deuss, P. J.; Popa, G.; Botting, C. H.; Laan, W.; Kamer, P. C. J. Angew. 
Chemie Int. Ed. 2010, 49, 5315. 
(73)  Liu, Y.; Yu, Y.; Lam, J. W. Y.; Hong, Y.; Faisal, M.; Yuan, W. Z.; Tang, B. Z. 
Chem. – A Eur. J. 2010, 16, 8433. 
(74)  Smyth, D. G.; Nagamatsu, A.; Fruton, J. S. J. Am. Chem. Soc. 1960, 82, 
4600. 
(75)  Smyth, D. G.; Blumenfeld, O. O.; Konigsberg, W. Biochem. J. 1964, 91, 580. 
(76)  Nampalli, S.; McDougall, M. G.; Lavrenov, K.; Xiao, H.; Kumar, S. Bioconjug. 
Chem. 2002, 13, 468. 
(77)  Alley, S. C.; Benjamin, D. R.; Jeffrey, S. C.; Okeley, N. M.; Meyer, D. L.; 
Sanderson, R. J.; Senter, P. D. Bioconjug. Chem. 2008, 19, 759. 
(78)  Shen, B.-Q.; Xu, K.; Liu, L.; Raab, H.; Bhakta, S.; Kenrick, M.; Parsons-
Reponte, K. L.; Tien, J.; Yu, S.-F.; Mai, E.; Li, D.; Tibbitts, J.; Baudys, J.; 
Saad, O. M.; Scales, S. J.; McDonald, P. J.; Hass, P. E.; Eigenbrot, C.; 
Nguyen, T.; Solis, W. A.; Fuji, R. N.; Flagella, K. M.; Patel, D.; Spencer, S. D.; 
Khawli, L. A.; Ebens, A.; Wong, W. L.; Vandlen, R.; Kaur, S.; Sliwkowski, M. 
X.; Scheller, R. H.; Polakis, P.; Junutula, J. R. Nat. Biotechol. 2012, 30, 184. 
(79)  Meister, A.; Anderson, M. E. Annu. Rev. Biochem. 1983, 52, 711. 
(80)  Baldwin, A. D.; Kiick, K. L. Bioconjug. Chem. 2011, 22, 1946. 
(81)  Wang, J.; Li, S.; Luo, T.; Wang, C.; Zhao, J. Curr. Med. Chem. 2012, 19, 
2976. 
(82)  Hill, B. G.; Bhatnagar, A. J. Mol. Cell. Cardiol. 2012, 52, 559. 
(83)  Hazebrouck, S.; Guillon, B.; Drumare, M.-F.; Paty, E.; Wal, J.-M.; Bernard, H. 
Mol. Nutr. Food Res. 2012, 56, 548. 
(84)  Rehder, D. S.; Borges, C. R. Biochemistry 2010, 49, 7748. 
254 
 
(85)  Lui, J. K. C.; Lipscombe, R.; Arthur, P. G. J. Proteome Res. 2009, 9, 383. 
(86)  Moroder, L.; Musiol, H.-J.; Götz, M.; Renner, C. Pept. Sci. 2005, 80, 85–97. 
(87)  Sando, S.; Narita, A.; Aoyama, Y. Bioorg. Med. Chem. Lett. 2004, 14, 2835. 
(88)  Ellman, G. L. Arch. Biochem. Biophys. 1958, 74, 443. 
(89)  Hallaway, B. E.; Hedlund, B. E.; Benson, E. S. Arch. Biochem. Biophys. 1980, 
203, 332. 
(90)  Onwochei Okonjo, K.; Nwozo, S. J. Chem. Soc. Faraday Trans. 1997, 93, 
1361. 
(91)  Lee, S.-Y.; Kim, S.; Tyler, J. Y.; Park, K.; Cheng, J.-X. Biomaterials 2013, 34, 
552. 
(92)  Xu, J.; Wang, J.; Luft, J. C.; Tian, S.; Owens, G.; Pandya, A. A.; Berglund, P.; 
Pohlhaus, P.; Maynor, B. W.; Smith, J.; Hubby, B.; Napier, M. E.; DeSimone, 
J. M. J. Am. Chem. Soc. 2012, 134, 8774. 
(93)  Davis, B. G.; Shang, X.; DeSantis, G.; Bott, R. R.; Jones, J. B. Bioorg. Med. 
Chem. 1999, 7, 2293. 
(94)  Takatsuka, Y.; Nikaido, H  In Vitro Mutagenesis Protocols SE  - 24; Ed.; 
Humana Press, 2010, Vol. 634, 343. 
(95)  Harpp, D. N.; Gleason, J. G. J. Am. Chem. Soc. 1971, 93, 2437. 
(96)  Bernardes, G. J. L.; Grayson, E. J.; Thompson, S.; Chalker, J. M.; Errey, J. 
C.; El Oualid, F.; Claridge, T. D. W.; Davis, B. G. Angew. Chemie Int. Ed. 
2008, 47, 2244. 
(97)  Rohde, H.; Seitz, O. Pept. Sci. 2010, 94, 551. 
(98)  Yan, L. Z.; Dawson, P. E. J. Am. Chem. Soc. 2001, 123, 526. 
(99)  Pentelute, B. L.; Kent, S. B. H. Org. Lett. 2007, 9, 687. 
(100)  Wan, Q.; Danishefsky, S. J. Angew. Chemie Int. Ed. 2007, 46, 9248. 
(101)  Bar-Or, R.; Rael, L. T.; Bar-Or, D. Rapid Commun. Mass Spectrom. 2008, 22, 
711. 
(102)  Patchornik, A.; Sokolovsky, M. J. Am. Chem. Soc. 1964, 86, 1860. 
255 
 
(103)  Bernardes, G. J. L.; Chalker, J. M.; Errey, J. C.; Davis, B. G. J. Am. Chem. 
Soc. 2008, 130, 5052. 
(104)  Chalker, J. M.; Lercher, L.; Rose, N. R.; Schofield, C. J.; Davis, B. G. Angew. 
Chemie Int. Ed. 2012, 51, 1835. 
(105)  Lin, Y. A.; Chalker, J. M.; Floyd, N.; Bernardes, G. J. L.; Davis, B. G. J. Am. 
Chem. Soc. 2008, 130, 9642. 
(106)  Chalker, J. M.; Lin, Y. A.; Boutureira, O.; Davis, B. G. Chem. Commun. 2009, 
, 3714. 
(107)  Chalker, J. M.; Wood, C. S. C.; Davis, B. G. J. Am. Chem. Soc. 2009, 131, 
16346. 
(108)  On-Yee Chan, A.; Lui-Lui Tsai, J.; Kar-Yan Lo, V.; Li, G.-L.; Wong, M.-K.; 
Che, C.-M. Chem. Commun. 2013, 49, 1428. 
(109)  Bader, H.; Cross, L. C.; Heilbron, I.; Jones, E. R. H. J. Chem. Soc. 1949, 619. 
(110)  Obermeier, B.; Frey, H. Bioconjug. Chem. 2011, 22, 436. 
(111)  Kramer, J. R.; Deming, T. J. J. Am. Chem. Soc. 2012, 134, 4112. 
(112)  Aimetti, A. A.; Feaver, K. R.; Anseth, K. S. Chem. Commun. 2010, 46, 5781. 
(113)  Hoyle, C. E.; Bowman, C. N. Angew. Chemie Int. Ed. 2010, 49, 1540. 
(114)  Lo Conte, M.; Pacifico, S.; Chambery, A.; Marra, A.; Dondoni, A. J. Org. 
Chem. 2010, 75, 4644. 
(115)  Conte, M. Lo; Staderini, S.; Marra, A.; Sanchez-Navarro, M.; Davis, B. G.; 
Dondoni, A. Chem. Commun. 2011, 47, 11086. 
(116)  Griesbaum, K. Angew. Chemie Int.Ed. 1970, 9, 273. 
(117)  Li, F.; Allahverdi, A.; Yang, R.; Lua, G. B. J.; Zhang, X.; Cao, Y.; Korolev, N.; 
Nordenskiöld, L.; Liu, C.-F. Angew. Chemie 2011, 123, 9785. 
(118)  Fiore, M.; Lo Conte, M.; Pacifico, S.; Marra, A.; Dondoni, A. Tetrahedron Lett. 
2011, 52, 444. 
(119)  Li, Q.-F.; Yang, Y.; Maleckis, A.; Otting, G.; Su, X.-C. Chem. Commun. 2012, 
48, 2704. 
(120)  Hoppmann, C.; Kühne, R.; Beyermann, M. Beilstein J. Org. Chem. 2012, 8, 
884. 
256 
 
(121)  Gorin, G.; Godwin, W. E. Biochem. Biophys. Res. Commun. 1966, 25, 227. 
(122)  Cole, R. D.  Enzyme Structure; Enzymology, Ed. Academic Press, 1967; Vol. 
11, 206. 
(123)  Dong, J.; Atwood, C. S.; Anderson, V. E.; Siedlak, S. L.; Smith, M. A.; Perry, 
G.; Carey, P. R. Biochemistry 2003, 42, 2768. 
(124)  Giulivi, C.; Davies, K. J. A. Oxygen Radicals in Biological Systems Part C  
(Enzymology) 1994, 233, 363. 
(125)  Chen, X.; Greenaway, F. J. Neural Transm. 2011, 118, 1111. 
(126)  Dias, C. R.; Jeger, S.; Osso Jr, J. A.; Müller, C.; De Pasquale, C.; Hohn, A.; 
Waibel, R.; Schibli, R. Nucl. Med. Biol. 2011, 38, 19. 
(127)  Kellogg, B. A.; Garrett, L.; Kovtun, Y.; Lai, K. C.; Leece, B.; Miller, M.; Payne, 
G.; Steeves, R.; Whiteman, K. R.; Widdison, W.; Xie, H.; Singh, R.; Chari, R. 
V. J.; Lambert, J. M.; Lutz, R. J. Bioconjug. Chem. 2011, 22, 717. 
(128)  Kemp, D. S.; Galakatos, N. G. J. Org. Chem. 1986, 51, 1821. 
(129)  Bobyk, K. D.; Kim, S. G.; Kumar, V. P.; Kim, S.-K.; West, A. H.; Cook, P. F. 
Arch. Biochem. Biophys. 2011, 513, 71. 
(130)  Tzanavaras, P. D.; Mitani, C.; Anthemidis, A.; Themelis, D. G. Talanta 2012, 
96, 21. 
(131)  Shaunak, S.; Godwin, A.; Choi, J.-W.; Balan, S.; Pedone, E.; Vijayarangam, 
D.; Heidelberger, S.; Teo, I.; Zloh, M.; Brocchini, S. Nat. Chem. Biol. 2006, 2, 
312. 
(132)  Balan, S.; Choi, J.; Godwin, A.; Teo, I.; Laborde, C. M.; Heidelberger, S.; 
Zloh, M.; Shaunak, S.; Brocchini, S. Bioconjug. Chem. 2006, 18, 61. 
(133)  Brocchini, S.; Godwin, A.; Balan, S.; Choi, J.; Zloh, M.; Shaunak, S. Adv. 
Drug Deliv. Rev. 2008, 60, 3. 
(134)  Wang, Y.; Lu, Q.; Wu, S.-L.; Karger, B. L.; Hancock, W. S. Anal. Chem. 2011, 
83, 3133. 
(135)  Luo, X.; Jiang, Q.; Song, G.; Liu, Y.-L.; Xu, Z.-G.; Guo, Z.-Y. FEBS J. 2012, 
279, 3166. 
(136)  Chi, E.; Krishnan, S.; Randolph, T.; Carpenter, J. Pharm. Res. 2003, 20, 
1325. 
257 
 
(137)  Kiritsi, M. N.; Fragoulis, E. G.; Sideris, D. C. FEBS J. 2012, 279, 1318–1326. 
(138)  Tedaldi, L. M.; Smith, M. E. B.; Nathani, R. I.; Baker, J. R. Chem. Commun. 
2009, 6583. 
(139)  Smith, M. E. B.; Schumacher, F. F.; Ryan, C. P.; Tedaldi, L. M.; 
Papaioannou, D.; Waksman, G.; Caddick, S.; Baker, J. R. J. Am. Chem. Soc. 
2010, 132, 1960. 
(140)  Green, M. N. Avidin-Biotin Technology, Ed. Academic Press, 1990, Vol. 184, 
51. 
(141)  Ryan, C. P.; Smith, M. E. B.; Schumacher, F. F.; Grohmann, D.; 
Papaioannou, D.; Waksman, G.; Werner, F.; Baker, J. R.; Caddick, S. Chem. 
Commun. 2011, 47, 5452. 
(142)  Schumacher, F. F.; Nobles, M.; Ryan, C. P.; Smith, M. E. B.; Tinker, A.; 
Caddick, S.; Baker, J. R. Bioconjug. Chem. 2011, 22, 132. 
(143)  Reichlin, S. N. Engl. J. Med. 1983, 309, 1495. 
(144)  Freda, P. U. J. Clin. Endocrinol. Metab. 2002, 87, 3013. 
(145)  Rivier, J.; Brazeau, P.; Vale, W.; Guillemin, R. J. Med. Chem. 1975, 18, 123. 
(146)  Schumacher, F. F.; Sanchania, V. A.; Tolner, B.; Wright, Z. V. F.; Ryan, C. P.; 
Smith, M. E. B.; Ward, J. M.; Caddick, S.; Kay, C. W. M.; Aeppli, G.; Chester, 
K. A.; Baker, J. R. Sci. Rep. 2013, 3. 
(147)  Jones, M. W.; Strickland, R. A.; Schumacher, F. F.; Caddick, S.; Baker, J. R.; 
Gibson, M. I.; Haddleton, D. M. Chem. Commun. 2012, 48, 4064. 
(148)  Jones, M. W.; Strickland, R. A.; Schumacher, F. F.; Caddick, S.; Baker, J. R.; 
Gibson, M. I.; Haddleton, D. M. J. Am. Chem. Soc. 2011, 134, 1847. 
(149)  Moody, P.; Smith, M. E. B.; Ryan, C. P.; Chudasama, V.; Baker, J. R.; Molloy, 
J.; Caddick, S. ChemBioChem 2012, 13, 39. 
(150)  Rudolf, B.; Salmain, M.; Fornal, E.; Rybarczyk-Pirek, A. Appl. Organomet. 
Chem. 2012, 26, 80. 
(151)  Aldrich, J. V; Kumar, V.; Murray, T. F.; Guang, W.; Wang, J. B. Bioconjug. 
Chem. 2009, 20, 201. 
(152)  Ortiz, J. O.; Bubis, J. Arch. Biochem. Biophys. 2001, 387, 233. 
258 
 
(153)  Kao, M. W.-P.; Yang, L.-L.; Lin, J. C.-K.; Lim, T.-S.; Fann, W.; Chen, R. P.-Y. 
Bioconjug. Chem. 2008, 19, 1124. 
(154)  Lang, S.; Spratt, D. E.; Guillemette, J. G.; Palmer, M. Anal. Biochem. 2005, 
342, 271. 
(155)  Simon, M.; Zangemeister-Wittke, U.; Plückthun, A. Bioconjug. Chem. 2011, 
23, 279. 
(156)  Brustad, E. M.; Lemke, E. A.; Schultz, P. G.; Deniz, A. A. J. Am. Chem. Soc. 
2008, 130, 17664. 
(157)  Kim, J.; Seo, M.-H.; Lee, S.; Cho, K.; Yang, A.; Woo, K.; Kim, H.-S.; Park, H.-
S. Anal. Chem. 2012, 85, 1468. 
(158)  Wan, W.; Huang, Y.; Wang, Z.; Russell, W. K.; Pai, P.-J.; Russell, D. H.; Liu, 
W. R. Angew. Chemie Int. Ed. 2010, 49, 3211. 
(159)  Morales-Sanfrutos, J.; Lopez-Jaramillo, F. J.; Hernandez-Mateo, F.; Santoyo-
Gonzalez, F. J. Org. Chem. 2010, 75, 4039. 
(160)  Temming, R. P.; Eggermont, L.; van Eldijk, M. B.; van Hest, J. C. M.; van 
Delft, F. L. Org. Biomol. Chem. 2013, 11, 2772. 
(161)  Ratner, V.; Kahana, E.; Eichler, M.; Haas, E. Bioconjug. Chem. 2002, 13, 
1163. 
(162)  Lang, S.; Spratt, D. E.; Guillemette, J. G.; Palmer, M. Anal. Biochem. 2006, 
359, 253. 
(163)  Crochet, A. P.; Kabir, M. M.; Francis, M. B.; Paavola, C. D. Biosens. 
Bioelectron. 2010, 26, 55. 
(164)  Boersma, Y. L.; Plückthun, A. Curr. Opin. Biotechnol. 2011, 22, 849. 
(165)  Mazmanian, S. K.; Ton-That, H.; Su, K.; Schneewind, O. Proc. Natl. Acad. 
Sci. 2002, 99, 2293. 
(166)  Race, P. R.; Bentley, M. L.; Melvin, J. A.; Crow, A.; Hughes, R. K.; Smith, W. 
D.; Sessions, R. B.; Kehoe, M. A.; McCafferty, D. G.; Banfield, M. J. J. Biol. 
Chem. 2009, 28 , 6924. 
(167)  Antos, J. M.; Chew, G.-L.; Guimaraes, C. P.; Yoder, N. C.; Grotenbreg, G. M.; 
Popp, M. W.-L.; Ploegh, H. L. J. Am. Chem. Soc. 2009, 131, 10800. 
(168)  Muralidharan, V.; Muir, T. W. Nat. Methods. 2006, 3, 429. 
259 
 
(169)  Yang, J.-Y.; Yang, W. Y. J. Am. Chem. Soc. 2009, 131, 11644. 
(170)  De Rosa, L.; Cortajarena, A. L.; Romanelli, A.; Regan, L.; D’Andrea, L. D. 
Org. Biomol. Chem. 2012, 10, 273. 
(171)  Brenzel, S.; Cebi, M.; Reiß, P.; Koert, U.; Mootz, H. D. ChemBioChem 2009, 
10, 983. 
(172)  Minato, Y.; Ueda, T.; Machiyama, A.; Shimada, I.; Iwaï, H. J. Biomol. NMR 
2012, 53, 191. 
(173)  Becker, C. F. W.; Seidel, R.; Jahnz, M.; Bacia, K.; Niederhausen, T.; 
Alexandrov, K.; Schwille, P.; Goody, R. S.; Engelhard, M. ChemBioChem 
2006, 7, 891. 
(174)  Xie, N.; Elangwe, E. N.; Asher, S.; Zheng, Y. G. Bioconjug. Chem. 2009, 20, 
360. 
(175)  Jagadish, K.; Borra, R.; Lacey, V.; Majumder, S.; Shekhtman, A.; Wang, L.; 
Camarero, J. A. Angew. Chemie Int. Ed. 2013, 52, 3126. 
(176)  Von Sonntag, J.; Knolle, W.; Naumov, S.; Mehnert, R. Chemistry 2002, 8, 
4199. 
(177)  Tedaldi, L. M. PhD Thesis, University College London, 2010. 
(178)  Ban-y, J. F.; Wallace, T. W.; Walshe, N. D. A. 1995, 51, 12797. 
(179)  Jeyakumar, K.; Chakravarthy, R. D.; Chand, D. K. Catal. Commun. 2009, 10, 
1948. 
(180)  Trost, B. M.; Kallander, L. S. J. Org. Chem. 1999, 64, 5427. 
(181)  Bergman, J.; Desarbre, E.; Koch, E. Tetrahedron 1999, 55, 2363. 
(182)  Hénon, H.; Anizon, F.; Kucharczyk, N.; Loynel, A.; Casara, P.; Pfeiffer, B.; 
Prudhomme, M. Synthesis (Stuttg). 2006, 711. 
(183)  Duan, W.-L.; Imazaki, Y.; Shintani, R.; Hayashi, T. Tetrahedron 2007, 63, 
8529. 
(184)  Maki, B. E.; Chan, A.; Phillips, E. M.; Scheidt, K. A. Org. Lett. 2007, 9, 371. 
(185)  Ló, S. M. S.; Ducatti, D. R. B.; Duarte, M. E. R.; Barreira, S. M. W.; Noseda, 
M. D.; Gonçalves, A. G. Tetrahedron Lett. 2011, 52, 1441. 
(186)  Barnes, C. S.; Barton, D.H.R J. Chem. Soc. 1953, 1419. 
260 
 
(187)  Schumacher, F. PhD Thesis, University College London, 2012. 
(188)  Coleman, R. S.; Walczak, M. C.; Campbell, E. L. J. Am. Chem. Soc. 2005, 
127, 16038. 
(189)  Dubernet, M.; Caubert, V.; Guillard, J.; Viaud-Massuard, M.-C. Tetrahedron 
2005, 61, 4585. 
(190)  Ashraf, S. A.; Hill, J., N’Hamedi, A., Zerizer, H. Tetrahedron 1992, 48 (32), 
6747. 
(191)  Baker, J. R. PhD Thesis; University of Bristol, 2004. 
(192)  Booker-Milburn, K. I.; Baker, J. R.; Bruce, I. Org. Lett. 2004, 6, 1481. 
(193)  Exner, O.; Böhm, S. J. Org. Chem. 2002, 67, 6320. 
(194)  Moody, P.; Chudasama, V.; Nathani, R. I.; Maruani, A.; Martin, S.; Smith, M. 
E. B.; Caddick, S. Chem. Commun. 2014, 50, 4898. 
(195)  Beija, M.; Afonso, C. M.; Martinho, J. M. G. Chem. Soc. Rev. 2009, 38, 2410. 
(196)  Clerc, J.; Schellenberg, B.; Groll, M.; Bachmann, A. S.; Huber, R.; Dudler, R.; 
Kaiser, M. European J. Org. Chem. 2010, 2010, 3991. 
(197)  Castañeda, L.; Wright, Z. V. F.; Marculescu, C.; Tran, T. M.; Chudasama, V.; 
Maruani, A.; Hull, E. a; Nunes, J. P. M.; Fitzmaurice, R. J.; Smith, M. E. B.; 
Jones, L. H.; Caddick, S.; Baker, J. R. Tetrahedron Lett. 2013, 54, 3493. 
(198)  Wright, Z. V. F. Rotation report, Synthesis of Nitrogen-Substituted 2,3-
dibromomaleimides, University College London, 2011. 
(199)  Chen, X.; Wu, Q.; Henschke, L.; Weber, G.; Weil, T. Dye. Pigment. 2012, 94, 
296. 
(200)  Norberg, O.; Deng, L.; Aastrup, T.; Yan, M.; Ramstr, O.; Anal. Chem. 2011, 
1000. 
(201)  Shao, C.; Wang, X.; Zhang, Q.; Luo, S.; Zhao, J.; Hu, Y. J. Org. Chem. 2011, 
76, 6832. 
(202)  Mayer, P. Masters’ Report , A New Class of Reagents for Protein 
Modification; 2012. 
(203)  Iqbal, P.; Critchley, K.; Bowen, J.; Attwood, D.; Tunnicliffe, D.; Evans, S. D.; 
Preece, J. A. J. Mater. Chem. 2007, 17, 5097. 
261 
 
(204)  Martin, S. F.; Chen, K. X.; Eary, C. T. Org. Lett. 1999, 1, 79. 
(205)  Ösapay, G.; Ösapay, K. Expert Opin. Ther. Pat. 1998, 8, 855. 
(206)  Kossen, H. Masters’ Report A Powerful New Class of Reagents for Protein 
Modification; 2012. 
(207)  Nat. Biotechnol. 2009, 27, 1, 41. 
(208)  Chester, K.; Pedley, B.; Tolner, B.; Violet, J.; Mayer, A.; Sharma, S.; Boxer, 
G.; Green, A.; Nagl, S.; Begent, R. Tumour Biol. 2004, 25, 91–8. 
(209)  Emer, J. J.; Wolinsky, C. J. Clin. Aesthetic. Dermatol. 2009, 2, 29. 
(210)  Hudis, C. A. N. Engl. J. Med. 2007, 357, 39. 
(211)  Graff, C. P.; Chester, K.; Begent, R.; Wittrup, K. D. Protein Eng. Des. Sel. 
2004, 17 , 293. 
(212)  Castañeda, L.; Maruani, A.; Schumacher, F. F.; Miranda, E.; Chudasama, V.; 
Chester, K. A; Baker, J. R.; Smith, M. E. B.; Caddick, S. Chem. Commun. 
2013, 49, 8187. 
(213)  Iciek, M.; Chwatko, G.; Lorenc-Koci, E.; Bald, E.; Włodek, L. Acta Biochim. 
Pol. 2004, 51, 815. 
(214)  Schafer, F.Q., Buettner, G. R. Free Radic. Biol. Med. 2001, 30, 1191. 
(215)  Machida, M., Machida, M.I., Kanaoka, Y. Chem. Pharm. Bull. 2739, 25, 2739. 
(216)  Chudasama, V.; Smith, M. E. B.; Schumacher, F. F.; Papaioannou, D.; 
Waksman, G.; Baker, J. R.; Caddick, S. Chem. Commun. 2011, 47, 8781. 
(217)  Dunbar, J.; Yennawar, H. P.; Banerjee, S.; Luo, J.; Farber, G. K. Protein Sci. 
1997, 6, 1727. 
(218)  Marino, S. M.; Gladyshev, V. N. J. Biol. Chem. 2012, 287, 4419. 
(219)  De Meyer, T.; Muyldermans, S.; Depicker, A. Trends Biotechnol. 2014, 32, 
263. 
(220)  Zhiqiang, A. Trend Bio/Pharm. Ind. 2008, 24. 
(221)  Schmitt, M.; Bourguignon, J.-J.; Wermuth, C.-G.; Schott, D.; Rousseau, B.; 
Beaucourt, J.-P. J. Label. Compd. Radiopharm. 1989, 27, 23. 
262 
 
(222)  Salazar, J.; Fernández, F.; Restrepo, J.; López, S. E. J. of Chem. Res. 2007, 
170. 
(223)  Harrison, T.; Myers, P. L.; Pattenden, G. Tetrahedron 1989, 45, 5247. 
(224)  Lattmann, E.; Dunn, S.; Sattayasai, N.; NiamsitI, S. ANTIBACTERIAL 
PYRROLS; WO2007/39749, 2007. 
(225)  Silber, C. Gazz. Chim. Ital. 1883, 13, 413. 
(226)  Issa, F.; Fischer, J.; Turner, P.; Coster, M. J. J. Org. Chem. 2006, 71, 4703. 
(227)  Anhydrides, A.; Sahoo, K.; Mhaske, S. B.; Argade, N. P. Synthesis (Stuttg). 
2003, 346–349. 
(228)  Anschuetz.,J. Liebigs Ann. Chem. 1928, 461, 168. 
(229)  Ryan, C. P. PhD Thesis, University College London, 2010.  
 
 
 
 
